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Clinicians are continually looking for effective treatments for multiple sclerosis (MS)- 
fatigue, but this has been hampered by unclear definitions of fatigue and studies of 
heterogeneous people with MS, including those who are highly-fatigued (MS-HF) and 
those who are less-fatigued (MS-LF). By directly comparing neuromuscular and 
transcranial magnetic stimulation measures between MS-HF and MS-LF, more light 
could be shed on the underpinning mechanisms of MS fatigue, and this could serve as a 
stronger foundation for therapeutic interventions. In addition, progressive resistance 
exercise has shown potential as an accessible exercise intervention for alleviating MS 
fatigue, but most studies have not recruited MS-HF or did not include MS fatigue as a 
primary outcome measure. In addition to positively impacting a range of other functional 
and mental health outcomes in PwMS, an individually tailored progressive resistance 
exercise (PRE) intervention has the potential to improve symptoms of fatigue and 
fatigability by helping to promote the development of new neural pathways 
(neuroplasticity). Thus, the overarching aim of this thesis was to establish whether 
neurophysiological differences between MS-HF and MS-LF could be reliably 
distinguished, and to investigate the feasibility and potential of PRE as a therapeutic 
exercise intervention for ameliorating perceived MS-fatigue in MS-HF. The series of 
investigations that set out to address this aim have led to many novel and interesting 
findings. Firstly, study 1 was the first systematic review and meta-analysis to synthesis 
the current evidence base comprising studies which used a dichotomised model (MS-HF 
versus MS-LF) to provide insights into structural and neurophysiological correlates of 
MS-fatigue. Secondly, Study 2 reports on the good to excellent test-retest reliability for a 
range of neuromuscular and transcranial magnetic stimulation measures assessed in the 
upper- and lower-limb muscles in MS-HF and MS-LF. Thirdly, based on the test-retest 
reliability findings of study 2, study 3 presents data for the differences between MS-HF 
compared to MS-LF and HC on a range of neuromuscular measures, including an 
isometric fatiguing exercise task in the upper- and lower-limb (performance fatigability 
measure). Finally, Study 4 presents important feasibility data regarding the utility of PRE 
as a therapeutic exercise option for MS-HF. In addition, this study provides preliminary 
evidence of the efficacy of PRE for ameliorating perceived MS-fatigue, a range of other 
patient-reported health outcomes and indices of neuromuscular function. 
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Figure 2.1 Multiple Sclerosis Pathology (adapted from Lipsy et al., 2006). APC: antigen 
presenting cell; TH: T helper cell; MMP: matrix metalloproteinases; BBB: 
blood brain barrier. 
 
Figure 2.2 Worldwide prevalence of MS, per 100,000 population (Atlas multiple sclerosis 
resources in the world, 2008, page 15). 
 






Figure 3.1 Visual representation of the EDSS (Adapted from Kurtzke, 1983). 
 
 
Figure 3.2 The custom-modified and adjustable isometric dynamometer set-up for the 
(A) wrist-flexor and (B) knee-extensor muscles. 
 
 
Figure 3.3 Transcranial magnetic stimulation applied over the motor cortex to the brain 
surface projecting on spinal motorneurons, also termed the corticospinal 
tract. Motorneuron activation in response to corticospinal volleys induced 
by transcranial magnetic stimulation leads to a contraction in the target 
muscle evoking a MEP, recorded by using surface EMG electrodes over 





Figure 4.1 PRISMA flow chart for literature search and study selection. 
 
 
Figure 4.2  Methodological quality of the included studies evaluated using the Cross- 
Sectional/Prevalence Study Quality Scale, recommended by the Agency 
XIV  
for Healthcare Research and Quality (AHRQ). Scores of 0-3 indicate “low 
quality”, 4–7 “moderate quality” and 8–11 “high quality”. 
 
Figure 4.3 Summary of results of meta-analyses comparing neuroimaging and 
neurofunctional data for MS-HF versus MS-LF. Data are presented as 
standardised mean difference and 95% confidence intervals. The figure 
presents summary data for neuroimaging variables, with the abscissas 
representing a decrease or increase for MS-HF in comparison with MS-LF. 
TBV, total brain volume; BPF, brain parenchymal fraction; GMV, Grey 
matter volume, WMV, white matter volume, T1-WLV, T1-weighted lesion 
volume, T2-WLV, T2-weighted lesion volume, NAA/Cr, N-acetylaspartate 
to creatine ratio Cho/Cr, choline to creatine ratio, UL, upper-limb; LL, 
lower-limb. 
 
Figure 4.4 Summary of results of meta-analyses comparing neurofunctional data for MS-
HF versus MS-LF. Data are presented as standardised mean difference and 
95% confidence intervals. The figure presents summary data for 
neurofunctional variables, with the abscissas representing a decrease or 
increase for MS-HF in comparison with MS-LF. UL, upper-limb; LL, lower- 
limb; MEP, motor evoked potential; CMCT, central motor conduction time; 
SICI, short-interval intracortical inhibition, ICF, intracortical facilitation; 





Figure 5.1 Schematic of test re-test neuromuscular protocol, (A) test re-test 
neuromuscular intervals of 2-14 days between knee-extensors and wrist- 
flexors, (B) Neuromuscular assessment including, percutaneous nerve 
stimulation, transcranial magnetic stimulation and submaximal task to 
failure. 
 
Figure 5.2 Scatter plot for test intraclass correlation (ICC) for test re-test of 
neurophysiological measurements, including (A) knee-extensors and (B) 
wrist-flexors, and (C) patient reported outcomes and fatigue scales in 
healthy control (HC), less-fatigued (MS-LF) and highly-fatigued (MS-HF) 
XV  
PwMS. The ICC was used to assess the relationship of each measure across 
the two experiential visits days and was defined as: <0.5 = poor, 0.5-0.75 = 






Figure 6.1 Schematic of neuromuscular protocol, (A) Neuromuscular assessment 
intervals of 2-14 days between knee-extensors and wrist-flexors, (B) 
Neuromuscular assessment including motor nerve stimulation, transcranial 
magnetic stimulation and sub-maximal, intermittent task at 40% MVC to 
task failure. 
 
Figure 6.2 Differences between groups for patient reported outcomes, with indicating 
clinically important cut off levels of symptom scores. When a significant 
effect of symptom exacerbation was found, * MS-HF vs MS- LF; + MS-
HF vs HC; # MS-LF vs HC (p <0.05). 
 
Figure 6.3. Performance fatigability measures: (A) Rate of Force Decline as MVC (N. m), 
(B) Muscle Fatigue (MVC as % of baseline) and (C) Time to Task Failure 
(TTF, minutes). Significant effect between groups was shown as * MS-HF 







Figure 7.1.   Schematic of Study Design, illustrating screening and recruitment through 
to follow up assessments. 
 
Figure 7.2 Participants in the PRE group demonstrating some of the upper- and lower- 
limb theraband resistance exercises, (A) seated wrist-flexion, (B) standing 
and seated bicep curl, (C) hip- flexion, (D) hip -abduction and (E) seated 
knee-extension. 
 
Figure 7.3 Feasibility was measured by recruitment rates, acceptability of the 
XVI  
intervention, compliance and attrition, and appropriateness of outcome 
measures. 
 
Figure 7.4 FSS (A), MFIS (B), CFS (C ), HADS (D), HADS-Anxiety, (E), HADS- 
Depression (F), Pain (G), QOL-Physical (H), and QOL-Mental (I) all 
expressed as a percentage of baseline before and 6, 12-weeks follow-up in 
the exercise group (open circles) and control group (closed squares). 
 
Figure 7.5 MVC (A), Qtw,pot (B ), N.Min (C ), TTF (D), VA, (E), MEP/Mmax (F), 
SICI (G), SP (H), and MEP Amplitude (I) of the lower-limb muscle, all 
expressed as a percentage of baseline before and 6, 12-weeks follow-up in 
the exercise group (open circles) and control group (closed squares). 
 
Figure 7.5 MVC (A), Qtw,pot (B ), N.Min (C ), TTF (D), VA, (E), MEP/Mmax (F), 
SICI (G), SP (H), and MEP Amplitude (I) of the upper-limb muscle, all 
expressed as a percentage of baseline before and 6, 12-weeks follow-up in 
the exercise group (open circles) and control group (closed squares). 
XVII  







Table 3.1 Overview of Thesis Participant characteristics (Mean ± SD). 













Table 5.1 Participant Characteristics. 
 
 
Table 5.2 Typical error expressed in raw units and coefficient of variation (%) for 
between-day measures of force and electromyography derived outcomes for 
the knee-extensor muscle (Mean ± SD). 
 
Table 5.3 Typical error expressed in raw units and coefficient of variation (%) for 
between-day measures of force and electromyography derived outcomes for 
the wrist-flexors muscle (Mean ± SD). 
 
Table 5.4 Typical error expressed in raw units and coefficient of variation (%) for 
between-day measures of self-reported fatigue and patient-reported outcome 





Table 6.1 Participant characteristics (Mean ± SD). 
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Table 6.2. Differences in knee-extensor outcomes between groups’ pre -and post- 
exercise task. When a significant effect of exercise was found, the Δ in a 
variable from pre-post exercise was reported. * MS-HF vs. MS-LF; + MS- 
HF vs. HC; # MS-LF vs. HC (P <0.05). 
 
Table 6.3  Differences in wrist-flexors outcomes between groups’ pre -and post- 
exercise task. When a significant effect of exercise was found, the Δ in a 
variable from pre-post exercise was reported. * MS-HF vs MS-LF; + MS- 





Table 7.1 Characteristics of the resistance PRE and usual care control group. 
 
Table 7.2 Self-reported fatigue and patient reported Outcomes Mean (SD) of groups, 
mean (SD) difference within groups, and mean difference (95%CI) between 
groups. 
 
Table 7.3 Neurophysiological measures in lower-limb (knee-extensors). Mean (SD) of 
groups, mean (SD) difference within groups, and mean difference (95%CI) 
between groups. 
 
Table 7.4 Neurophysiological measures in upper-limb (wrist-flexors). Mean (SD) of 
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CHAPTER 1 – INTRODUCTION 
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1.1 Introduction 
Fatigue is one of the most common and severe symptoms, experienced in up to 75% 
of people with multiple sclerosis (PwMS; (Fisk et al., 1994b; Lerdal et al., 2007; Loy 
et al., 2017; Penner & Paul, 2017). In proposing a unified taxonomy of fatigue in 
neurologic illness, Kluger et al. (2013a) highlighted the importance of differentiating 
between perceived fatigue and fatigability. Perceived fatigue includes subjective 
perceptions of weariness and an increased perception of effort needed to perform 
everyday tasks (irrespective of recent physical exertion). In contrast, fatigability is 
defined as the rate of change in a performance criterion (e.g., maximum voluntary 
contraction force [MVC]) relative to a reference (baseline) value over a given time of 
task performance or measure of mechanical output. The consequences of fatigue have 
been well-described in the literature, and include profound impacts on quality of life 
(Aronson, 1997; Amato et al., 2001) and mental alertness (Weinges-Evers et al., 
2010), cognitive processing (Andreasen et al., 2010b), poorer general health and 
increased disability (Janardhan & Bakshi, 2002; Krause et al., 2013). MS-fatigue is 
also a major contributor to the high levels of unemployment in PwMS (Krupp et al., 
1988; Pompeii et al., 2005). As such, MS-fatigue is a leading cause of increased 
healthcare visits (Khan et al., 2014), inactivity and future comorbidities, and presents 
a significant economic burden to the National Health Service and wider society. 
 
Despite widespread research efforts, the underpinning cause(s) of MS-fatigue is 
poorly understood and is an area of debate, partly due to unclear definitions of fatigue 
(Kluger et al., 2013a). However, there is general agreement that disease pathology 
plays an important role, including axonal degeneration, inflammation and/or myelin 
destruction at multiple levels of the central and peripheral nervous system (Kos et al., 
2008). Such underlying disease pathology compromises the integrity of sensory 
pathways, as well as causing muscle weakness, lack of movement coordination and 
neuroplasticity impairments (Lublin & Reingold, 1996; Compston & Coles, 2008; 
Trapp & Nave, 2008; Kister et al., 2013). As revealed by magnetic resonance imagery, 
neurostructural damage to multiple brain areas and altered activity and connectivity of 
brain regions are the central stimuli considered to be implicated in the perception of 
MS-fatigue (Tanasescu et al., 2014; Biberacher et al., 2018). As such, this widespread 
damage and resultant dysfunctional brain connectivity is thought to underpin fatigue 
perceptions at rest and increase the perception of effort during simple motor tasks 
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(Filippi et al., 2002; Novo et al., 2018). Everyday tasks such as walking, balance and 
performing simple errands require muscle strength, coordination and constant 
neuromuscular adjustments (Dobkin, 2009; Dall & Kerr, 2010); however, because of 
the underlying neuropathology, such movements require greater effort in PwMS. 
 
While only a few investigations have investigated the relationship between fatigue and 
functional imaging (Filippi et al., 2002), studies involving stimulation have found that 
impaired central motor activation is present in MS-fatigue (Andreasen et al., 2009; 
Morgante et al., 2011; Steens et al., 2012c). Other investigations have reported 
increased central activation or altered activation of brain regions at rest and during 
motor task, probably reflecting additional compensatory central activation 
(Thickbroom et al., 2008; Andreasen et al., 2009; Andreasen et al., 2010a). In addition, 
neurophysiological studies using the superimposed twitch (Merton (1954b) 
interpolation technique have reported a progressive impairment of central motor drive 
during sustained upper- and lower-limb maximum voluntary muscle actions in 
fatigued PwMS (Sheean et al., 1997; Andreasen et al., 2009; Steens et al., 2012b; 
Steens et al., 2012c). In one study, this was accompanied by an inability to increase 
cortical activation during sustained maximal muscle actions, in contrast to what was 
observed in healthy age-matched controls (Steens et al., 2012c). An attenuation of 
cortical inhibitory pathways in fatigued PwMS (Liepert et al., 2005; Morgante et al., 
2011), is consistent with an augmentation of cortical activation at rest and during sub- 
maximal motor tasks, and an inability to increase cortical activation during sustained 
maximal muscle actions. It has been argued that excess cortical activity or a mismatch 
between the estimated and actual “neural work” needed during sub-maximal motor 
tasks could contribute to the clinical symptoms of fatigue in PwMS (Leocani et al., 
2008). Although this altered neurophysiological function could underpin increased 
perceived effort and MS-fatigue, it might also reflect compensatory adaptations for 
the neurostructural damage associated with the disease, which requires further 
exploration. 
 
Pharmacological and psychosocial interventions for fatigue management are reported 
to be ineffective or modest at best (Lee et al., 2008; Phyo et al., 2018). However, 
exercise has shown considerable promise as an intervention for helping PwMS to 
manage fatigue symptoms. Most of the studied therapeutic interventions in clinical 
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and exercise science research have been aerobic exercise or combined aerobic and 
resistance exercise. More recently, a growing body of research has been aimed at 
delineating the physiological and psychosocial effects of exercise (aerobic or 
combined aerobic and resistance exercise programmes), and how exercise 
programmes can be tailored to improve muscle function/performance and quality of 
life (Rietberg et al., 2005a; Motl & Gosney, 2008; Asano et al., 2009). There is 
evidence that resistance exercise can improve muscle power, strength/force generating 
capacity, physical and psychosocial functioning and quality of life in PwMS (Rietberg 
et al., 2005a; Motl & Gosney, 2008; Asano et al., 2009). Although, less well studied, 
an emerging body of work has also shown that resistance exercise can improve self- 
reported MS-fatigue (Dalgas et al., 2010; Dodd et al., 2011; Hayes et al., 2011b; 
Sabapathy et al., 2011). However, it is yet to be explored whether the magnitude of 
fatigue in highly fatigued PwMS can be attenuated following a programme of 
progressive resistance exercise and if so, what practical recommendations should be 
provided to optimise efficacy and adherence to such programmes, in order to preserve 
the health benefits to PwMS. The proposed relationship between MS-fatigue, neural 
lesions and muscle function/activation loss means that (hypothetically) an individually 
tailored progressive resistance exercise intervention has the potential to improve 
symptoms of fatigue and fatigability by helping to promote the development of new 
neural pathways (neuroplasticity). 
 
Despite the high prevalence and pronounced impact of MS-fatigue on the lives of 
PwMS, techniques for improving our understanding of the different underlying causes 
of fatigue are limited and therefore, opportunities for mechanism-guided MS-fatigue 
treatment in PwMS are lacking. Therefore, this thesis comprises a set of interrelated 
but standalone studies, which have the objectives of (i) synthesising current evidence 
of the neuro-structural and neurophysiological correlates of MS-fatigue; (ii) 
ascertaining whether neurophysiological correlates of MS-fatigue differ between 
highly-fatigued and less-fatigued PwMS, and (iii) reporting on the feasibility of a 
progressive resistance exercise programmes in highly-fatigued PwMS, as well as 
providing early indicative evidence of changes MS-fatigue symptoms and 
neurophysiological correlates of MS-fatigue. 
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1.2 Statement of Thesis Aims 
1.2.1 Study 1 (Chapter 4) 
Title: Neurostructural and Neurophysiological Correlates of Multiple Sclerosis 
Fatigue: Systematic Review and Meta-Analysis of Cross-Sectional Studies 
Aim: The aim of this study was to provide the most precise estimates of cross- 
sectional neurostructural and neurophysiological differences between people 
experiencing high and low levels of MS-fatigue. 
 
1.2.2 Study 2 (Chapter 5) 
Title: Test-Retest Reliability of Transcranial Magnetic Stimulation and Motor 
Nerve Stimulation Measures of Neurophysiological function in People 
Experiencing High and Low Levels of Multiple Sclerosis Fatigue 
Aim: The aim of this study was to establish the test-retest reliability, variability and 
measurement error of a comprehensive battery of upper- and lower-limb transcranial 
magnetic stimulation and neurophysiological measures (knee-extensors and wrist- 
flexors, respectively) in people experiencing high and low levels of MS-fatigue. 
 
1.2.3 Study 3 (Chapter 6) 
Title: Neurophysiological Responses to a Sub-maximal Isometric Task in Highly 
Fatigued and Less Fatigued People with Multiple Sclerosis and healthy 
individuals: A Cross-Sectional Study 
Aim: The aim of this study was to compare baseline neurophysiological responses and 
neurophysiological responses to a fatiguing exercise task between PwMS 
experiencing high and low levels of fatigue and a group of healthy controls. 
 
1.2.4 Study 4 (Chapter 7) 
Title: Feasibility of External-Paced Resistance Training in Highly Fatigued 
People with Multiple Sclerosis 
Aim: The aim of this study was to evaluate the feasibility and early efficacy of a 
supported (supervised and home-based) externally paced resistance training 
programme in people experiencing high levels of MS-fatigue via a randomised 
controlled feasibility trial. 





























CHAPTER 2 – REVIEW OF LITERATURE 
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2.1 Introduction to Review of Literature 
This chapter provides a review of the literature, focusing on the following topics: 1) 
MS disease characteristics, 2) underlying mechanisms of MS-fatigue, 3) exercise 
training for the management of fatigue in PwMS. The chapter concludes with a 
rationale for undertaking this PhD research before stating the aims of the thesis. 
 
2.2 Overview of Pathogenesis of MS 
In 1868, Jean-Martin Charcot first recognised demyelination as the most striking 
pathologic feature of MS, and the interaction between inflammation and degeneration 
(Kumar et al., 2011). Subsequently, strong evidence suggested that relapses are the 
expression of acute, focal, disseminated and recurrent inflammation occurring within 
the central nervous system ( Youl et al. (1991)). For example, for each clinical episode 
(MS relapse) there is an average of 10 new magnetic resonance imagery lesions (Chard 
& Trip, 2019), signifying the active nature of MS. Hence, relapses are a direct clinical 
expression of inflammation and support the premise that MS is predominantly an 
inflammatory demyelinating disease (Tillema & Pirko, 2013). In recent years, studies 
investigating the pathology of MS have become increasingly widespread (Evangelou 
et al., 2000) and magnetic resonance imagery techniques (Losseff et al., 1996; Fu et 
al., 1998; Rudick et al., 1999; Tortorella et al., 2000; Brex et al., 2002; Filippi et al., 
2003) have shown that progression and accumulation of disability correlate with early, 
diffuse, chronic and progressive axonal loss, which is the hallmark of the 
neurodegenerative process in MS. 
 
MS disease activity can be divided into two phases, with the early phase characterised 
by inflammation of the central nervous system, caused by infiltration of activated T- 
cells, B-cells and Macrophages (Lipsy et al., 2009). The macrophages, T-cells, and 
antibodies secreted from the B-cells, attack selected neurons causing demyelination, 
progressing in severity, and leading to the second phase, characterised by axonal loss 
and neurodegeneration (Lipsy et al., 2009). See Figure 2.1 below. 




Figure 2.1 Multiple Sclerosis Pathology (adapted from Lipsy et al., 2006). APC: 
antigen presenting cell; TH: T helper cell; MMP: matrix metalloproteinases; BBB: 
blood brain barrier. 
 
Therefore, MS is characterised by demyelinating lesions within the white matter of the 
central nervous system. This presents as a degradation of the myelin sheath, which 
normally serves as an insulator and speeds up conduction along nerve fibres to permit 
co-ordinated movements (Chang et al. (2011). However, once the myelin sheath of 
nerve fibers has been damaged, nerve signals become impeded. MS lesions (damaged 
areas as seen on magnetic resonance imagery) form with hardened scars or plaques 
that can impair normal myelin repair processes. Evidence suggests that PwMS have a 
slowing of nerve conduction and/or blocks in nerve conduction within the central 
nervous system and are unable to transmit high frequency electrical impulses to 
targeted muscles (Thickbroom et al., 2006). This causes impaired movement during 
motor tasks and a range of other neurological symptoms and clinical manifestations. 
 
2.2.1 Epidemiology and Prevalence of MS 
It is estimated that approximately 2.5 million people live with MS worldwide, 
signifying that MS is not a rare disease (Flachenecker & Stuke, 2008). In fact, MS is 
the most common cause of non-traumatic neurological disability in young adults, with 
a prevalence of around 1 in 1,000, and with evidence that incidence is increasing 
(Koch-Henriksen & Sørensen, 2010). Global prevalence rates are unevenly distributed 
and vary (see Figure 2.2), e.g. <5 cases per 100,000 in regions of Asia and South 
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America, 11-74 cases per 100,000 in Australia, and >100-200 cases per 100,000 in 
North America and Scotland (Tesar et al., 2003). 
 
 
Figure 2.2 Worldwide prevalence of MS, per 100,000 population (Atlas multiple 
sclerosis resources in the world, 2008, page 15) 
 
A population-based study using general practice databases also revealed that 
approximately 126,669 (203.4/100,000 population) people have MS in the UK 
(Mackenzie et al., 2014) and a large general practice will normally have between 10– 
20 patients with MS (Compston & Coles, 2002, 2008). Environmentally, MS is more 
prevalent in northern Europeans who live in a more temperate climate compared with 
people living in the tropics. This is believed to be due to lack of sunlight (necessary 
for mediating vitamin D synthesis), ultraviolet radiation and greater risk of infectious 
agents such as Epton-Barr virus (Compston & Coles, 2008; Milo & Kahana, 2010; 
Melcon et al., 2014). Likewise, there is an increased familial risk of MS occurrence of 
up to 20%, with the observed age-adjusted higher risk being in first degree relatives 
(siblings, 5%; parents, 2%; children, 2%) compared to second- and third-degree 
relatives (Compston & Coles, 2008). Gender and age bias affect MS risk, specifically 
with a ratio of 2:1 woman to men with MS (Compston & Coles, 2002; Koch-Henriksen 
& Sørensen, 2010) and an age-span of 15-75 years, with young adults being most 
frequently affected between 20 - 40 years. Additionally, a five-year difference in the 
peak incidence rate of MS is observed between men (45 years) and women (40 years) 
(Mackenzie et al., 2014). Thus, men tend to be diagnosed later in years and are thought 
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to have a more aggressive pattern of disease (Compston & Coles, 2002; Koch- 
Henriksen & Sørensen, 2010). While it has been reported that the average life span of 
PwMS is similar to the general population, a further study suggested that PwMS might 
have a reduced life span of approximately 5-10 years (Hurwitz, 2011). However, as 
the disease tends to be diagnosed in the prime of the individuals’ life, there are 
physical, social and economic implications of living with MS (Patwardhan et al., 2005; 
McCrone et al., 2008). 
 
2.2.2 Classification of MS 
MS presents a highly heterogeneous disease course, with a number of distinct clinical 
subtypes defined by The National MS Society Advisory Committee on Clinical Trials 
in MS (1996). The most common subtype is relapsing remitting MS, which accounts 
for 80–90% of all cases (Compston & Coles, 2008) and is often characterised by 
demyelinating events where there is loss-of-function, inter-spaced by periods of partial 
or complete recovery. However, after 10 years approximately 50% of those with 
relapsing remitting MS will go onto develop secondary progressive MS with fewer 
relapses but a progressive worsening of disability. Yet around 10% of patients with 
MS have a progressive decline in disability from the outset, termed primary 
progressive MS. See Figure 2.3 for a visual representation of MS subtypes. 
 
2.2.3 Symptoms of MS 
People with MS experience a variety of symptoms, including impaired vision, 
sensations of numbness, pains, spasms and tingling, weakness (which can be 
unilateral), balance problems, and bladder, sexual and cognitive dysfunction issues. 
Fatigue is the most common symptom experienced by 75 to 92% of PwMS and is 
difficult to treat (Freal et al., 1984; Braley & Chervin, 2010; Berger et al., 2013). 
Fatigue is considered one of the most debilitating symptoms of MS and can 
significantly affect an individual’s quality of life, interfere with activities of daily 
living, cause reduced work performance and contribute to loss of employment (Smith 
& Arnett, 2005; Blaney & Lowe-Strong, 2009; Göksel Karatepe et al., 2011; Glanz et 
al., 2012) . Additionally, fatigue in MS tends to follow a diurnal circadian pattern, with 
fatigue severity peaking in the afternoon (Schwid et al., 2002). Fatigue experienced 
by PwMS differs to that experienced by the general population, as shown by Kurtzke 
(1983) who interviewed 32 patients with MS and 33 control subjects and 
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found differences between the groups such as: MS-fatigue is worse with heat, causes 
an inability to sustain function, comes on suddenly and causes frequent problems in 
daily living. Whilst the disease process itself underpins symptoms of fatigue, other 
prevalent comorbidities likely contribute to fatigue in PwMS, include depression 
(Lobentanz et al., 2004; Siegert & Abernethy, 2005), sleep disorders (Bamer et al., 
2008; Bol et al., 2009; Veauthier et al., 2011) and cognitive impairment. Thus, MS- 
related fatigue is a multi-dimensional phenomenon (Krupp & Elkins, 2000; Diamond 
et al., 2008; Bol et al., 2009; Weinges-Evers et al., 2010). Collectively the 
symptomatic manifestations of MS have been associated with barriers to engaging in 
exercise and physical activity within the home and community (Kayes et al., 2011; 
Asano et al., 2013). Although many of the initial symptoms may resolve, repeated 
attacks to the central nervous system often result in an exacerbation of MS-fatigue 
symptoms and a more pronounced decline in physical functioning, thereby affecting 
ability to engage in daily life activities as well as exercise and physical activity 
(Finlayson et al., 2004; Compston & Coles, 2008). This variation of clinical features 
and symptoms highlights some of the complexities in managing the disease and the 
importance of understanding how MS impacts the individual. Further detail of the 





Figure 2.3 Clinical types of MS (Lublin and Reingold 1996). 
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2.3 Fatigue in Multiple Sclerosis 
2.3.1 Perceived Fatigue and Fatigability Constructs 
The term ‘fatigue’ has widespread generic use across populations and disciplines, 
often being used interchangeably and is relatively broad (Enoka & Duchateau, 2016). 
A physiological definition is: “an exercise-induced reduction in the ability of a muscle 
to generate force or power” (Bigland-Ritchie & Woods, 1984; Gandevia, 2001), 
whereby fatigue comes after prolonged muscular activity, and is a predictable 
symptom resolved by rest (Kluger et al., 2013a). In the case of MS, no universally 
accepted definition of fatigue has been established. However, a unified approach has 
been recommended by (Kluger et al., 2013a), which suggests two domains including, 
perceptions of fatigue and performance fatigue within a fatigue taxonomy (Kluger et 
al., 2013a; Finsterer & Mahjoub, 2014; Zijdewind et al., 2021). Their approach 
distinguishes fatigue, as experienced and described by the individual with MS, and 
fatigue as objectively quantified. The former is termed perceived fatigue; the latter is 
called fatigability (Kluger et al., 2013a). While studies acknowledge the complexity 
and multi-factorial nature of MS-related fatigue, a clear definition has been lacking. 
 
The subjective nature and severity of fatigue (i.e., perceived fatigue) in healthcare is 
assessed using psychometric tools such as self-report questionnaires and scales 
(Whitehead, 2009; Elbers et al., 2012; Enoka & Duchateau, 2016). Whilst multiple 
self-reported scales have been used to assess perceived fatigue in PwMS, such scales 
can be limited in their ability to adequately capture the multi-dimensional nature of 
fatigue (Flachenecker et al., 2002b; Mota & Pimenta, 2006). The most commonly used 
fatigue scales are the Modified Fatigue Impact Scale (MFIS) (Fisk et al., 1994b), the 
Fatigue Severity Scale (FSS) (Krupp et al., 1989), and the Visual Analogue Fatigue 
Scale (VAFS) (Lee et al., 1991). Some current definitions of perceived fatigue include 
“overwhelming sense of tiredness, lack of energy or feeling of exhaustion” (Leocani 
et al., 2008) or “difficulty initiating or sustaining voluntary effort” (Chaudhuri & 
Behan, 2004) and “feelings of physical tiredness and lack of energy distinct from 
sadness or weakness” (Krupp et al., 1988). These example definitions of fatigue are 
incomplete, and use simplified and unclear terms to describe the complex symptom of 
fatigue. Moreover, some definitions encompass the perceived nature of fatigue but 
neglect fatigability (e.g. Leocani et al. (2008)), whereas others (e.g. Chaudhuri and 
Behan (2004)) include only the fatiguability component. For the purpose of this thesis, 
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fatigue will be defined as “a subjective lack of physical and mental energy that is 
perceived by the individual and caregiver to intervene with usual and desired 
activities”, in accordance with The MS Council for Clinical Practice Guidelines 
(1998). This definition is heavily biased towards the subjective experience of 
perceived fatigue. However, this thesis will also explore fatigability in PwMS, as 
assessed using objective measures of physical effort, to help capture the multi- 
dimensionality of MS-fatigue (Mills et al., 2010; Kluger et al., 2013a) and understand 
the relationship between them in this population. 
 
Fatigability has been defined as the magnitude of change in the performance of a 
physical or a cognitive task over a period of time (Kluger et al., 2013a; Finsterer & 
Mahjoub, 2014). Fatigability interferes with the individual’s everyday life, as it 
diminishes the individual’s ability to efficiently perform tasks that requires prolonged 
or effortful activity such as walking or engaging in a conversation (Kluger et al., 
2013a; Murphy & Schepens Niemiec, 2014). Physical fatigability is the measured 
change in the continuous performance of a prolonged physical task, such as repetitive 
or sustained movements and walking speed over a period of time. Fatigability is 
distinguished from perceived fatigue by the concept of change, i.e., a measurable 
difference in the performance of a task over a period of time (Schnelle et al., 2012; 
Zijdewind et al., 2021). Therefore, fatigability and perceived fatigue may be related 
but are different constructs. Development of the concept, classification and task 
preference of fatigability is ongoing (Eldadah, 2010; Zijdewind et al., 2016; Zijdewind 
et al., 2021). The definition and domain specification for fatigability used in this thesis 
were introduced recently by Kluger et al. and other researchers (Eldadah, 2010; 
Schnelle et al., 2012; Kluger et al., 2013a; Finsterer & Mahjoub, 2014; Murphy & 
Schepens Niemiec, 2014). 
 
2.3.2 The Neurophysiology of MS Perceived Fatigue 
In a recent review, Vucic et al. (2010) reported several neurophysiological 
mechanisms of MS-fatigue perceptions related to central nervous system dysfunction, 
from decreased gamma-aminobutyric acid activity, sodium (Na+) channel 
dysfunction, increased cortical activation and reduced glucose metabolism. 
Particularly in transcranial magnetic stimulation studies, an observation of 
intracortical inhibition in both the pre- and post- exercise is shown in PwMS who are 
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experiencing high levels of perceived fatigue (Perretti et al., 2004; Liepert et al., 2005). 
Intracortical inhibition is mediated by gamma-aminobutyric acid -generic inhibitory 
interneurons and -activity may be down regulated to compensate for the conduction 
that occurs in demyelinated pyramidal tract fibres (Vucic et al., 2010). Additionally, 
it has been shown that in highly fatigued PwMS, motor thresholds take longer to 
normalise during a post-exercise period compared to less-fatigued PwMS (Liepert et 
al., 2005). Motor threshold measures reflect membrane excitability, so this suggests a 
possible role of Na+ channel dysfunction in perceived fatigue. 
 
Magnetic resonance imagery studies have found that when conducting a simple motor 
task, PwMS have widespread cortical activation, including non-cortical areas (Reddy 
et al., 2000; Filippi et al., 2002; Rocca et al., 2002; Vucic et al., 2010). Notably, the 
increase in cortical activation may be an adaptive response to weakness that results 
from dysfunction in the motor pathways, thereby causing inducement of perceived 
fatigue (Vucic et al., 2010). Other studies reported impairments in cortico-subcortical 
interactions (which are utilised in motor planning and execution) and increased 
activation of the anterior cingulate cortex and basal ganglia in fatigued PwMS (Filippi 
et al., 2002; Calabrese et al., 2010; Rocca et al., 2014), leading to a higher perceived 
effort when executing a motor task (Filippi et al., 2002; Vucic et al., 2010). Functional 
brain imaging has also demonstrated that reduced glucose metabolism exists in the 
prefrontal cortex and basal ganglia in highly-fatigued PwMS compared to less- 
fatigued PwMS (Roelcke et al., 1997). Furthermore, this reduction in glucose 
metabolism was found to correlate with perceived fatigue severity (Roelcke et al., 
1997). Hypometabolism within grey matter structures might be a result of plaque 
deposits, iron deposition and neurodegeneration in people with MS (Haider et al., 
2014). For further details of neurostructural and neurophysiological differences 
between highly-fatigued (MS-HF) and less-fatigued (MS-LF) PwMS, see Chapter 4. 
 
2.3.3 The Neurophysiology of MS Fatiguability 
One of the main symptomatic manifestations of MS is muscle weakness and loss of 
strength and it is likely that the underpinning pathophysiology causing loss of strength 
is also linked to fatigability. Fatigability studies in PwMS have investigated changes 
in hand grip strength across repetitive movements, change in walking speed across 
time, and changes in sustained attention over time (Goldman et al., 2008a; Bruce et 
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al., 2010; Walker et al., 2012; Severijns et al., 2015; Wolkorte et al., 2015a, 2015b; 
Leone et al., 2016). Lower extremity muscles are more affected by muscle weakness 
than upper extremity muscles in PwMS (Benedetti et al., 1999; Dalgas et al., 2008; 
Souza et al., 2010), with 75% of PwMS reporting a lower-limb muscle strength defect 
(Benedetti et al., 1999; White et al., 2004; Dalgas et al., 2008; Souza et al., 2010), and 
66% reporting that upper-limb impairments have a dramatic effect on activities of 
daily living (Spooren et al., 2012). PwMS often exhibit reduced muscle strength during 
both dynamic (Armstrong et al., 1983; Lambert et al., 2001) and static (Armstrong et 
al., 1983; Schwid et al., 1999) muscle actions. The mechanisms underlying the 
observed strength deficit in PwMS are considered to be of both muscular and neural 
origin. Some studies (Formica et al., 1997; Kent-Braun et al., 1997; Garner & Widrick, 
2003) but not all (Lambert et al., 2002; Ng et al., 2004; Carroll et al., 2005) have 
indicated a loss of muscle mass in PwMS, which inevitably leads to relative reductions 
in muscle strength. Furthermore, the distribution of muscle fibre types may differ 
between PwMS and healthy controls, but the findings are inconsistent (Kent-Braun et 
al., 1997; de Haan et al., 2000; Garner & Widrick, 2003; Zijdewind et al., 2021). Neural 
mechanisms influencing loss of muscular strength in PwMS result from a reduced 
ability to fully activate motor units in the thigh and lower leg muscles (47–93%) during 
maximal voluntary contractions (MVCs) when compared with healthy controls (94–
100%; (Rice et al., 1992; de Haan et al., 2000; Ng et al., 2004). Other studies have 
shown an increased central motor drive during muscular contractions, which is likely 
to be a compensatory strategy allowing PwMS to generate a desired force despite the 
underlying neural pathology (Ng et al., 2004; Thickbroom et al., 2006) but potentially, 
with a concomitant increase in the perception of effort and consequent increase in 
fatigability. Thus, the underpinning physiological mechanisms causing impaired 
strength and physical function, in conjunction with an altered sense of effort to engage 
in everyday tasks, probably influence the magnitude of fatigability experienced by 
PwMS. 
 
2.4 Other Contributing Factors to MS-related Fatigue 
A broad range of secondary factors can contribute to MS-related fatigue and are 
important to consider in both assessment and management. Fatigue as a symptom may 
arise and be amplified as a result of numerous factors such as medical conditions 
including infections, injury to the brain, medication, psychiatric disorders (e.g., 
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depression, anxiety, etc.), pain, sleep disorders and unhealthy lifestyles (DeLuca, 
2005; DeLuca et al., 2008; Kos et al., 2008). This form a fatigue is referred to as 
secondary fatigue. Triggers and underpinning contributors of secondary fatigue can be 
identified by guided interviews (Ayache & Chalah, 2017). Factors such as depression 
and anxiety may be identified by key warning signs such as sadness, anhedonia, 
motivation loss, social isolation, nervousness and irritability. Sleep disorders such as 
sleep apnea, nocturia, nocturnal spasms, neuropathic pain, snoring or restless leg 
syndrome may also be a contributory cause of secondary MS-fatigue. Thyroid 
dysfunction (hypo- & hyper-thyroidism) could also cause conditions which influence 
symptoms of secondary fatigue, such as constipation, diarrhea, restlessness and cold or 
heat intolerance. Medications such as analgesics, anti-epileptics, anti- spasmodics or 
even immunosuppressants can have side effects which include fatigue. Other clinical 
deficiencies, such as anemia and vitamin D deficiency, have also been shown to lead 
to feelings of fatigue (Roy et al., 2014; Johnson & Sattari, 2015). 
 
2.4.1 Fatigue and Depression 
Depression is very common in PwMS, affecting almost half of the MS population 
(Feinstein, 2011; Giordano et al., 2011). Several studies have found an association 
between depression and MS-fatigue (Lobentanz et al., 2004; Bol et al., 2009; 
Kinsinger et al., 2010). In fact, depression and fatigue are two components of MS 
which often appear in conjunction and are strongly related (Bakshi et al., 2000; 
Kroencke et al., 2000; Chwastiak et al., 2002; Schreurs et al., 2002; Voss et al., 2002; 
Lobentanz et al., 2004; Patrick et al., 2009), although the causality of the relationship 
has not yet been established (Kos et al., 2008). In addition, mood and behavioral 
changes may be prominent symptoms at MS presentation but can remain under- 
diagnosed in PwMS (Skegg et al., 1988) and may also be observed in early stages of 
the disease (Sullivan et al., 1995). It has also been found that anxiety and depression 
levels can be elevated during peri-diagnostic periods (Mattarozzi et al., 2012) or 
during periods of increased MS activity (Legge et al., 2003; Moore et al., 2012). In a 
longitudinal follow-up study including 236 PwMS over a period of 5 years, it was 
found that clinical anxiety, depression and fatigue were frequent in the early stages of 
the disease and that the co-occurrence of these three conditions was in total 3.76 times 
higher than the expectation under statistical independence, suggesting these three 
symptoms tend to cluster together in the disease process (Simpson et al., 2016). 
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Interestingly, a magnetic resonance imagery study which investigated the involvement 
of specific regional patterns of lesion distribution and GM, as well as WM atrophy, on 
the experience of fatigue in PwMS, revealed an interesting link with symptoms of 
depression (Gobbi et al., 2014b). The researchers recruited 123 PwMS and 90 controls 
and acquired 3D T1-weighted images on which Voxel-based morphometry was 
performed to assess lesion distribution, GM and WM atrophy. They found that GM 
atrophy within the frontal, parietal and occipital lobes showed a mutual effect for 
depressed as well as fatigue patients. Additionally, atrophy specifically in the left 
middle frontal and right inferior frontal gyrus was found to be solely related to 
depression, concluding that atrophy within the aforementioned cortical areas is linked 
to depression and that more distributed GM atrophy contributes to the concomitant 
occurrence of fatigue and depression in PwMS (Gobbi et al., 2014a; Gobbi et al., 
2014b). Thus, it seems that GM atrophy in specific brain regions is more linked to 
symptoms of depression rather than fatigue. A further positron emission tomography 
study (Brody et al., 2001) examined the association between change in depressive 
symptoms and change in regional brain metabolism following treatment for 
depression. The findings indicated that a decrease in bilateral ventral prefrontal cortex 
activity correlated with a decrease in fatigue before and after treatment. 
 
2.4.2 Fatigue and Sleep Disorders 
Sleep quality is an important factor to consider in the assessment of MS-related 
fatigue. Sleep disturbances are common in PwMS (Fleming & Pollak, 2005; Bamer et 
al., 2008) and are associated with an increase in the perception of fatigue in this 
population (Veauthier et al., 2011; Veauthier & Paul, 2014). Around 87% of PwMS 
have reported poor sleep (Ghaem & Borhani Haghighi, 2008) and whilst the exact 
relationship and interaction between fatigue and sleep quality, including the disorders 
of sleep and quantity of sleep are meaningful, it remains to be fully understood 
(Induruwa et al., 2012). An increasing appreciation for the importance of the influence 
of sleep disorders on MS-fatigue has arisen over the last few years, with reports of 
reduced sleep quality in PwMS being twice as high as in healthy controls and often 
being associated with pain, spasms, medication, disorders of bladder control, anxiety 
and other external factors (Clark et al., 1992; Tachibana et al., 1994; Lobentanz et al., 
2004; Stanton et al., 2006). Some studies investigating the relationship between 
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fatigue and sleep in PwMS found no relation between fatigue and sleep-wake rhythm, 
difficulties falling asleep, early wakening and nocturnal apneas or oxygen 
desaturations (Taphoorn et al., 1993; Wunderlin et al., 1997; Stanton et al., 2006), 
whilst moderate correlations between fatigue and disruptions of sleep by nocturnal 
activity and middle insomnia (i.e. waking during the night; Stanton et al. (2006)) could 
be identified. Other studies indicated that disruptions and deviations of circadian 
rhythm, sleep architecture and cycles, daytime sleepiness, nocturnal activity and 
waking due to nocturia were important factors in the relationship between fatigue and 
sleep disorders amongst PwMS (Attarian et al., 2004; Hossain et al., 2005; Kaynak et 
al., 2006; Stanton et al., 2006; Braley & Chervin, 2010; Kaminska et al., 2012). 
 
The causality between fatigue and sleep disorders is not explained by the 
abovementioned relationships (Kos et al., 2008) and many studies have come to the 
conclusion, that a differentiation between fatigue and daytime sleepiness is necessary 
(Hossain et al., 2005; Stankoff et al., 2005; Merkelbach et al., 2006; Stanton et al., 
2006). In light of the above, the importance and potentially confounding influence of 
depressive symptoms on the complex interaction between sleep disorders and fatigue 
has been highlighted (Kaynak et al., 2006). This exemplifies the complexity of MS- 
fatigue and attempts to delineate primary (disease pathology-related) from secondary 
factors brought about by other accompanying disorders such as depression and poor 
sleep quality. Improved sleep quality recently has been shown to be a relieving factor, 
and poor sleep quality as an aggravating factor of self-reported MS-fatigue (Mills & 
Young, 2008). However, no studies as yet give evidence if and how sleep quality 
contributes to fatigability. 
 
2.4.3 Fatigue, Pain and Quality of Life 
Pain has been recognised as a symptom of MS since the first descriptions of the disease 
and can broadly be classified as nociceptive or neuropathic (O'Connor et al., 2008). 
The overall point prevalence of pain in MS is around 50% (O'Connor et al., 2008) and 
it is often ranked by patients as one of the most distressing symptoms of the disease 
(Kalia & O'Connor, 2005). In spite of the prevalence and clinical importance of pain 
in MS, its mechanisms remain poorly understood. One case-control study in women 
with relapsing remitting MS found that pain and pain intensity were significantly 
greater in the relapsing remitting MS group in comparison to healthy controls 
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(Newland et al., 2009), likely due to the clinical disease of MS. Additionally, five 
different MS body pain syndromes were identified within the literature, all 
neuropathic from pseudo-radicular pain (Ramirez-Lassepas et al., 1992; Tosi et al., 
1998; Marchettini et al., 2006), dysesthetic pain (Burkey & Abla-Yao, 2010; Deppe et 
al., 2013), painful itching (Hellwig et al., 2006), painful tonic spasms (Andrade et al., 
2012) and visceral pain (Marchettini et al., 2006). The identification/location of 
neurological lesions was thought to explain the body pain syndromes, as these were 
located in the spinal cord, except for painful tonic spasms, where lesions were 
identified in the pyramidal tract in the brain (Andrade et al., 2012). In this sense, pain 
is likely to be linked to fatigue due to the central origin and might be directly disturbing 
sensory afferent pathways, or by disrupting descending inhibitory pathways 
(Svendsen et al., 2011). Further investigations are warranted. 
 
Quality-of-life (QoL) is defined as individual perception of their position in life in the 
context of the culture and value systems in which they live and in relation to their 
goals expectations, standards and concerns (Huh et al., 2014). Several studies have 
reported that QoL is worse in PwMS in comparison with healthy controls with a higher 
prevalence of depression and fatigue (Murphy et al., 1998; Amato et al., 2001; 
Lobentanz et al., 2004; Pittion-Vouyovitch et al., 2006; Kargarfard et al., 2012). One 
small study of 31 PwMS showed that increased fatigue intensity was a predictor of 
decreased physical QoL (Newland et al., 2009). The aforementioned symptoms are 
important, and all play a role in MS-fatigue, as such the thesis will measure them 
accordingly. 
 
2.4.4 Relationship Between Perceived Fatigue and Fatiguability 
Some studies have failed to associate perceived fatigue and fatigability (Krupp & 
Elkins, 2000; Lou et al., 2003; Bailey et al., 2007), while others have shown an 
association (Goldman et al., 2008b; Bruce et al., 2010; Severijns et al., 2015) . These 
previous studies may have failed to establish a relationship because fatigue and 
fatigability are poorly understood, and self-reported fatigue scales do not accurately 
capture the perception of fatigue (perceived fatigue) in relation to change in physical 
performance (fatigability). The extent to which high levels of MS perceived fatigue 
and more pronounced fatigability are the result of the disease process per se (i.e., 
demyelination and axonal degeneration in the central nervous system) or secondary 
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factors is difficult to delineate at the individual level, and the extent to which both 
constructs can be modulated by therapeutic interventions (e.g., exercise rehabilitation) 
is unknown. 
 
2.5 Exercise Therapy for Fatigue in MS 
2.5.1 Introduction to Therapeutic Exercises 
Clinical fatigue treatments for PwMS have primarily focused on the effectiveness of 
pharmacological and psychosocial interventions, however, their efficacy has been 
found to be modest at best and most often reported to be ineffective (refer to review 
(Lee et al., 2008). Alternative approaches to fatigue management are clearly needed 
and treatment modalities that can be incorporated into long-term self-management 
strategies would have particular appeal to PwMS, their carers and healthcare 
providers. One highly promising approach to managing MS-fatigue is exercise (Pilutti 
et al., 2013; Heine et al., 2015). Exercise is reported as a safe, non-pharmacological 
treatment strategy for PwMS, with numerous systematic reviews highlighting many 
health benefits, including improvements in muscle power, fatigue, physical and 
psychosocial functioning and quality of life (Rietberg et al., 2005a; Motl & Gosney, 
2008; Asano et al., 2009; Kluger et al., 2013a). However, despite the known health 
benefits of exercise, PwMS are considered to be relatively inactive (Motl et al., 2005; 
Sandroff et al., 2012), which might place them at a higher risk of developing secondary 
health complications associated with inactivity (Motl & Goldman, 2011), in particular 
cardiovascular disease (including, stroke, peripheral artery disease etc.) and type 2 
diabetes (Motl et al., 2005; Lee et al., 2012). Other studies have explored the barriers 
and facilitators of exercise in PwMS (Kayes et al., 2011; Asano et al., 2013) but there 
is a lack of in-depth understanding about how these translate to MS-fatigue 
management. 
 
Nowadays, a combination of pharmacological and/or non-pharmacological treatments 
(which may include exercise) are often recommended in the fatigue management plan. 
Medications such as Amantadine, Pemoline, and Modafinil are frequently used in an 
attempt to lessen fatigue and its effects in PwMS (Krupp et al., 1988; Janardhan & 
Bakshi, 2002), whereas non-pharmacological interventions include education to avoid 
extreme weather conditions like heat and humidity, addressing lifestyle factors like 
diet and exercise, learning strategies for energy conservation, and adapting to work 
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and household environments (Krupp et al., 1988; Merkelbach et al., 2002; Shah, 
2009). However, a review by Khan et al. (2014) showed that the effects of 
pharmacological and non-pharmacological treatments of fatigue in the MS population 
vary considerably, and that the best treatment option for MS-fatigue is often difficult 
to determine. There is no standardised agreement for the recommended dose of 
structured exercise or physical activity for fatigue management in PwMS. World 
Health Organisation Guidelines on physical activity and sedentary behaviour 
(published 25th November 2020) recommends similar to the general population, that 
the traditional interventions are based around 30–60 minutes of moderate-intensity 
aerobic activity, 3 days per week, and/or 2–3 sessions of resistance training per week 
to enhance functional capacity and prevent falls 
(https://www.who.int/publications/i/item/9789240015128). Similarly for PwMS, 
Dalgas et al. (2008) recommended 10 to 40 minutes of moderate intensity aerobic 
activity (2-3 days per week) and moderate intensity (1-4 sets of 8-15 repetition) 
resistance training (2-3) days per week. The American College of Sports Medicine 
(ACSM) recommends 30 min of moderate intensity aerobic activity (3 days per week; 
Ferguson (2014)). Latimer-Cheung et al. (2013) recommend 30 min of moderate 
intensity aerobic exercise (2 days per week) and strength training for major muscle 
groups (2 days per week). These guidelines are aimed at PwMS who are mildly or 
moderately affected by the condition and the activities used in the guidance are 
structured forms of exercise. Nonetheless, there is no specific MS guidance that 
considers how the broad range of physical activity options should be used to manage 
MS-fatigue. Clinical guidance in the UK recommends the use of exercise as one 
strategy in the management of PwMS, including MS-fatigue (NICE, 2014). These 
recommendations focus on moderate progressive resistance training, aerobic, balance 
and stretching exercises to improve mobility and symptom severity. 
 
2.5.2 Resistance Exercise 
Prior to 1990, resistance exercise was not a part of the recommended guidelines for 
exercise training and rehabilitation for either the American Heart Association or the 
ACSM. In 1990, the ACSM first recognized resistance training as a significant 
component of a comprehensive fitness program for healthy adults of all ages 
(Ferguson, 2014). In this respect, resistance training shows particular promise for 
reducing the impact of MS, including symptoms of fatigue (Dalgas et al., 2010; Dodd 
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et al., 2011). The optimal method of achieving a resistance training effect depends on 
many factors and approaches have varied in the literature, with many studies using 
resistance machines, some using body weight, and one study using resistance bands. 
From these, no single form suggests particular benefits over the other, however, access 
to resistance machines may be limited for some PwMS due to either geographical 
location or physical ability. Thus, free weights or exercises which use body weight or 
resistance bands as the form of resistance may offer a more practical solution. 
Furthermore, resistance training offers advantages in that it can easily be done at home 
for individuals with mobility difficulties, and the intensity/amount of resistance 
applied can easily be modified throughout. However, a major limitation of current 
studies examining the effects of exercise training, including resistance training, on 
fatigue is that participants have not been recruited on the basis that they are 
experiencing severe levels of fatigue (Pilutti et al., 2013; Motl et al., 2017) and in 
many studies, fatigue has been a secondary outcome. 
 
A systematic review of exercise therapy and fatigue in PwMS suggested that resistance 
training may have more consistent fatigue-reducing effects than aerobic exercise but 
fewer well controlled trials have studied this exercise modality (Andreasen et al., 
2011). One single-blind randomised controlled trial trained severe fatigue PwMS three 
times a week for duration of 16 weeks of high activity aerobic exercise, and did not 
show a clinically meaningful reduction in fatigue or societal participation when 
compared to a low-intensity control intervention (Heine et al., 2017). Randomised 
controlled trials that have investigated the effects of resistance training on fatigue in 
PwMS have reported significant improvements in symptoms (Dalgas et al., 2010; 
Ushiyama et al., 2010; Dodd et al., 2011; Hayes et al., 2011b; Sabapathy et al., 2011). 
These studies and others showed improvements in self-reported fatigue following 8- 
12-week programmes of twice-weekly resistance exercise (White et al., 2004; 
Gutierrez et al., 2005; Dalgas et al., 2010; Dodd et al., 2011), whereas other studies 
incorporating higher volumes of aerobic exercise (e.g. thrice-weekly aerobic exercise 
for 12-15 weeks) showed no effect (Petajan et al., 1996; Geddes et al., 2009). A 
randomised controlled trial that did not to show an effect on fatigue symptoms 
compared thrice-weekly high-intensity eccentric resistance exercise with standard 
exercises (Hayes et al., 2011b) but this type of high intensity resistance exercise is 
atypical and might not be suitable for all patients. 
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Several further resistance training studies adopted an experimental methodology with 
no control group (White et al., 2004; Gutierrez et al., 2005; Taylor et al., 2006b; Ayán 
Pérez et al., 2007; Filipi et al., 2010). Another study used a “within subjects” controlled 
design (de Souza-Teixeira et al., 2009). The remainder adopted a randomised 
controlled trial design (DeBolt & McCubbin, 2004; Dalgas et al., 2010; Broekmans et 
al., 2011; Dodd et al., 2011; Hayes et al., 2011a). However, there is a risk of bias with 
studies often not achieving assessor blinding and failing to use an intention to treat 
paradigm when analysing results from a fatigued group of PwMS. In addition, more 
studies that exclusively recruit highly fatigued PwMS are needed to better understand 
the impact of exercise programmes on this debilitating symptom. Additionally, 
differences between studies with respect to training variables included, the intensity 
of resistance exercise (Muellbacher et al., 2000), type of muscle contractions 
(Howatson et al., 2011), degree of fatigue, and the external pacing of muscular 
contractions (Leung et al., 2015) might affect the adaptations in motor cortex and 
perception of fatigue experienced in PwMS. 
 
Resistance exercise training may be a better system of exercise training for evoking 
sustained improvements in fatigue as it is easily transferrable to the home environment 
through body resistance, weighted vest and thera-band exercises (Taylor et al., 2006b). 
There is evidence of high adherence to home-based resistance training as well as 
improvements in leg extensor power (White et al., 2004; Taylor et al., 2006b). One 
study that encouraged PwMS to maintain progressive resistance exercise (PRE) after 
a 12-week period of supervision at home showed a sustained improvement in fatigue 
up to 24 weeks, though this was not significant (Fimland et al., 2010). The venue of 
many of the studies has been hospital or university laboratories, however these studies 
show that it may be more effective for long term continuation of the exercise 
programme to allow study participants to undertake exercise in the home-environment 
or community leisure facility – particularly if participants can somehow be remotely 
supported. Doing so, also fits well with government guidelines which encourages 
community rehabilitation (Scottish Executive, 2007). Taylor et al. (2006b) and Dodd 
et al. (2011) have shown this is feasible by carrying out interventions in community 
spaces. Furthermore, a systematic review did not find any evidence of adverse events 
or symptom exacerbations in studies of resistance training in PwMS (Motl et al., 2008; 
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Asano et al., 2009). Another potentially important issue is that aerobic exercise can 
present problems for PwMS with ambulatory difficulties and can raise the body’s core 
temperature to levels that can exacerbate symptoms in thermosensitive PwMS. 
Resistance training overcomes both these problems, as exercises can be performed in 
fully supported (or seated) positions and core temperature does not increase to the 
same extent (White et al., 2004). 
 
2.5.3 External Pacing of Resistance Training 
Co-coordinated movements and rhythmic perception are intuitively connected. 
Cognitive neuroimaging studies have found motor areas in the brain are involved in 
perceiving the beat when listening to musical rhythms, suggesting a connection 
between the cerebral auditory and motor system (Grahn & Brett, 2007; Chen et al., 
2008). Hence, resistance training using simple movements might be synchronised to 
sound and therefore improve connectivity between motor and auditory areas (Thaut & 
Thaut, 2005). People with MS with low physical activity levels have been suggested 
to inappropriately use activity pacing as a reactionary response to their multiple 
sclerosis symptoms (Abonie et al., 2020). Hence, the use of pacing devices during 
resistance training (e.g., a metronome) might increase brain activation during 
movement, promote neuroplastic adaptations and pacing response (Abonie et al., 
2021). The use of externally paced resistance training with an audible metronome was 
shown to produce a large magnitude of cross-education in the lower limb in healthy, 
untrained individuals (Goodwill & Kidgell, 2012). This may be due to the increased 
cognitive demand and control of movement pattern, which likely results in greater use- 
dependent neuroplasticity (Ackerley et al., 2011; Leung et al., 2015). For example, 
Leung et al. (2015) investigated the effects on excitability and inhibition of a single 
bout of visuomotor tracking compared with self-paced resistance training and 
metronome-based resistance training and found that both skilled training and 
metronome-paced resistance training, but not self-paced resistance training, increased 
excitability and released inhibition in both the trained limb and in the untrained limb. 
This has implications for rehabilitation: for example, an improved understanding of 
the methods that maximise the opportunity for neuroplasticity may result in an 
important progression in how we prescribe exercise-based rehabilitation for motor 
performance, fatigue perception and potentially restoration of the corticospinal control 
of the muscle in PwMS. 
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2.5.4 Neural Adaptation to Resistance Training 
An increase in force is a common result of resistance training, even with studies of 
short duration (Hood & Forward, 1965; Gabriel et al., 1997; Holtermann et al., 2005; 
Schnelle et al., 2012). Some studies have reported an increase in rate of force 
development as a common finding (Aagaard et al., 2002a; Brown & Whitehurst, 2003; 
Gruber et al., 2007; Holtermann et al., 2007a; Holtermann et al., 2007b), with 
improvements seen in as little as two days (Brown & Whitehurst, 2003). Additionally, 
changes in muscle activation, such as increases in motor neuron firing rate (Van 
Cutsem et al., 1998; Patten et al., 2001; Klass et al., 2008) and decreases in motor 
neuron recruitment threshold (Cracraft & Petajan, 1977; Adam et al., 1998; Van 
Cutsem et al., 1998), are commonly implicated among early neural adaptations to 
strength training (Aagaard et al., 2002b; Holtermann et al., 2007a). Numerous studies 
have shown an increase in level of muscle activation, as measured via surface EMG, 
subsequent to strength training (Knight & Kamen, 2001; Aagaard et al., 2002a; Gruber 
et al., 2007). 
 
Furthermore, there are a number of studies that have employed transcranial magnetic 
stimulation to investigate the integrity of the corticospinal pathway following a single 
session of strength training (Hendy & Kidgell, 2014; Leung et al., 2015; Latella et al., 
2016; Nuzzo et al., 2016; Latella et al., 2018). For example, a single session of heavy- 
load elbow flexion strength training increased MEPs evoked by single-pulse 
transcranial magnetic stimulation (Leung et al., 2015). Neuroplastic adaptations 
evoked by resistance training could reduce or eliminate the need for compensatory 
downregulation of inhibitory cortical neural pathways, with evidence showing that 
SICI reduces following a single session of strength training in healthy controls, 
suggesting improved motor performance (Hendy & Kidgell, 2014; Leung et al., 2015; 
Latella et al., 2016; Latella et al., 2018). However, further investigation is needed to 
determine whether such resistance-training effects are possible in PwMS and if so, 
what impact they may have on MS-fatigue. 
 
Several studies have provided evidence of neuroplasticity (including cortical 
plasticity) in response to habitual exercise and physical inactivity/immobilisation 
(Hortobagyi et al., 2009; Falvo et al., 2010; Kidgell & Pearce, 2010; Ushiyama et al., 
2010; Carroll et al., 2011; Weibull et al., 2011; Langer et al., 2012). Interestingly, 
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short-term programmes of resistance training have shown an increase in central motor 
activation (Folland & Williams, 2007), enhanced neural economy (Falvo et al., 2010) 
and adaptations in corticospinal inhibitory mechanisms (Kidgell & Pearce, 2010) in 
healthy volunteers. In PwMS, a 3-week programme of lower-limb resistance training 
resulted in an increase in motor output from spinal motor neurons (Fimland et al., 
2010), consistent with an augmented descending drive from higher centres (Aagaard 
et al., 2002b). 
 
2.6 Summary 
In an attempt to understand and reduce MS-related fatigue, this chapter has provided 
evidence that MS-fatigue is multi-factorial, with interplay of perceived (self-reported) 
and fatiguability components. Although there is still a lack of well-conducted trials 
which precludes any definitive conclusions as to the potential mechanisms underlying 
MS-fatigue, there is evidence to suggest that PwMS experiencing high levels of fatigue 
are ‘neurophysiological different’ to less-fatigued PwMS. Additionally, there is 
evidence that resistance exercise is capable of inducing neuroplastic adaptations which 
may have a positive impact on MS-fatigue symptoms. With these points in mind, the 
first aim of this thesis was to provide a greater understanding of the neurostructural 
and neurophysiological aetiology of MS-fatigue. Secondly, to investigate the 
feasibility and early indicative efficacy of externally paced resistance exercise training 
as a strategy for reducing MS-fatigue symptoms in PwMS. 





















CHAPTER 3 – GENERAL METHODS 
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3.1 Introduction 
This chapter describes the common methods used for the experimental work contained 
within this thesis. Additional detail, which is only specific to individual chapters, is 
further described in the methods section of the relevant chapter. 
 
3.2 Pre-Test Procedures 
3.2.1 Ethical Approval 
Institutional ethical approval was received from the Northumbria University, Faculty 
of Health & Life Sciences Ethics Committee (HLSPE111114: Chapters 5 and 6 and 
HLSPE010216: Chapter 7, Appendix 1), in accordance with the ethical standards and 
principles of local ethics committees, as established in the Declaration of Helsinki 
(1975, as revised in 2013). Chapters 5-7 received additional ethical approval from the 
respective Newcastle upon Tyne National Health Service Hospital Review Committee 
(14/LO/2290: Chapter 5 - 6 and 16/SS/0142 Chapter 7, Appendix 2). 
 
3.2.2 Health and Safety 
All experimental research was carried out in hospitals of the Newcastle upon Tyne 
national health service Foundation Trust (i.e., Royal Victoria Infirmary and the 
Newcastle General Hospital), in accordance with established Newcastle upon Tyne 
national health service Foundation Trust health and safety policies and standard 
operating procedures. Prior to, and following all experimental work, the assessment 
room and all apparatus were cleaned using alcohol wipes (PMC0062, Clinell 
Universal Sanitising Wipes), in accordance with relevant national health service 
guidelines. During each session of data collection, the lead researcher and one nurse 
(Band 6) were present throughout, both qualified in emergency first aid and use of an 
automated external defibrillator. Experiments were stopped prematurely if the 
participant displayed signs of discomfort, syncope or nausea. In the likelihood of an 
adverse event, the participant would be moved to the hospital ward on the same floor 
and monitored by the lead researcher and clinical team until any adverse physiological 
responses subsided. Participants were informed they could stop an experiment 
prematurely at any time and were under no obligation to provide a reason. 
Additionally, in Chapter 7, participant reasons for drop-out were recorded to ascertain 
feasibility outcomes. Participants were informed to contact the lead researcher if prior 
to the visits they felt unwell so that experimental sessions could be reorganised. In the 
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unlikely case that the participant presented any adverse symptoms related to their MS, 
the lead researcher contacted the clinical team for a review. 
 
3.3 Participants 
Clinically diagnosed people with definite relapsing-remitting multiple sclerosis 
(relapsing remitting MS) were selected and recruited according to the Poser criteria 
(Poser et al., 1983; McDonald et al., 2001). Disease severity was determined by a 
consultant neurologist using the Expanded Disability Status Scale (EDSS, refer to 
Figure 3.1) with 0.0 representing “normal neurological function” and 10.0 representing 
“Death”. A visual representation of the EDSS is shown in Figure 3.1 (Kurtzke, 1983). 




Figure 3.1 Visual representation of the EDSS (Adapted from Kurtzke, 1983). 
 
In Chapters 6 and 7, PwMS were divided into two sub-groups, 'Highly-Fatigued 
PwMS' (MS-HF) and 'Less-Fatigued PwMS' (MS-LF). High levels of MS-fatigue 
were defined using a Fatigue Severity Scale (FSS) cut-off score ≥ 5 (Krupp et al., 
1989). Please refer to the overview of thesis participant characteristics presented in 
Table 3.1. 
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Table 3.1 Overview of Thesis Participant characteristics (Mean ± SD). 
 
















FSS: Fatigue Severity Scale; HADS: Hospital and Anxiety Depression Scale; HC: Healthy Controls; MS-LF: Less-Fatigued 
People with Multiple Sclerosis; MS-HF: Highly-Fatigued People with Multiple Sclerosis N: Numbers; F: Females; M: Males; 




Furthermore, selection of participants was based on the participant’s medical notes 
and the inclusion and exclusion criteria (see Table 3.2). For the experimental Chapters 
5 and 6, a cohort of age- and gender- matched healthy participants were also recruited 
as a comparison group and assessed for eligibility to take part via study-specific 




MS-LF MS-HF Exercise Control 
N 20 20 20 16 17 
Age (years) 44.8 ± 15.1 45.9 ± 9.0 43.6 ± 10.2 51.7 ± 9.3 48.2 ± 7.7 
Gender (F/M) 13/7 15/5 15/5 12/4 11/6 
EDSS (arbitrary - 
units) 
2.1 ± 1.2 2.4 ± 1.4 2.7 ± 1.4 3.3 ± 5.3 
Disease Duration - 
(years) 
9.3 ± 3.8 9.9 ± 5.5 10.8 ± 4.5 8.8 ± 4.4 
Disease - 17/3 14/6 13/3 15/2 
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■ Adults >18 years with definite multiple sclerosis (Poser criteria) 
■ EDSS score of 0.0-5.0 (Kurtzke, 1983). 
■ FSS ≥ 5 (highly-fatigued group); FSS < 5 (less-fatigued group) 
(Krupp et al., 1989) 
■ Able to walk without rest or aid for 300 metres (as defined by 
EDSS). 
■ Able to understand spoken and written English and stage two 
instructions. 
■ Clinically stable (no relapses) for at least 4 weeks prior to 
entering the study. 
■ Stable on disease modifying therapy (Interferon, Glatiramer 
Acetate, Mitoxantrone and Natalizumab) for at least 3 months 
prior to entering the study. 
■ No contra-indications to transcranial magnetic stimulation or 
other neurophysiological measurements (Rossi et al., 2009). See 
Appendix 3. 
■ Must be able to provide written informed consent. 
■ Right handedness and have normal function of the right limbs 




■ Any other conditions that may be associated with fatigue, e.g., 
anaemia, dementia, alcoholism, implanted pacemaker, metal 
implants, and pregnancy. 
■ Medication taken within the past 3 months, which may directly 
affect level of fatigue (Amantadine, Modafinil). 






■ Adults >18 years. 
■ No contra-indications to transcranial magnetic stimulation or 
other neurophysiological measurements (Rossi et al., 2009). See 
Appendix 3. 
■ Must be able to provide written informed consent. 
■ Able to understand spoken and written English and stage two 
instructions. 
■ Right handedness and have normal function of the right limbs 






■ Any other conditions that may be associated with fatigue, e.g., 
anaemia, dementia, alcoholism, implanted pacemaker, metal 
implants, and pregnancy. 
■ Medication taken within the past 3 months, which may directly 
affect level of fatigue. 
 
3.3.1 Recruitment 
Participants were recruited from the Neurology Department outpatient’s clinic at the 
Royal Victoria Infirmary Hospital, Newcastle upon Tyne, UK between April 2015 and 
June 2018 for Chapters 5 to 7 via voluntary response to advertising flyers, clinic 
attendance and postal letters of invitation, with further details being provided below: 
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• Advertising flyers were placed in the waiting room of the neurology 
outpatient clinics and day unit clinics (i.e., day unit for Lemtrada, an 
intravenous infusion disease modification treatment. Potential eligible PwMS 
were invited to speak to the lead researcher and/or a MS specialist 
nurse/consultant neurologist and a participant information sheet was sent out 
(Appendix 5). Followed two-weeks later with a follow-up phone call. 
• Patient referral from the neurology outpatient clinics. Eligible PwMS were 
referred by an MS Specialist Nurse and/or Consultant Neurologist to the lead 
researcher, who attended three weekly clinics. A participant information sheet 
was provided, with a follow-up phone call two-weeks later. 
• Postal letters of invitation were sent out to eligible PwMS who matched the 
inclusion and exclusion criteria assessed by an MS Research Nurse (see 
Appendix 6), followed two-weeks later with a follow-up phone call. 
Further details of each recruitment method can be found within each chapter. 
 
 
For Chapters 5 and 6, a cohort of healthy volunteers was recruited using flyers and 
posters in local community centres and universities and screened for eligibility by the 
lead researcher. For Chapter 7, participants from Chapters 5 and 6 who previously 
expressed interest in participating in further research, were identified from database 
records by the lead researcher and MS Specialist Nurse before the study information 
(i.e., letter of invitation and participant information sheet) was sent out. Thereafter, 
potential participants were advised to phone contact the MS Research Nurse for 
eligibility criteria screening and were then invited for an informed consent visit. 
 
3.3.2 Informed Consent 
Prior to entering the study and <5 days prior to the familiarisation visit, eligible 
participants were invited to attend a preliminary visit with the lead researcher and a 
MS Research Nurse in the Clinical Research Facility at the Royal Victoria Infirmary 
Hospital, Newcastle upon Tyne, to complete the informed consent documentation 
(Appendix 7). Participants were also required to complete the FSS (Appendix 8) and 
HADS (Appendix 9), as it is often reported that depression and anxiety are co-existing 
symptoms amongst PwMS and may explain some of the variance of MS-fatigue 
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Participants attended a ~1-hour familiarisation visit to go through the experimental 
procedure of the measures to be assessed, to be screened for any contra-indications to 
transcranial magnetic stimulation and/or other neurophysiological measurements 
(Rossi et al., 2009) and to complete the patient-reported outcome questionnaires. Any 
participant presenting a contraindication was excluded and provided with an 
explanation for their exclusion, with any uncertainty being followed-up with the 
clinical research team, including the Consultant Neurologist and MS Specialist Nurse. 
Data collected during familiarisation were not used for subsequent analysis. 
 
3.5 Experimental Criterion 
Demographic data (including gender, age, disability, type of MS), comorbidities, 
disease modification treatment and additional medication were recorded. All 
experimental testing was performed at the same time of the day (± 2 h) to control for 
diurnal variations in corticospinal excitability and inhibition (Tamm et al., 2009; Lang 
et al., 2011) Participants were instructed to arrive at the hospital in a rested state, to 
avoid strenuous exercise in the 48-hours preceding assessment sessions and to refrain 
from caffeine intake 24-hours prior to testing (Taylor et al., 2006a; de Carvalho et al., 
2010) Moreover, participants were advised to wear a loose-fitting short-sleeved top, 
shorts and sports trainers. For safety reasons, they were advised to contact the lead 
researcher if they felt an oncoming exacerbation of MS (i.e., relapse, attack or flare- 
up) and, in such circumstances, the experimental testing session would be reorganised. 
To encourage recruitment amongst participants living in Newcastle and surrounding 
areas of the North East of England, reimbursement of taxi travel was available for all 
roundtrips to hospital. 
 
3.6 Neuromuscular Assessment 
All neuromuscular assessments presented in Chapters 5 to 7 were performed at the 
Clinical Research Facility, located in the Royal	 Victoria	 Infirmary	 Hospital. 
Participants were required to visit the laboratory on two separate occasions for knee 
extensor and wrist flexor muscle assessments, performed in a randomised order with 
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a minimum of 48-h between visits. During the neurophysiological assessments, 
participants were comfortably seated upright with the involved limb fixed into position 
with a custom-made adjustable isometric dynamometer (see Figure 3.2). Additional 




Figure 3.2 The custom-modified and adjustable isometric dynamometer set-up for the 
(A) wrist-flexor and (B) knee-extensor muscles. 
 
3.6.1 Force and Electromyography Recordings 
Calibrated load cells recorded muscle force in Newton’s (N), during an isometric 
maximal voluntary contraction of the knee extensors and wrist flexors. For each 
participant, the height of the load cell was adjusted at the beginning of each trial to 
ensure that force was applied in a direct line tangentially to the joint axis of rotation. 
Wrist flexor force was measured using a calibrated load cell (NL62, Neurolog, 
Digitimer, Welwyn Garden City, Hertfordshire, UK) attached to a flat metal plate 
positioned midway in the palm of the right hand. The arm and wrist were immobilised 
and positioned using a goniometer at 45° angle away from the right shoulder during 
voluntary contraction (Langer et al., 2012; as shown in Figure 3.2.A). Knee extensor 
force was measured using a calibrated load cell (NL63, Neurolog, Digitimer, Welwyn 
Garden City, Hertfordshire, UK), connected to an adjustable strain gage and non- 
compliant strap, attached superior to the ankle malleoli. Hip, knee and ankle angle 
were measured using a goniometer and set at 90° of flexion, supported with a seatbelt 
to restrict rise of the hips during voluntary muscle actions of the knee-extensors. 
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Visual feedback was displayed on a screen in front of the participant during voluntary 
and evoked muscle actions, to assist in providing maximal efforts during MVC 
(Baltzopoulos et al., 1991). 
 
Skeletal muscle activity during voluntary and evoked muscle actions of the rectus 
femoris (knee-extensor muscle) and flexor carpi radialis (wrist-flexor muscle) were 
recorded from pairs of surface Ag/AgCI electrodes (1041PTS-Kendall, Henley’s 
medical supplies, Welyn Garden City, Herts, UK). Prior to attachment of electrodes 
and to reduce impedance, the participant’s skin was shaved (if required) and cleaned 
with an alcohol wipe. Then, following palpation of the muscle under a resisted 
contraction, the electrodes were spaced parallel to the alignment of muscle fascicles 
and 2 cm apart over the muscle belly (Rainoldi et al., 2004). The placement of EMG 
electrodes was marked with indelible ink and recorded on acetate in relation to 
anatomical landmarks based on SENIAM guidelines to ensure they were placed in the 
same location at both assessment visits. Reference electrodes were placed over the 
patella and the olecranon process, respectively. In addition, antagonist muscle activity 
was recorded from the biceps femoris (knee-extensor muscle) and the extensor carpi 
radialis (wrist-flexor muscle), as antagonist activation can affect the measurement of 
agonist voluntary activation when using the interpolation twitch technique (Todd et 
al., 2004, 2016). The maximal EMG amplitude during the MVC was quantified as the 
root-mean-square (RMS) value during a 0.5 s interval that spanned the peak of the 
EMG. In other assessments, EMG responses were recorded from transcranial 
magnetic stimulation motor evoked potentials (MEPs) and compound muscle action 
potential (M-wave) from percutaneous nerve stimulation, these are explained in further 
detail below. The EMG (gain × 1000; Cambridge Electronic Design [CED] 1401, 
Cambridge, UK) and force (gain × 300; CED 1902, Cambridge, UK) signals were 
amplified, then band-pass filtered (EMG only; 20-2000 Hz), digitised (4 kHz; CED 
micro1401, Cambridge, UK) and acquired for later off-line analysis on a password 
secured laptop (Spike2 v6, CED, UK). 
 
3.7 Percutaneous Nerve Stimulation 
Percutaneous nerve stimulation of the femoral and ulnar nerve was administered using 
single electrical stimuli (200 µs pulse width, 100 Hz) via a constant-current stimulator 
(DS7AH, Digitimer Ltd., Hertfordshire, UK) to elicit a maximum M-wave (Mmax) in 
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the rectus femoris and flexor carpi radialis muscles, used to assess changes in 
membrane excitability. Before placing the adhesive electrodes (ST50D [50 mm], Nidd 
Valley Medical Ltd., Bordon, UK), the skin was cleansed with an alcohol wipe to 
improve the signal-to-noise ratio. For the femoral nerve, the cathode was positioned 
high, over the femoral triangle and the anode was placed midway between the greater 
trochanter and the iliac crest (Sidhu et al., 2009; Weavil et al., 2015). For the ulnar 
nerve, a cathode was positioned 3-5 cm above the medial epicondyle and the anode 
was placed on the lateral epicondyle of the right elbow. The stimulation intensity was 
determined by applying a gradual increase, beginning at 100 mA and increasing by 20 
mA until plateaus were evident in the resting muscle twitch and M-wave. To ensure 
supramaximal stimulation, the stimulation intensity was then increased by 30% 
(Oğuzhanoğlu et al., 2010). To determine the potentiated twitch force (Qtw,pot) 
percutaneous nerve stimulation of the femoral and ulnar nerve was delivered 2 s after 
an MVC (McKenzie et al., 1992). The mean of three attempts was recorded pre- and 
post- the sub-maximal test. The Qtw,pot was used in the calculation of peripheral 
voluntary activation. 
 
3.7.1 Voluntary Activation 
Voluntary activation (VA) is defined as the level of neural drive to a muscle during 
exercise (Gandevia et al., 1995) and was estimated using the interpolation twitch 
technique, with a single electrical stimulation of the femoral and ulnar nerve delivered 
during and 2 s following a MVC (Merton, 1954b; Strojnik & Komi, 2000). If during 
an MVC, the super-imposed twitch is small or absent, it is suggested that this reflects 
an ability to drive most of the motorneurons voluntarily to produce maximal force 
(Belanger & McComas, 1981; Gandevia & McKenzie, 1988; Lyons et al., 1996; Allen 
et al., 1998; Herbert & Gandevia, 1999). To quantify VA, the amplitude of the 
potentiated twitch was compared with the super-imposed twitch evoked during an 
MVC, and VA was derived from the following equation: 
 
Voluntary Activation (%) = (1 – super-imposed twitch/ Qtw, pot) × 100 
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3.7.2 Sub-maximal Test Protocol 
In Chapters 5 and 6, a sub-maximal isometric test using intermittent muscle actions at 
40% MVC was performed by all participants. The target force at 40% MVC was 
determined from the MVC obtained at the start of the visit. Participants performed 
intermittent isometric muscle actions (3 s on, 2 s off) until the target force could not 
be met. Participants were instructed to increase force to the target (40% MVC), 
matching the displayed force on the monitor screen in front of them and hold it as 
steady as possible. At the end of each minute, they were instructed to produce an 
MVC, before returning to targeted sub-maximal muscle actions (Bigland-Ritchie et 
al., 1986; Burnley et al., 2012). All sub-maximal and maximal muscle actions were 
prompted by an interval timer (Gymboss LLC Interval Timer) with the lead researcher 
providing verbal prompts for the participant to begin each muscle action with “push” 
and “rest”. The test was continued for 60 minutes or until task failure, i.e., the point at 
which a participant was unable to maintain the target force within ~5% of 40% MVC 
for three muscle actions. Data acquisition for performance fatigability was quantified 
as the change in MVC force before to after the sub-maximal test (Burnley et al., 2012). 
Ratings of perceived exertion were also measured using the Borg scale (6–20) after 
every set, with 6 representing “rest or no exertion”, and 20 corresponding to the 
“maximal effort” (see section 3.9.6 for more details). 
 
3.8 Transcranial Magnetic Stimulation 
Single- and paired-pulse transcranial magnetic stimulation was applied over the left 
motor cortex (M1) projecting onto spinal motorneurons (i.e., corticospinal tract). 
Consequently, motorneuron activation in response to corticospinal volleys induced by 
transcranial magnetic stimulation leads to a contraction in the target muscle, evoking 
a MEP on EMG recorded with surface electrodes applied over the muscle belly. When 
the Mmax is compared to the MEP peak-to-peak amplitude estimates of excitability of 
the corticospinal tract can be made (Figure 3.3). Transcranial magnetic stimulation 
was delivered through a concave double 110 mm cone coil (maximum output 1.4 T) 
for the knee-extensor muscle and an 8 cm figure-of-eight coil for the wrist-flexor 
muscles, powered by two Magstim 2002 stimulators and a BiStim unit (The Magstim 
Company Ltd, Whitland, UK). Identification of the optimal coil position for the rectus 
femoris and flexor carpi radialis was found by the junction of the double-cone coil 
aligned tangentially to the sagittal plane, with its centre 1–2 cm to the left of the vertex 
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to stimulate the contralateral hemisphere of the chosen dominant muscle. The optimal 
position to stimulate the flexor carpi radialis was found using the figure of eight- 
shaped coil held over the left M1, with the handle pointing backwards at 45° away 
from the midline sagittal plane invoking a posterior–anterior current flow. The optimal 
coil placement was determined at the start of each trial as the position that elicited 
consistently large MEPs from separate spots for the right rectus fermoris and flex 
muscles. The position was then marked with indelible ink to ensure consistent 
placement throughout the trials. Specific details of the protocols used to assess cortical 
and subcortical drive are presented below. Stimulator intensity was based on the active 
motor threshold (AMT). The AMT was determined at the beginning of each 
assessment during a 10% MVC, with stimulator intensity set at 50% and increasing in 
5% increments until consistent MEP with peak-to-peak amplitudes of ≥ 0.05 mV in 
three out of five stimulation attempts in the rectus femoris and flexor carpi radialis 
were evident (Sharshar et al., 2004; Groppa et al., 2012; Weier et al., 2012). Abnormal 
MEPs were noted, visually inspected and agreed for inclusion by the lead researcher 
and a clinical neurophysiologist (clinical team member). 
 
Figure 3.3 Transcranial magnetic stimulation applied over the motor cortex to the 
brain surface projecting on spinal motorneurons, also termed the corticospinal tract. 
Motorneuron activation in response to corticospinal volleys induced by transcranial 
magnetic stimulation leads to a contraction in the target muscle evoking a MEP, 
recorded by using surface EMG electrodes over the muscle belly. 
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3.8.1 Short-Interval Intracortical Inhibition 
Paired pulse transcranial magnetic stimulation was used to quantify corticospinal 
inhibition performed during a 10% MVC and delivered by a Magstim 2002 and a 
BiStim module (The Magstim Company Ltd, Whitland, UK). For single-pulse 
transcranial magnetic stimulation, the stimulus intensity was set at 120% AMT. The 
configuration used for short interval intracortical inhibition (SICI) consisted of a sub- 
threshold conditioning stimulus of 70% AMT, followed by supra-threshold of 120% 
AMT unconditioned test stimulus; test stimulus delivered in a randomised order of 20 
stimuli (i.e., 10 single and 10 paired pulses (Conte et al., 2009; Garry & Thomson, 
2009). The inter-stimulus interval was 2 ms, which has been shown to elicit the 
greatest amount of inhibition in the RF (Brownstein et al., 2018; Goodall et al., 2018). 
SICI was determined as the ratio between the test stimulus and conditioning stimulus 
using Spike2 (v6, CED, UK). A conditioned versus unconditioned ratio of 100% 
indicates facilitation. If the ratio for SICI was >100% or the ratio for ICF was <100%, 
the data from the corresponding participant were removed from analysis. 
 
3.8.2 Corticospinal Silent Period 
The corticospinal silent period (CSP) was measured during 50% MVC contractions 
where single-pulse transcranial magnetic stimulation was applied with an intensity of 
140% AMT. The CSP was quantified as the duration (ms) from the point of 
stimulation to the resumption of pre-stimulus EMG. There is some inconsistency in 
the literature in relation to identifying the resumption of pre-stim EMG with visual 
inspection techniques having previously been used (Todd et al., 2005; Sidhu et al., 
2009; Astorino et al., 2015). In this thesis, CSP was quantified as the duration from 
stimulation to the continuous resumption of post-stimulus EMG, which is as reliable 
as an automated procedure (Hermsen et al., 2016b). The mean of three evoked 
responses was used for subsequent analysis. 
 
3.9 Perceptual Scales 
In Chapters 5-7, participants were asked to complete several perceptual scales of 
patient reported outcomes on fatigue, mood, sleep, pain and quality of life. 
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3.9.1 Perceived Fatigue 
Fatigue Severity Scale 
The FSS was developed for use in PwMS (Krupp et al., 1989) and comprises 9-items 
that rate the level of agreement with statements about the severity, frequency and 
impact of fatigue in everyday life. A total FSS score ≥ 5 (Likert Scale) classifies PwMS 
as experiencing clinically-important levels of fatigue (Krupp et al., 1989). The FSS 
enables two sub-groups to be classified as 'highly-fatigued' and 'less-fatigued', as 
reported in previous studies with cut off > 5 (Liepert et al., 2005; Tellez et al., 2005; 
Andreasen et al., 2009). Chipchase et al. (2003) reported good discernment between 
PwMS and healthy controls and good test-retest reliability (Intraclass correlation=0.84; 
(Krupp et al., 1989; Chipchase et al., 2003). The FSS requires five minutes to complete 
and no prior training, supporting the feasibility of this scale in clinical research 
(Appendix 8). 
 
Modified Fatigue Impact Scale 
The Modified Fatigue Impact Scale (MFIS) is a modified form of the Fatigue Impact 
Scale, developed by Fisk et al. (1994) and is a measure of the impact of fatigue 
experienced in everyday life (Fisk et al., 1994b). The MFIS comprises 21-items, with 
patients required to rate agreement with each statement (0 “never” to 4 “almost 
always”, Appendix 10). A recommended global MFIS score cut-off of ≥ 38 classifies 
PwMS as experiencing clinically important levels of fatigue (Tellez et al., 2005; 
Johansson et al., 2008). Rietberg, (2010) reported good test-retest reliability (ICC = 
0.85, (Rietberg et al., 2010) ) and good internal consistency (Cronbach’s alpha = 0.80). 
Furthermore, correlation between the MFIS and FSS in PwMS has been reported as r 
= 0.66 (Rietberg et al., 2010), suggestive of good convergent validity, with similar 
results also reported in an alternative MS study (Tellez et al., 2005). 
 
Chalder Fatigue Scale 
The Chalder Fatigue Scale (CFS) measures a composite of physical and mental fatigue 
(i.e. a total score) as a measure of fatigue severity in PwMS (Chalder et al., 1993). The 
CFS comprises 11-items that measure fatigue intensity (Appendix 11). A total CFS 
score of ≥ 4 (bimodal scale) classifies PwMS as experiencing clinically important 
levels of fatigue (Johansson et al., 2008). The CFS has reported high internal 
consistency, with small to moderate correlations with impact of fatigue and mood, and 
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it is sensitive to change across low and high intensity behavioural interventions 
(Chilcot et al., 2016). 
 
3.9.2 The Hospital Anxiety and Depression Scale 
People with MS often report depression and anxiety, and this may exacerbate and 
explain some of the variance of fatigue (Ehde et al., 2003). The Hospital Anxiety and 
Depression Scale (HADS) is an appropriate screening measure for major depression 
and generalized anxiety disorder in PwMS (Honarmand & Feinstein, 2009; Watson et 
al., 2014). Global mood, depression and anxiety were assessed using the self- 
administered HADS questionnaire (Zigmond & Snaith, 1983), a 14-item self- 
assessment questionnaire, with responses scored on a 4-point (0–3) scale, (3 indicating 
a high-frequency of experienced symptoms, Appendix 9). The HADS consists of two 
subscales, anxiety (HADS-Anxiety) and depression (HADS-Depression) with each 
subscale consisting of seven items and the total score ranging from 0 to 21 (Zigmond 
& Snaith, 1983; AS, 1994). An applied cut-off score of :;7 indicates non-cases, and 
with scores >7 indicating possible and definite cases (Zigmond & Snaith, 1983). To 
score global mood, a score between 0 and 7 is “normal,” between 8 and 10 “mild,” 
between 11 and 14 “moderate,” and between 15 and 21 “severe” mood. The MFIS 
takes 2–5 minutes to complete, which supports the feasibility of this scale in clinical 
research. 
 
3.9.3 Sleep Quality 
Poor quality of sleep is very common in PwMS (Veauthier et al., 2011) and has been 
reported to relate to fatigue, as well as being associated with impairments in cognitive 
function (Cameron et al., 2014). Sleep quality was assessed using the Pittsburgh Sleep 
Quality Index (PSQI) over a 1-month time interval (Buysse et al., 1989). The PSQI is 
a self‐rated questionnaire which consists of 19-items generating 7 component scores: 
subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep 
disturbances, use of sleeping medication and daytime dysfunction (Appendix 12. Each 
component has a possible score of 0–3, where a higher score indicates a greater sleep 
problem. The global PSQI score was used in all analyses and was the sum of all 
component scores (range: 0–21); a score ≥5 represents poor sleepers; <5 represents 
patients with normal sleep quality. 
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3.9.4 Pain 
Throughout the course of MS, >50% of PwMS report pain as a common and varying 
symptom. Pain influences quality of life, mood, behaviour and the ability to partake 
in physical activity and structured exercise (Archibald et al., 1994; Ehde et al., 2003). 
Pain was measured by the recommended North American Research Committee on 
Multiple Sclerosis (NARCOMS) registry, which reports pain with one question; “in 
the past months, how intense was your pain?”. The score ranges from 0 “no pain” to 
5 “totally disabling pain”. The NARCOMS pain questionnaire is an easy and efficient 
measure (Appendix 13), has good test-retest reliability (r = 0.84) and has been 
validated with the MS Pain Effects Scale criterion measure (Marrie et al., 2005). 
 
3.9.5 Quality of Life 
QOL was assessed using the Multiple Sclerosis Quality of Life (MSQOL)-54, 
comprising the generic Short-Form 36-item (SF-36) instrument (Ware & Sherbourne, 
1992) in addition to 18 MS-specific items derived from professional opinion and a 
literature review (Vickrey et al., 1995). These enquire about QOL over the preceding 
month, except item 2 (Change in Health) which refers to the preceding year. Two 
composite scores (Physical Health Composite and Mental Health Composite) are 
derived by combining scores of the relevant subscales (Vickrey et al., 1995). MSQOL- 
54 scale scores were created using the Likert method by averaging items within the 
scales and, then row scores were linearly transformed into 0–100 scales. Higher values 
are indicative of a better quality of life. The MSQOL-54 has well documented validity, 
in terms of content, constructs, reliability, discrimination (Vickrey et al., 1995; Solari 
et al., 1999; Füvesi et al., 2008) and responsiveness (Giordano et al., 2010). 
 
3.9.6 Ratings of Perceived Exertion 
The Borg rating perceived exertion Scale quantifies perceived exertion during exercise 
(G., 1985 ) (6 = Very Very light – 20 =Maximal, see Appendix 14). The Borg rating 
perceived exertion Scale has been shown to be a reliable measure for functional tests 
such as the 6 Minute Walk Test, Functional Stair Test, Static Standing Balance Test 
and Sit-to-Stand Test in PwMS (Wetzel et al., 2011). To standardise the procedure and 
improve the accuracy of the rating perceived exertion scale, it was important that 
participants understand both the verbal anchors and the numerical value and as such, 
the same verbal instructions were given to each participant. 
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3.10 Statistical Analysis 
Data are presented in this thesis as mean ± SD and mean ± SEM in figures unless 
stated otherwise. All data were analysed using SPSS (version 20, SPSS Inc., Chicago, 
IL, USA). Statistical significance was set at p < 0.05. Normal Gaussian distribution of 
data was confirmed using the Kolmogorov-Smirnov test and in the likely event a 
violation was detected, the data was logarithmically transformed. 
 
3.10.1 Sample Size 
Chapters 5 and 6 included the same cohort of participants. In accordance with previous 
cross-sectional studies that have provided preliminary evidence of neurophysiological 
differences between ‘fatigued’ and ‘less-fatigued’ people with MS, a sample size of 
~20 participants are sufficient to show differences in measures of central and 
peripheral activation between the groups (Chalder et al., 1993; Greim et al., 2007). 
Thus, a sample of 20 participants per group (3 groups, 60 participants in total) was 
recruited to assess the test re-test reliability of the measures. In Chapter 7, consecutive 
sampling was used to recruit 30 participants (2 groups, 15 participants per group). This 
conforms to guidance on feasibility and pilot studies, with justification that a sample 
size ranging 24–50 has been recommended as sufficient and appropriate for 
determining the variability data of key outcome measures for use in sample size 
calculations for a larger trial (Sim & Lewis, 2012). Allowing for 20% attrition, 36 
participants were aimed to be recruited and randomised. 
 
3.10.2 Analysis of Variance 
Chapter 5 
In Chapter 5, between session test-retest reliability of all measures was assessed using 
reliability indices; intra-class correlation coefficient (ICC), coefficient of variation and 
typical error. According to the guidelines recommended by Koo and Li (2016), ICCs 
less than 0.5 were considered low agreement, between 0.5 and 0.75 were considered 
as moderate agreement, values between 0.75 and 0.9 as good agreement, and values 




In Chapter 6, in order to ensure equivalence between groups, all baseline variables 
(demographic, disease-related, fatigue, and physical measures) were compared 
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between groups using t-tests or chi-square tests where appropriate and using a 
significance threshold of p < 0.05. Analysis of variance (ANOVA) was used to 
compare neurophysiological outcomes between 'highly-fatigued' and 'less-fatigued' 
PwMS and healthy controls (Portney, 2000). Following a significant main effect from 
ANOVA, post-hoc comparisons were made using Bonferroni test using a critical value 
for the studentised range statistic of α = 0.05. 
 
Chapter 7 
In Chapter 7, process and scientific feasibility was determined by the recruitment, (i.e., 
willingness to be randomised, optimal recruitment method, expected recruitment, 
refusal rates), acceptability of outcome measures, retention, adherence rates of 
attendance at supervised and home-based sessions and any adverse advents. Process 
and scientific feasibility were examined via percentage and descriptive statistics. The 
proportion of sessions completed by each participant was determined by taking the 
number of supervised sessions attended divided by the total number supervised 
sessions offered. This information is important because it provides acceptability and 
highlights considerations for alterations. Determining compliance will further allow 
correct conclusions to be drawn from the results. Specific details of the feasibility 
measures are outlined in the respective experimental chapter. Exploratory analysis was 
conducted using intent-to-treat analysis to determine change in neurophysiological 
and patient report outcomes, with missing data points checked to be random (Little's 
Chi Squared test), and then imputed using the SPSS Expectation Maximisation 
method. Outcome data were analysed using analysis of covariance (ANCOVA), with 
baseline values used as the covariate, to compare differences between groups at each 
time point (Follow-up 1/6 weeks and Follow-up 2/12 weeks). Results are presented as 
mean (± SD) at each time point and changes in outcome data are considered to be 
preliminary, and a cautious approach to interpretation has been taken. 





















CHAPTER 4 Neurostructural and Neurophysiological Correlates of Multiple 
Sclerosis Fatigue: Systematic Review and Meta-Analysis of Cross-Sectional 
Studies 
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4.1 Introduction 
Studies show that ≥75% of people with multiple sclerosis experience fatigue 
symptoms persistently or sporadically (Lerdal et al., 2007) and over half the MS 
population describe it as their most severe symptom (Fisk et al., 1994a). In proposing 
a unified taxonomy for fatigue in neurologic illness, (Kluger et al., 2013b) highlighted 
the importance of differentiating between perceived fatigue and fatigability and the 
application of neuroimaging, neurophysiology and neuropathologic measures to 
improve our understanding of these two constructs was identified as a research 
priority. Perceived fatigue and fatigability are analogous to the constructs of ‘central’ 
and ‘peripheral’ fatigue proposed by (Chaudhuri & Behan, 2000). Perceived fatigue 
includes subjective feelings of weariness and an increased subjective perception of 
effort for everyday tasks (irrespective of recent physical exertion) and is commonly 
rated in PwMS with the FSS and MFIS (Krupp et al., 1989; Fisk et al., 1994b). The 
FSS is a 9-item scale which focuses on the severity, frequency and impact of fatigue 
on daily life during the past seven days, whereas the MFIS is a 21-item scale yielding 
data on the level of cognitive, physical, psychosocial and total fatigue experienced 
during the past 4 weeks. Validated cut-points of >4 and ≥38 for the FSS (Krupp et al., 
1995) and MFIS (Flachenecker et al., 2002a), respectively, have been used to classify 
people experiencing higher (MS-HF) versus lower (MS-LF) levels of perceived MS 
fatigue. However, other threshold scores have been used as the criterion for higher 
levels of perceived fatigue in some studies (Colombo et al., 2000; Niepel et al., 2006; 
Tomasevic et al., 2013; Cogliati Dezza et al., 2015). In contrast, fatigability, 
sometimes referred to as motor fatigability or performance fatigability (Zijdewind et 
al., 2016; Severijns et al., 2017), is defined as the rate of change in a performance 
criterion, e.g. an objective measure of voluntary force relative to a reference (baseline) 
value over a given time of task performance or measured mechanical output (Kluger 
et al., 2013b). 
 
Neuroimaging studies that have investigated associations between perceived fatigue 
severity and morphometric measures of global brain atrophy or regional atrophy 
within grey or white matter structures have yielded conflicting results (Tedeschi et al., 
2007; Pellicano et al., 2010; Cruz Gomez et al., 2013; Rocca et al., 2014). 
Nevertheless, evidence of impaired functional connectivity between cortical and sub- 
cortical regions, implicates basal ganglia structures, the thalamus, and specific areas 
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within the frontal, parietal, and temporal lobes in perceived MS fatigue (Roelcke et 
al., 1997; Filippi et al., 2002; Tartaglia et al., 2004; Wilting et al., 2016; Jaeger et al., 
2018). Although neuromuscular studies have yielded inconsistent data for voluntary 
activation of the upper- and lower-limb skeletal muscles in PwMS versus healthy 
controls (Ng et al., 2000a; Andreasen et al., 2009; Steens et al., 2012a), 
neurophysiological impairments could underpin the reductions in maximal voluntary 
force (Ng et al., 2004; Liepert et al., 2005; Wolkorte et al., 2016) and motor function 
(Ng et al., 2004) and the more pronounced levels of fatigability (Sheean et al., 1997; 
Liepert et al., 2005; Wolkorte et al., 2016) that have been reported in PwMS. Such 
neurophysiological changes are likely to have a direct bearing on perceived effort for 
everyday tasks and perceptions of fatigue amongst PwMS. 
 
Current knowledge on the underlying neurobiological substrate of MS fatigue, as 
assessed by neuroimaging and neurophysiological measures, is impeded by 
inconsistent findings, insufficiently powered cross-sectional studies and comparisons 
between healthy controls and PwMS, without partitioning the latter by fatigue status. 
This makes it difficult to draw definitive conclusions about neurobiological 
differences between MS-HF and MS-LF and there is a need to consolidate an extensive 
and somewhat conflicting evidence-base. This systematic review and accompanying 
meta-analyses addressed these limitations by synthesizing all current evidence, 
including peer-reviewed (published) neuroimaging and neurophysiological data 
acquired from senior authors which were not originally presented by fatigue status of 
PwMS in the published report. By meta-analysing previously reported dichotomised 
data for MS-HF versus MS-LF, the main aim was to gain an improved insight into 
structural and neurophysiological correlates of MS fatigue. 
 
4.2 Methods 
4.2.1 Search Strategy 
This systematic review and meta-analysis was conducted in accordance with the 
preferred reporting items for systematic reviews and meta-analyses (PRISMA) 
statement (Liberati et al., 2009) and the protocol was pre-registered with the 
PROSPERO International Prospective Register of Systematic Reviews 
(https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=17934). A 
systematic literature search of PubMed/MEDLINE, ProQuest, CINAHL and Web of 
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Science from inception until 31st December 2019 was undertaken, blinded to title and 
authorship, by two reviewers (PE & SG). The search strategy was conducted using 
Medical Subject Headings and search terms included those related to MS, fatigue, 
neurophysiology, neuroimaging, voluntary contractions, transcranial magnetic 
stimulation and motor nerve stimulation (Table 4.1). We also searched the grey 
literature (theses, conference abstracts/posters), along with the reference lists of 
retrieved systematic reviews and included studies to identify other pertinent articles. 
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Up to December 
31st, 2019 
Search 
PubMed/MEDLINE (("multiple sclerosis"[MeSH Terms] OR ("multiple"[All Fields] AND "sclerosis"[All Fields]) 
OR "multiple sclerosis"[All Fields]) AND (twitch[All Fields] AND interpolation[All Fields])) 
AND central[All Fields] AND ("transcranial magnetic stimulation"[MeSH Terms] OR 
("transcranial"[All Fields] AND "magnetic"[All Fields] AND "stimulation"[All Fields]) OR 
"transcranial magnetic stimulation"[All Fields] OR ("transcranial"[All Fields] AND 
"magnetic"[All Fields] AND "stimulation"[All Fields] AND "paired"[All Fields] AND 
"pulse"[All Fields]))) AND (intracortical[All Fields] AND excitability[All Fields]) AND 
(("nerve tissue"[MeSH Terms] OR ("nerve"[All Fields] AND "tissue"[All Fields]) OR "nerve 
tissue"[All Fields] OR "nerve"[All Fields]) AND stimulation[All Fields])) AND (maximal[All 
Fields] AND contraction[All Fields]) AND (motor[All Fields] AND execution[All Fields]) 
AND (maximal[All Fields] AND contraction[All Fields]) AND force[All Fields] AND 
(motor[All Fields] AND execution[All Fields]) AND motor fatigue AND force AND/OR 
(multiple sclerosis) AND motor fatigue AND fatigue scores AND ("neurophysiology"[MeSH 
Terms] OR "neurophysiology"[All Fields])) AND ("fatigue"[MeSH Terms] OR "fatigue"[All 
Fields]) AND muscle action potentials AND neural activity AND ("motor activity"[MeSH 
Terms] OR ("motor"[All Fields] AND "activity"[All Fields]) (10) "magnetic resonance 
imaging" MeSH Terms] OR ("magnetic"[All Fields] AND "resonance"[All Fields] AND 
"imaging"[All Fields]) OR "magnetic resonance imaging"[All Fields] OR "functional 
magnetic resonance imagery "[All Fields]) "functional magnetic resonance imaging"[All 
Fields]) "functional"[All Fields] OR “volumetric” AND “brain structures” (("brain"[MeSH 
Terms] OR "brain"[All Fields]) AND structures[All Fields]) OR “brain function” 
(("brain"[MeSH Terms] OR "brain"[All Fields]) AND ("physiology"[Subheading] OR 
"physiology"[All Fields] OR "function"[All Fields] OR "physiology"[MeSH Terms] OR 
"function"[All Fields])) AND “brain activation "brain"[MeSH Terms] OR "brain"[All Fields]) 
AND activation [All Fields]. 
ProQuest, multiple sclerosis, nerve stimulation, twitch interpolation, transcranial magnetic stimulation, 
motor cortical excitability, muscle strength, peripheral and central fatigue, maximal voluntary 
contraction, motor task, maximal force, motor fatigue, fatigue scores, neurophysiology, muscle 
action potential, neural activity, magnetic resonance imaging, functional magnetic 
resonance imaging, volumetric, brain structures, brain function, brain activation. 
CINAHL multiple sclerosis, nerve stimulation, twitch interpolation, transcranial magnetic stimulation, 
motor cortical excitability, muscle strength, peripheral and central fatigue, maximal voluntary 
contraction, motor task, maximal force, motor fatigue, fatigue scores, neurophysiology, muscle 
action potential, neural activity, magnetic resonance imaging, functional magnetic resonance 
imaging, volumetric, brain structures, brain function, brain activation. 
Web of Science TS=('multiple sclerosis' AND 'transcranial magnetic stimulation, paired pulse') 
TS=('multiple sclerosis' AND 'transcranial magnetic stimulation, single pulse') 
TS=('multiple sclerosis' AND 'twitch interpolation') 
TS=('multiple sclerosis' AND 'muscle strength') 
TS=('multiple sclerosis' AND 'muscle fatigue, peripheral') 
TS=('multiple sclerosis' AND 'muscle fatigue, central') 
TS=('multiple sclerosis' AND 'motor performance') 
TS=('multiple sclerosis' AND ‘nerve stimulation’) 
TS=('multiple sclerosis' AND ‘brain stimulation’) 
TS=('multiple sclerosis' AND ‘fatigue scales’) 
TS=('multiple sclerosis' AND ‘magnetic brain imaging’) 
TS=('multiple sclerosis' AND ‘functional magnetic brain imaging’) 
TS=('multiple sclerosis' AND ‘brain function, brain structures’) 
TS=('multiple sclerosis' AND ‘brain activation’) 
TS=('multiple sclerosis' AND ‘neurophysiology’) 
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4.2.2 Study Selection 
Eligible articles reported data from cross-sectional studies using a validated fatigue 
scale and defined cut-points for differentiating MS-HF from MS-LF. Adults >18 years 
with definite multiple sclerosis (Poser or McDonald criteria) and all types of MS 
(relapsing-remitting; secondary progressive; primary progressive) were eligible for 
inclusion. The included studies must have reported neuroimaging measures or 
neurophysiological variables for MS-HF and MS-LF. However, 14 authors of 16 peer- 
reviewed published studies provided original data (neurofunctional or 
neurophysiological) partitioned by perceived fatigue status of PwMS (MS-HF versus 
MS-LF), where it was available but not reported as such in the published article, and 
these authors have been acknowledged. In the case of the same cohort data being 
reported in >1 article, only the most recent publication was included. Non-English 
animal studies, case studies, review articles, randomised controlled trials and other 
controlled trials, pharmacological trials and studies that only reported other 
physical/psychological outcomes (e.g., gait analysis variables, mental health status, 
disability, cognitive impairment and spiro-ergometric) were excluded. 
 
4.2.3 Methodological Quality Assessment 
The methodological quality of included studies was evaluated using the Cross- 
Sectional/Prevalence Study Quality Scale, recommended by the Agency for 
Healthcare Research and Quality (http://www.ncbi.nlm.nih.gov/books/NBK35156/) 
(Zeng et al., 2015). This scale is an 11-item tool that is used to evaluate study quality, 
with an item scoring “1” if it was answered “Yes” and “0” if it was answered “No”, 
“Unclear” or “Not Applicable”. Scores of 0-3 indicate “low quality”, 4–7 “moderate 
quality” and 8–11 “high quality” (Appendix 17). Two reviewers (PE and SG) assessed 
each included study independently, with disagreements being resolved by consensus 
and the opinion of a third reviewer (JS). 
 
4.2.4 Data Extraction and Analysis 
Data were extracted independently by three reviewers (PE, SG and JS) as follows: (1) 
Study design; (2) Characteristics of the participants (number, subtype of MS, disease 
duration, age, gender and EDSS score, fatigue score); (3) Primary outcomes; (4) 
Secondary outcomes. Means and standard deviations for each variable were extracted 
for meta-analyses using RevMan 5.0 (http://www.cc- 
- 51 -  
ims.net/RevMan/download.htm). Due to variation in clinical and/or demographic 
characteristics and fatigue assessments across studies, a random-effects model was 
applied throughout. A p value <0.05 indicated statistical significance for an overall 
effect and the magnitude of heterogeneity across studies was tested using the I2 
statistic: I2 values <25%, 25–50%, or >50% indicate low, moderate and high 
heterogeneity, respectively (Higgins et al., 2003). Funnel plots were not constructed, 
owing to the number of meta-analyses which included <10 studies (Sutton et al., 
2000). Sub-group analyses were planned based on brain region and limb targeted. Data 
were not included in meta-analyses if means, standard deviations and number of 
participants allocated to each group were not reported or available. 
 
4.3 Results 
Figure 4.1 shows that the search yielded 66 studies, with data from 46 studies included 
in meta-analyses (42 neuroimaging studies, 19 neurophysiological studies and 5 
combined neuroimaging and neurophysiological studies). Appendix 15 and 16 present 
details of each included study. A total of 1761 MS-HF and 1391 MS-LF participants 
were compared in the cross-sectional studies, with the majority (2345) having a 
definite relapsing remitting MS diagnosis, 150 being classified as PRIMARY 
PROGRESSIVE MS or secondary progressive MS and 575 participants of unspecified 
disease type. In 48 studies, healthy controls were included as an additional 
comparison. Studies which provided details of the gender balance for MS-HF and MS- 
LF (N=43) showed there were approximately twice as many women than men in each 
subgroup (729:357 and 657:387, respectively), reflecting the higher prevalence of MS 
amongst women (Harbo et al., 2013). The MS-HF and MS-LF groups were well- 
balanced for age, disease duration and EDSS score. The mean age was 40 years for 
MS-HF versus 38 years for MS-LF (reported in 56 studies). MS-HF had a mean 
disease duration (years) and EDSS score of 8.7 years (reported in 41 studies) and 2.6 
(reported in 52 studies) respectively, versus 8.1 years and 2.0, respectively for MS- 
LF. EDSS scores indicated a mild to moderate level of disability with no impairment 
to walking for the majority of MS-HF and MS-LF participants (EDSS :; 3.5 in 85% of 
studies). 
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Full-text articles assessed for 
eligibility 
(n=185) 
Full-text articles excluded (n=119) 
No reported perceived fatigue 
score or MS-HF/MS-LF 
subgroups (n=66) 
Unsuitable outcomes (n=14) 
Same cohort used in earlier 
study (3) 
Data reported as correlations 
(n=13) 
Qualitative study (n=15) 
Intervention study (n=5) 
Drug Trial (n=1) 
Review (n=1) 
Case study (n=1) 
Records excluded after screening 
of title and abstracts (n=1,877) 

































































Figure 4.1. PRISMA flow chart for literature search and study selection 
Studies included in meta- 
analyses (n=46) 
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4.3.1 Perceived Fatigue Measures 
The most frequently used scale to differentiate MS-HF from MS-LF was the FSS 
(Krupp et al., 1989), which was used in 48 of the included studies, using mean cut-off 
scores for MS-HF of >4 or >5 and total scores ranging from >25 to >36. A further 10 
studies used the MFIS (Fisk et al., 1994a) with cut-off scores for MS-HF in the range 
of >35 to >38 or ≥16 for the MFIS physical scale. Three studies used the cognitive 
scale of the Fatigue Scale for Motor and Cognitive Functions using cut-points in the 
range of ý22 to ý28, two further studies used the MFIS-5 and a validated French 
version of the Fatigue Impact Scale, and three studies used subjective perceptions to 
classify MS-HF, e.g., “mostly or daily tired” (Appendix 15 and 16). 
 
4.3.2 Neuroimaging and Neurophysiological Measures 
Neuroimaging measures for meta-analyses were obtained using magnetic resonance 
imaging, diffusion tensor imaging and magnetic resonance spectroscopy (MRS). 
Measures included total normalised brain volume, grey and white matter volumes, T1- 
weighted hypointense and T2-weighted lesion volumes, white matter microstructural 
integrity (diffusion tensor imaging indices of fractional anisotropy and mean 
diffusivity) and neuronal/axonal integrity and function (N-acetylaspartate to creatine 
[NAA/Cr] ratio and choline to creatine [Cho/cr] ratio by MRS). Neurophysiological 
measures for meta-analyses were obtained using transcranial magnetic stimulation, 
electroencephalography (EEG), neuromuscular electrical stimulation (NMES) and 
electromyography (EMG) and included motor evoked potential (MEP) amplitude, 
MEP latency, MEP threshold, central motor conduction time, short-interval intracortical 
inhibition (SICI), and voluntary activation (central motor drive) using the twitch-
interpolation technique during MVC (Merton, 1954a). Brain region functional 
connectivity data determined using functional magnetic resonance imagery were not 
included in meta-analyses, but the key findings are reported in Supplementary 
Appendix 15. MVC force data were determined using upper- or lower-limb rigs that 
fixed the joint in position for isometric muscle actions, with fatigability being assessed 
using a sustained MVC or intermittent % MVC isometric fatiguing protocol and 
reported as percent of the baseline force. 
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4.3.3 Quality Assessment 
Most of the included studies (70%) were classified as being of “moderate quality”, 16 
(24%) studies were rated as “low quality” and four studies (6%) as “high quality” 
(Figure 4.2; Appendix 17). Key limitations representing risk of bias included 
inadequate details of the time period used to identify and recruit participants, use of 
non-blinded evaluators and lack of quality control data for the methods used to 
compare MS-HF with MS-LF. 
 
Figure 4.2. Methodological quality of the included studies evaluated using the Cross- 
Sectional/Prevalence Study Quality Scale, recommended by the Agency for Healthcare 
Research and Quality. Scores of 0-3 indicate “low quality”, 4–7 “moderate quality” 
and 8–11 “high quality”. 
 
4.4 Meta-Analyses Overview 
The results of meta-analyses are presented as absolute mean differences with 95% 
confidence intervals (CI). Detailed forest plots showing comparisons of MS-HF versus 
MS-LF, MS-HF versus HC and MS-LF versus HC are presented in Appendix 18-23. 
A summary of meta-analyses results for all neuroimaging and neurophysiological 
variables (MS-HF versus MS-LF) are presented as standardised mean difference 
(SMD) and 95% CI in Figures 4.3 and 4.4, with Cohen’s categories (SMD = 0.2 - 0.5; 
0.5 - 0.8; ≥ 0.8) indicating small, medium and large overall effect sizes, respectively. 
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4.5 Neuroimaging Meta-Analyses 
4.5.1 Brain Volume 
Meta-analysis indicated a reduction in mean normalised brain volume (-22.74 ml; 95% 
CI: -37.72 to -7.76 ml; p=0.003) in MS-HF versus MS-LF, accompanied by a reduction 
in the volume of grey matter in MS-HF versus MS-LF (-18.81 ml; 95% CI: 
-29.60 to -8.03 ml; p<0.001). There was no significant difference in white matter 
volume between MS-HF and MS-LF (-6.41ml; 95% CI: -13.98 to 1.15 ml; p=0.10). 
Larger reductions in mean normalised brain volume, grey and white matter volumes 
(all p<0.001) were apparent for MS-LF and MS-HF versus HC (Figure 4.3, and 





TBV (ml): 11 studies; 336 MS-HF vs 375 MS-LF 
BPF (%): 6 studies; 129 MS-HF vs 159 MS-LF 
GMV (ml): 9 studies: 306 MS-HF vs 318 MS-LF 
WMV (ml): 9 studies; 306 MS-HF vs 318 MS-LF 
Thalamas volume (ml):8 studies; 234 MS-HF vs 286 MS-LF 
Putamen volume (ml): 4 studies; 163 MS-HF vs 178 MS-LF 
Caudate volume (ml): 4 studies; 163 MS-HF vs 178 MS-LF 
Accumbens volume (ml):2 studies; 53 MS-HF vs 59 MS-LF 
Amygdala volume (ml):2 studies; 53 MS-HF vs 59 MS-LF 
Pallidus volume (ml):2 studies; 46 MS-HF vs 46 MS-LF 
T1-WLV (ml):9 studies; 483 MS-HF vs 334 MS-LF 
T2-WLV (ml): 21 studies; 730 MS-HF vs 596 MS-LF 
Fractional anisotrophy: 3 studies; 60 MS-HF vs 60 MS-LF 
Mean diffusivity (×10−3 mm2/s): 3 studies; 60 MS-HF vs 60 MS-LF 
NAA/Cr: 3 studies; 67 MS-HF vs 56 MS-LF 
Cho/Cr: 2 studies; 51 MS-HF vs 39 MS-LF 
 
-2.0 -1.5 -1.0 -0.5 0.0 0.5 1.0 1.5 2.0 
Reduced Increased 
 
Figure 4.3. Summary of results of meta-analyses comparing neuroimaging and 
neurofunctional data for MS-HF versus MS-LF. Data are presented as standardised 
mean difference and 95% confidence intervals. The figure presents summary data for 
neuroimaging variables, with the abscissas representing a decrease or increase for MS- 
HF in comparison with MS-LF. TBV, total brain volume; BPF, brain parenchymal 
fraction; GMV, grey matter volume, WMV, white matter volume, T1-WLV, T1- 
weighted lesion volume, T2-WLV, T2-weighted lesion volume, NAA/Cr, N- 
acetylaspartate to creatine ratio Cho/Cr, choline to creatine ratio, UL, upper-limb; LL, 
lower-limb. 
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4.5.2 Subcortical Grey Matter Structure Volumes 
Where data for sub-cortical structures were reported for the left and right sides, data 
were summed to provide a single volumetric measure for comparison with studies in 
which a single volumetric measure was reported. Meta-analysis showed a reduction in 
putamen (-0.40 ml; 95% CI: -0.69 to -0.10 ml; p=0.008) and accumbens (-0.09 ml; 
95% CI: -0.15 to -0.03 ml; p=0.003) volumes for MS-HF versus MS-LF. Larger effect- 
size reductions in thalamus and caudate volumes did not reach statistical significance 
because of wider confidence intervals and there were high levels of heterogeneity 
(I2ý89%; Figure 2). Volumetric reductions were apparent for the thalamus, putamen 
and caudate (p:;0.02) in MS-LF and MS-HF versus HC, and for the accumbens in MS- 
HF versus HC (p=0.04; Figure 4.3 and Appendix 18, 20 and 22). 
 
4.5.3 Lesion Volume, White Matter and Axonal Integrity and Function 
There was an increased volume of T1-weighted hypointense lesions in MS-HF versus 
MS-LF (1.10 ml; 95% CI: 0.47 to 1.73 ml; p<0.001) and for MS-LF and MS-HF 
versus HC (p<0.0001). However, there were no differences between MS-HF and MS- 
LF for T2-weighted lesion volume (1.19 ml; 95% CI: -0.43 to 2.80 ml; p=0.15), white 
matter microstructural integrity (diffusion tensor imaging indices of fractional 
anisotropy and mean diffusivity) or axonal integrity/function (NAA/Cr or Cho/Cr by 
MRS). There was an increase in diffusion tensor imaging mean diffusivity for MS-HF 
(0.02 ×10−3 mm2/s; 95% CI: 0.01 to 0.03 ×10−3 mm2/s; p<0.001) and MS-LF (0.03 
×10−3 mm2/s; 95% CI: 0.00 to 0.06 ×10−3 mm2/s; p=0.03) versus HC, and a reduction 
in the NAA/Cr ratio in MS-HF versus HC (-0.10; 95% CI: -0.18 to -0.01; p<0.03), 
indicating relative impairment of microstructural and axonal integrity/function (Figure 
4.3 and Appendix 18, 20 and 22). 
 
 
4.6 Neurophysiological Meta-Analyses 
4.6.1 Corticospinal Integrity and Intra-Cortical Inhibition 
There were no significant differences between MS-HF and MS-LF in MEP amplitude, 
latency, threshold, CMCT or SICI. However, higher MEP thresholds were apparent 
for MS-LF and MS-HF versus HC (p :; 0.02; Figure 4.4 and Appendix 19, 21 and 23). 
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Neurofunctional studies 
 
UL MVC (N): 6 studies; 130 MS-HF vs 69 MS-LF 
 
LL MVC (N): 4 studies; 72 MS-HF vs 55 MS-LF 
 
UL VA (%): 3 studies; 33 MS-HF vs 29 MS-LF 
 
LL VA (%): 3 studies; 36 MS-HF vs 29 MS-LF 
 
MEP threshold (%): 3 studies; 61 MS-HF vs 34 MS-LF 
 
MEP amplitude (mV): 2 studies; 40 MS-HF vs 17 MS-LF 
 
MEP latency (ms): 2 studies; 40 MS-HF vs 17 MS-LF 
 
CMCT (ms): 2 studies; 32 MS-HF vs 19 MS-LF 
 
SICI (%): 3 studies; 45 MS-HF vs 42 MS-LF 
 
ICF (%): 3 studies; 45 MS-HF vs 42 MS-LF 
 
UL fatigability (% baseline MVC): 5 studies; 139 MS-HF vs 87 MS-LF 
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Figure 4.4. Summary of results of meta-analyses comparing neurofunctional data for 
MS-HF versus MS-LF. Data are presented as standardised mean difference and 95% 
confidence intervals. The figure presents summary data for neurofunctional variables, 
with the abscissas representing a decrease or increase for MS-HF in comparison with 
MS-LF. UL, upper-limb; LL, lower-limb; MEP, motor evoked potential; CMCT, 
central motor conduction time; SICI, short-interval intracortical inhibition, ICF, 
intracortical facilitation; MVC, maximum voluntary contraction force. 
 
4.6.2 Skeletal Muscle Maximum Voluntary Contraction Force and Voluntary 
Activation 
There were reductions in lower-limb (-19.23 N; 95% CI: -35.93 to -2.53 N; p=0.02) 
and upper-limb MVC force (-3.55 N; 95% CI: -7.11 to 0.01 N; p=0.05) in MS-HF 
versus MS-LF, with the latter of borderline statistical significance. Reductions in 
upper-limb MVC force were also apparent in MS-LF and MS-HF versus HC (p:;0.03). 
Meta-analysis of studies which used the twitch-interpolation technique during a MVC 
showed reduced voluntary activation in MS-HF versus MS-LF for upper-limb (-5.77 
%; 95% CI: -8.61 to -2.93%; p<0.0001) and lower-limb skeletal muscles (-2.16%; 
95% CI: -4.24 to -0.07%; p=0.04). Upper-limb muscles included finger and thumb 
flexors/extensors and lower-limb muscles included the quadriceps and dorsiflexors 
(Figure 4.4 and Appendix 19, 21 and 23). 
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4.6.3 Fatigability 
Meta-analysis of the percent decline in MVC from baseline after an upper-limb (finger 
or thumb flexor/extensor) skeletal muscle fatigue task (either sustained [N=3] or 
intermittent [N=2] isometric MVC) revealed greater fatigability for MS-HF versus 
MS-LF (-5.61%; 95% CI: -9.57 to -1.65%; p=0.006). A more pronounced level of 
upper-limb fatigability was also observed for MS-HF versus HC (-7.43%; 95% CI: - 




Using a dichotomised model (MS-HF versus MS-LF), this systematic review and 
accompanying meta-analyses aimed to provide an improved insight into structural and 
neurophysiological correlates of MS fatigue. By robustly consolidating an extensive 
and somewhat conflicting evidence-base, we demonstrate that higher levels of MS 
fatigue are characterised by greater cortico-subcortical atrophy, and with indications 
of greater neural damage, as evidenced by an increased volume of T1-weighted 
hypointense lesions (Napoli & Bakshi, 2005). These neurostructural impairments are 
accompanied by neurophysiological decrements, manifest as impaired MVC force and 
reduced skeletal muscle voluntary activation. The synthesis of cross-sectional data in 
published reports of included studies, together with published peer-reviewed data 
(acquired from senior authors) that were not originally presented by fatigue status of 
PwMS, means these results provide the most precise effect-size estimates of 
neurobiological differences between MS-HF and MS-LF to date. 
 
Although the meta-analyses provided clear evidence of white matter atrophy in MS- 
HF and MS-LF versus HC, the smaller normalised brain volume in MS-HF versus 
MS-LF appears to be mainly attributable to a volumetric reduction in grey matter. 
Cortical regions with reduced volumes for MS-HF versus MS-LF in the included 
studies were the precentral gyrus, inferior and superior temporal gyrus, superior and 
inferior frontal gyrus, anterior cingulate gyrus, central sulcus, superior and inferior 
parietal lobules (Sepulcre et al., 2009; Andreasen et al., 2010a; Riccitelli et al., 2011; 
Rocca et al., 2014). This meta-analysis also consolidated the evidence for sub-cortical 
grey matter structures, revealing volumetric reductions in the putamen and accumbens 
for MS-HF versus MS-LF. Evidence suggests that putamen atrophy is present early in 
the MS disease cycle (Kramer et al., 2015) and many participants recruited to the 
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included studies are likely to have fallen into this category (EDSS :; 3.5 in over 80% 
of studies). Interestingly, larger effect size reductions in caudate and thalamus 
volumes were also observed in MS-HF versus MS-LF and HC but these only reached 
statistical significance for comparisons with the HC data. Other sub-cortical and basal 
ganglia structures reported to have reduced volumes in MS-HF versus MS-LF which 
were inversely correlated with perceived fatigue were the pallidum and superior 
cerebellar peduncle (Rocca et al., 2014; Damasceno et al., 2016; Bernitsas et al., 2017) 
but there were insufficient data for meta-analyses. In addition, studies reported 
microstructural changes within the basal ganglia, thalamus and frontal lobe and 
impaired functional connectivity between basal ganglia structures and the 
sensorimotor cortex, frontal, parietal and temporal lobes (Wilting et al., 2016; Jaeger 
et al., 2018). Impaired basal ganglia circuitry, including striatocortical and 
striatothalamic networks and potentially implicating regions that are heavily reliant on 
dopamine neurotransmission (e.g., ventral striatum), have been postulated to be 
important mechanistic factors underpinning perceived MS fatigue (Chaudhuri & 
Behan, 2000; Dobryakova et al., 2015). These regions are primarily responsible for 
motor control, motor planning, attentional control and the integration of afferent and 
efferent information. 
 
MS-HF showed an increased number of T1-weighted hypointense lesions in 
comparison with MS-LF, a difference that was even more pronounced in comparison 
with HC. However, there was no difference in the number of T2-weighted lesions or 
diffusion tensor imaging indices of white matter microstructural integrity between 
MS-HF and MS-LF. The increased number of T1-weighted hypointense lesions could 
reflect associations between MS fatigue symptoms and recently activated immune 
inflammatory pathways or irreversible pathological changes which are features of the 
disease (Morris et al., 2016). Recently formed T1-weighted scan-identified 
hypointense lesions represent current disease activity, including reversible oedema, 
inflammation, demyelination and remyelination, whereas chronic T1-weighted 
hypointense lesions reflect irreversible demyelination and axonal loss (Napoli & 
Bakshi, 2005). In contrast, T2-weighted scan-identified lesions, which are non- 
specific for the underlying pathology, reflect the accumulated lesion load or “burden 
of disease” (Sinnecker et al., 2012) and occur throughout the brain and white matter, 
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but less commonly, the grey matter (Napoli & Bakshi, 2005). Nevertheless, the 
possibility that localised white matter atrophy and loss of white matter microstructural 
integrity within specific brain regions could influence MS fatigue symptoms should 
not be overlooked. Consistent with this observation, there is evidence that atrophy 
progression within the corpus callosum (largest collection of brain white matter) is 
implicated in the evolution of MS-related fatigue (Yaldizli et al., 2010). Furthermore, 
other studies have provided evidence of localised metabolic alterations or anisotropic 
changes in white matter adjacent to the lateral and medial pre-frontal cortex and in 
fibres connecting basal ganglia structures (Hanken et al., 2015). 
 
Meta-analysis revealed a reduction in muscle strength (MVC) in MS-HF versus MS- 
LF, which consolidates a conflicting body of data on this measure from studies 
investigating PwMS (irrespective of fatigue status) versus HC (Zijdewind et al., 2016). 
Greater cortico-subcortical grey matter atrophy and/or structural damage in MS-HF 
versus MS-LF could have a more pronounced effect on neural transmission from the 
brain to active skeletal muscles, and this could account for the reduced MVC. (Rocca 
et al., 2012) reported a more diffuse pattern of spinal cord interneuron activation in 
the axial and longitudinal planes in MS-HF versus MS-LF, which they speculated 
could be attributable to abnormally functioning local circuits, altered modulation from 
supraspinal pathways and/or local and remote structural damage. However, findings 
from our meta-analyses suggest that the relative integrity of corticospinal motor 
pathways is similar in MS-HF and MS-LF, as there were no differences in MEP 
variables or central motor conduction time between the groups. In contrast, a 
significant increase in MEP threshold was apparent for MS-HF and MS-LF versus 
HC, consolidating inconsistent data from previous studies on this measure of 
corticospinal excitability (Zijdewind et al., 2016). 
 
Our meta-analyses revealed clear evidence of impaired voluntary activation (central 
motor drive) in MS-HF versus MS-LF, suggesting MS-HF have a relatively impaired 
ability to fully activate skeletal muscles in comparison with MS-LF. This may explain 
the observed reduction in MVC in MS-HF versus MS-LF, as previous studies have 
reported significant correlations between the decline in MVC and voluntary activation 
during sustained muscular contractions in PwMS (Zijdewind et al., 2016; Mamoei et 
al., 2020). Although females are reported to record lower MVC and voluntary 
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activation values than males (Solianik et al., 2017), the higher female to male ratio in 
the included studies is unlikely to account for these findings, as MS-HF and MS-LF 
comparison groups tended to be well-balanced for sex. An alternative explanation for 
the lower MVC and voluntary activation scores in MS-HF could be the deconditioning 
effects of relative physical inactivity after an MS diagnosis, which may be further 
compounded by the experience of severe MS fatigue (Sebastiao et al., 2017). Relative 
inactivity leads to disuse atrophy and neurophysiological changes affecting skeletal 
muscle activation, leading to impaired muscular strength and function (Rice et al., 
1992). In turn, this could increase the amount of effort required for everyday tasks, 
thus exacerbating perceived fatigue and fatigability. 
 
Current data provides no clear evidence of a link between MS fatigue and altered 
intracortical inhibition (SICI) or intracortical facilitation (ICF), despite reports of 
altered functional connectivity and hyperactivation in fronto-parietal cortical regions, 
sensorimotor network and subcortical areas important for motor, sensory and 
cognitive processing in MS-HF (Tartaglia et al., 2008; Specogna et al., 2012; Rocca 
et al., 2016; Bisecco et al., 2017; Jaeger et al., 2018). Evidence from functional 
magnetic resonance imagery and electroencephalogram studies suggests that 
functional reorganisation within cortico-subcortical networks as a compensatory 
response to MS brain lesions could account for an increased energy demand for neural 
processing within certain networks (Filippi & Rocca, 2004; Kos et al., 2008). This 
could at least partially explain increased perceptions of fatigue in PwMS because of 
an elevated demand on functioning neural circuits. However, at present very few 
studies have compared SICI or ICF variables between MS-HF and MS-LF, making it 
difficult to draw conclusions about the extent to which modulation of intracortical 
inhibitory or facilitatory networks could be implicated in MS fatigue. The limited 
conflicting data that is currently available for SICI may be a reflection of different MS 
populations studied, as two of the published studies were focused on people with 
relapsing-remitting MS (Liepert et al., 2005; Morgante et al., 2011), whereas a third 
was focused on progressive MS (Chalah et al., 2019). 
 
Meta-analysis of five studies revealed an increased level of upper-limb fatigability for 
MS-HF versus MS-LF, showing a more pronounced decline in force production. In 
contrast, only one of the included studies with a small sample size (N=9) compared 
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lower-limb fatigability between MS-HF and MS-LF (Ng et al. 2000) using a sustained 
30% MVC dorsi-flexor protocol. There is no standardised method for assessing 
fatigability (Severijns et al., 2017) and this is reflected in the broad range of protocols 
used in comparisons of PwMS versus HC. It is also acknowledged that fatigability is 
task specific, being influenced by task complexity (Wolkorte et al., 2015b), and that 
heterogeneity between patients (attributable to MS-specific functional impairments 
and differences in motor control) can confound fatigability measures (Severijns et al., 
2017). However, aside from measurement of force decline over time, consistent 
fatigability data for MS-HF versus MS-LF have been reported in studies that have 
used exercise duration and number of muscular contractions before reaching a fatigue 
criterion (Perretti et al., 2004; Liepert et al., 2005). Evidence suggests that fatigability 
resulting from a sustained voluntary muscle contraction in PwMS mainly results from 
a decline in voluntary activation, whereas in healthy controls fatigability seems to be 
mainly of peripheral origin at the level of skeletal muscle (Sheean et al., 1997; Steens 
et al., 2012c; Severijns et al., 2017). An elegant study that combined imaging and 
electrophysiological techniques showed that in PwMS there was an inability to 
increase cortical activation in response to fatigability-related changes downstream of 
the motor cortex, which was at odds with the increase in cortical activation observed 
in HC (Steens et al., 2012c). Our meta-analysis of upper-limb data suggests that MS- 
HF may have less ability than MS-LF to increase cortical activation as a compensatory 
response to peripheral fatigue and this warrants further study. In addition, the relative 
paucity of lower-limb studies needs to be addressed, as PwMS more commonly report 




Key limitations of this meta-analysis include the diversity of magnetic resonance 
imagery techniques used for neuroimaging studies and heterogeneity of methods used 
to assess self-reported perceived fatigue and fatigability. Furthermore, many studies 
collected either neuroimaging or neurophysiological data, which prevented an 
exploration of relationships between neuroanatomical and neurophysiological 
impairments (including the impact on fatigability measures) within the same 
participants. The broad-ranging patient characteristics and lack of participant ethnicity 
data across different studies may also be considered as a limitation, although 
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confounders such as disease severity, level of disability, sex and age were minimised 
in the larger data-set meta-analyses. Nevertheless, some of the meta-analyses included 
a small number of studies and as the overall quality rating of included studies was 
‘moderate’, as such, caution is needed when interpreting these results. In addition, 
although the Agency for Healthcare Research and Quality (Zeng et al., 2015) is 
suitable for use in systematic reviews of cross-sectional studies, there is no obvious 
candidate tool for assessing the quality of observational/cross-sectional studies, which 
may be considered a study limitation. Finally, the method used to differentiate MS- 
HF and MS-LF in the included studies was based on previously published cut-points 
for the FSS and MFIS that rely on recollections of fatigue experiences over the 
previous 1 - 4 weeks. Fatigue can be sporadic and the intensity of fatigue symptoms 
amongst PwMS at the time of testing was not well-documented in many studies. 
 
4.9 Conclusion 
In conclusion, this is the first meta-analysis to synthesise published cross-sectional 
data on structural and neurophysiological measures between MS-HF and MS-LF. The 
results indicate that higher levels of MS fatigue are characterised by greater cortico- 
subcortical grey matter atrophy and brain lesions, reduced muscular strength, reduced 
central drive (voluntary activation), and increased upper-limb fatigability. By 
consolidating an extensive and somewhat conflicting evidence-base, the meta-analysis 
provides new insights into neurobiological differences that exist between MS-HF and 
MS-LF. This is an important step in delineating key homeostatic and 
psychophysiological pathways underpinning perceived fatigue and fatigability in 
PwMS. 





















CHAPTER 5 – Test-Retest Reliability of Neurophysiological Measures in 
People Experiencing High and Low Levels of MS-Fatigue 
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5.1 Introduction 
Neurofunctional deficiencies are associated with perceived fatigue in MS, often 
experienced as extreme tiredness or exhaustion (unrelated to recent physical exertion) 
and an increased sense of effort for everyday tasks, frequently accompanied by mood 
changes, poor sleeping patterns and pain (Kluger et al., 2013a). Neurophysiological 
correlates of perceived MS-fatigue can be assessed using techniques that evaluate 
cortical function, the integrity of the corticospinal pathway and performance of motor 
behaviours (Anand & Hotson, 2002; Rocca et al., 2009). Previous work has reported 
impairments in muscle strength (Ng et al., 2004; Liepert et al., 2005; Wolkorte et al., 
2016; Jørgensen et al., 2017), increased skeletal muscle fatigability (Sheean et al., 
1997; Liepert et al., 2005; Wolkorte et al., 2016) and reductions in voluntary muscle 
activation (Wolkorte et al., 2016) in MS patients. On the basis of current evidence, it 
is unclear whether there are alterations in corticospinal excitability or intracortical 
inhibition (Perretti et al., 2004; Todd et al., 2004; Liepert et al., 2005) in people 
experiencing high levels of perceived MS-fatigue, in comparison with healthy adults., 
To date, no studies have investigated the test-retest reliability and measurement error 
of such neuromuscular measures in people experiencing high (clinically important) 
and low levels of  perceived MS-fatigue. 
 
For the useful application of neuromuscular and transcranial magnetic stimulation 
measures, they must be able to yield reproducible data over repeated assessment 
sessions and/or multiple muscle representations (Malcolm et al., 2006; Furlan & Sterr, 
2018) with low measurement error. Test-retest reliability has been shown to vary 
widely across different neurophysiological measures in upper-limb studies of healthy 
individuals (Cicinelli et al., 1997; Fritz et al., 1997; Carroll et al., 2001; Wassermann, 
2002; De Gennaro et al., 2003b; Orth & Rothwell, 2004; Wolf et al., 2004; Koski et 
al., 2005; Nuzzo et al., 2019). Furthermore, limited evidence exists informing the 
reliability of these measurements in lower limb muscles (Frontera et al., 1993; Cacchio 
et al., 2009; Wheaton et al., 2009; Jørgensen et al., 2017). Moreover, very few 
neurophysiological studies have assessed variability of measurement and test-retest 
reliability in PwMS (Schwid et al., 2002; Surakka et al., 2004b; Sehle et al., 2014) and 
none have compared the test-retest reliability of neurophysiological correlates in 
people experiencing high and low levels of perceived MS-fatigue. Approximately 
75% of PwMS are affected by lower-limb sensorimotor impairment (Johansson et 
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al., 2007) and the majority of experimental studies have focused on the lower-limbs 
(Dalgas et al., 2008; de Souza-Teixeira et al., 2009). Nonetheless, 66% of the PwMS 
experience upper-limb motor impairment (Spooren et al., 2012). These studies 
highlight the high level of lower- and upper-limb neuro-dysfunctional heterogeneity 
amongst PwMS, which has important consequences for studies of neurophysiological 
function and the temporal stability of neurophysiological measures. For example, the 
degree of neuromuscular impairment in a particular limb could influence the test-retest 
reliability of related neurophysiological measurements. 
 
The most commonly reported measure of test re-test reliability is intraclass correlation 
coefficients (ICC). Test-retest measurements using ICC of muscle strength in PwMS 
vary between 0.46 and 0.96 (Djaldetti et al., 1996; Schwid et al., 1999; Surakka et al., 
2004b). One study by Surakka et al. (2004b) used a sample size of 28 and reported 
excellent day-to-day reliability using the ICC = 0.97 for maximal isometric torque of 
the knee flexors and extensors using a knee dynamometer in PwMS. Another study 
reported larger variability for motor fatigability measures for muscles of the lower- 
and upper-limbs in PwMS, but showed that elbow extensor fatigability correlated with 
hand grip fatigability (Schwid et al., 1999), supporting a probable central underlying 
mechanism of performance fatigability in PwMS (Schwid et al., 2002). 
 
To date, no studies have reported on the reliability of neurophysiological correlates of 
MS perceived fatigue or fatigability in upper- and lower-limb muscle groups in well- 
characterised PwMS on the basis of fatigue status (i.e., MS-HF versus MS-LF). 
Understanding the repeatability and measurement error measures are fundamental to 
our understanding of the neurophysiology of perceived MS-fatigue and performance 
fatigability and will provide guidance for the design of experimental protocols used in 
subsequent Chapters of this Thesis. Test-retest reliability data of neurophysiological 
fatigue correlates in people experiencing high levels of perceived MS-fatigue is also a 
fundamental step in understanding how exercise-induced improvements in these 
measures are associated with the magnitude of MS-fatigue symptoms. The aim of this 
study was to establish the test-retest reliability, variability and measurement error of a 
comprehensive set of upper- and lower-limb neuromuscular and transcranial magnetic 
stimulation measures (knee-extensors and wrist-flexors, respectively) in people 
experiencing higher and lower levels of perceived MS-fatigue and healthy controls. 
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5.2 Methods 
5.2.1 Participants 
Following ethical approval (3.2.1 Ethical Approval), 40 PwMS from the Department 
of Neurology at the Royal Victoria Infirmary Hospital, Newcastle upon Tyne national 
health service Foundation Trust volunteered to partake in the study. The 40 relapsing- 
remitting MS patients (EDSS <5) met all criteria for participation (3.3.1 Inclusion and 
Exclusion Criteria) and were recruited as follows; patient referral at clinic (n=23), 
advertising flyers (n=11), and postal letters (n=6) (3.3.1 Recruitment). Additionally, 
twenty right-handed healthy volunteers (HC) without a history of neurological illness, 




Table 5.1 Participant Characteristics.  
HC MS-LF MS-HF 
N 20 20 20 
Age (years) 44.8 ± 15.1 45.9 ± 9.0 43.6 ± 10.2 
Gender (F/M) 13/7 15/5 15/5 
EDSS (arbitrary units) - 2.1 ± 1.2 2.4 ± 1.4 
Disease Duration (years) - 9.8 ± 3.8 9.9 ± 5.5 
Disease modification Therapy - 17/3 14/6 
(Y/N)   
Other comorbidities (Y/N) 4/16 6/14 9/11 
FSS 2.2 ± 1.0 3.5 ± 1.1 6.0 ± 0.6 
HADS 6.8 ± 5.6 9.0 ± 5.4 13.7 ± 4.8 
FSS: Fatigue Severity Scale; HADS: Hospital and Anxiety Depression Scale; HC: Healthy Control; MS-LF: 
Less-Fatigued People with Multiple Sclerosis; MS-HF: Highly-Fatigued People with Multiple Sclerosis N: 
Numbers; F: Females; M: Males; EDSS: Extended Disability Status Scale; Y: Yes; N: No, Data reported as 
Mean ± SD. 
 
 
5.2.2 Experimental Protocol 
Prior to engaging in studies of neurophysiological function, participants attended the 
laboratory where their perceived symptoms of fatigue were measured (3.9.1 Fatigue 
Severity Scale). Mood was also determined (3.9.2 Anxiety and Depression) (Bakshi 
et al., 2000), and contraindications to the experimental procedures were assessed with 
a study-specific health questionnaire. Eligible participants then provided written 
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informed consent (3.3.2 Informed Consent) before undergoing a 60 min 
familiarisation of the entire neuromuscular protocol (see 3.4 Familiarisation and 3.6 
Neuromuscular Assessment), with experimental controls being implemented as 
previously described (3.5 Experimental Criterion). Participants visited the laboratory 
on four separate occasions, comprising of two visits for the neuromuscular assessment 
of the knee-extensors, and two visits for the wrist-flexor muscles. The order of 
experimental visits was randomised and separated by 2-14 days. Each experimental 
visit involved approximately 35 minutes of neuromuscular data collection at rest, 
followed by a submaximal intermittent exercise task to task failure, as previously 
described (3.7.2 Submaximal Test Protocol). All neuromuscular measures were then 
repeated. 
 
5.2.3 Neuromuscular Assessment 
Neuromuscular assessments were performed according to Figure 5.1. Following 
determination of supramaximal motor nerve stimulation intensity (3.7 Percutaneous 
Stimulation), the participant performed MVCs (3.6.1 Force and Electromyography 
Recordings). The twitch interpolation technique (Allen et al. 1995b) was used for the 
measurement of voluntary activation (3.7.1 Voluntary Activation) and to record the 
potentiated resting twitch (3.7 Percutaneous Stimulation). EMG was recorded during 
voluntary and evoked contractions at rest (3.6.1 Force and Electromyography 
Recordings). Determination of active motor threshold for transcranial magnetic 
stimulation-related measurements, corticospinal excitability and inhibition were 
recorded (3.8 Transcranial Magnetic Stimulation and 3.8.1 Short Interval Intracortical 
Inhibition) as well as CSP (3.8.2 Corticospinal Silent Period). During each 
experimental visit, the participant performed a submaximal intermittent exercise task 
to task failure for the wrist flexor and the knee extensor, defined as previously 
described (3.7.2 Submaximal Test Protocol). 




Figure 5.1 Schematic of test re-test neuromuscular protocol, (A) test re-test 
neuromuscular intervals of 2-14 days between knee-extensors and wrist-flexors, (B) 
Neuromuscular assessment including, percutaneous nerve stimulation, transcranial 
magnetic stimulation and submaximal task to failure. 
 
5.2.4 Perceived Fatigue 
To assess subjective fatigue and determine two fatigue groups, PwMS completed the 
nine-item self-report FSS questionnaire developed and validated by Krupp et al. 
(1989). High-fatigue was defined as FSS>5 and low-fatigue as FSS<4. The FSS has a 
high internal consistency was demonstrated by a Cronbach's alpha of 0.88. Test-retest 
analysis between two time points, separated by 5 to 33 weeks, have shown no 
statistically significant differences in a group of clinically stable patients with MS or 
systemic lupus erythematosus (Krupp et al., 1989). Additionally, to measure 
symptomatic fatigue, a small number of scales were completed at the beginning of two 
separate experimental visits with severity, frequency and impact of fatigue in everyday 
life recorded (Fatigue Severity Scale; Modified Fatigue Impact Scale and Chalder 
Fatigue Scale). 
 
5.2.5 Patient Reported Outcomes 
Mood (3.9.2 Anxiety and Depression), sleep quality (3.9.3 Sleep Quality) and pain 
experienced (3.9.4 Pain) were also measured by means of perceptual scales at the 
beginning of two separate experimental visits. 
- 70 -  
5.2.6 Data Analysis 
Voluntary activation using motor nerve stimulation was determined using the 
interpolation twitch technique (Allen et al., 1998) by comparing the amplitude of the 
superimposed twitch with the amplitude of the potentiated resting twitch (Qtw,pot) using 
the formula: VA (%) = (1 – [superimposed twitch ÷ Qtw, pot]) × 100]. SICI was 
quantified as the ratio between the amplitude of conditioned MEPs to the amplitude 
of unconditioned MEPs. Corticospinal excitability was inferred from the AMT and 
expressed as the mean MEP amplitude during the 10% MVC as a percentage of Mmax. 
The root-mean-square of EMG activity (RMSEMG) was also recorded during the 
middle 500 ms epoch of a 3 s maximal contraction. All data analysis was performed 
offline using Spike 2 (v6, CED, UK). 
 
5.2.7 Statistical Analysis 
Data are presented as group mean ± SD within the text and figures and the level of 
statistical significance was set at P ≤0.05. Normal Gaussian distribution of data was 
confirmed using the Kolmogorov–Smirnov test. If a violation was detected, the data 
were logarithmically transformed. For between-session test-retest reliability, multiple 
indices were calculated: paired samples t-tests, intraclass correlation coefficient (ICC; 
Atkinson and Nevill (1998) and Hopkins (2000)) between the two time points (2-14 
days) and typical error. Within-subjects variation was calculated as the standard 
deviation of the mean differences divided by the square root of 2 and termed typical 
error. The intra-subject coefficient of variation was the typical error expressed as a 
percentage of the mean. The ICC was used to assess the relationship of each measure 
across the two experiential visits days and was defined as: <0.5 = poor, 0.5-0.75 = 
moderate, 0.75-0.9 = good, >0.9 = excellent, in accordance with Koo and Li (2016). 




5.3.1 Measurement Completion 
All participants completed neuromuscular assessments of the knee-extensors and 
wrist-flexors, except two PwMS who could not attend the last session for health 
reasons. There were incomplete transcranial magnetic stimulation measures in six 
PwMS. These MS participants were unable to complete all measurements due to 
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inadequate muscle force/inability to activate the muscle group sufficiently (n=2), 
being unable to obtain accurate MEP responses because of uncomfortableness (n=2) 
and injury (n=2). 
 
5.3.2 Reliability of Neuromuscular Measures of the Knee-Extensors 
Data for the knee extensor force variables are presented in Table 5.2. There were no 
between-day differences for MVC, Qtw, pot, TFF or VA (p >0.05) in any of the groups. 
Data for the neuromuscular variables showed good to excellent test-retest reliability 
(Qtw, pot, MVC), as evidenced by low coefficient of variation for these measures (2.6 
to 8.0%). The measure of VA also displayed good to excellent test-retest reliability for 
HC and MS-HF (ICC: 0.77 - 0.90), while for MS-LF reliability of VA was moderate 
(ICC = 0.58). VA for all groups showed a low degree of random error (coefficient of 
variation: 1.3 – 1.9%; typical error: 1.1 to 1.9%). Similarly, TTF showed excellent 
test-retest reliability for HC (ICC = 0.93), while for MS-LF and MS-HF test-retest 
TTF reliability was good (ICC ≥ 0.76) with relatively low typical error and coefficient 
of variation (3.0 to 4.3 min; 9.9 to 13.5%, Figure 5.2 respectively). 
 
The test-retest reliability of surface electromyography variables of the knee-extensors 
are presented in Table 5.2. There were no between-day differences for any of the EMG 
variables (Mmax, AMT, MEP/Mmax, RMSEMG, SICI or SP; p>0.05). Mmax 
demonstrated good test-retest reliability (ICC ≥ 0.84) for all the groups, with low 
typical error and coefficient of variation ranging from 0.39 to 0.97 mV and 7.2 to 
12.3%, respectively. AMT demonstrated good test-retest reliability in HC (ICC = 0.87, 
Figure 5.2) and was moderately reliable in MS-LF and MS-HF (ICC: 0.67 to 0.72), 
with low typical error and coefficient of variation ranging from 3.4 to 5.7% and 4.9 to 
8.3%, respectively. The measures of SICI and SP showed good to excellent day to day 
reliability for all groups (ICC: 0.79 to 0.92), with relatively low coefficient of variation 
ranging from 7.7 to 12.3%. Other surface EMG variables showed good to excellent 
reliability (MEP/Mmax, and RMSEMG; ICC ≥ 0.80), with moderately larger test-retest 


































































































































































Figure 5.2 Scatter plot for test intraclass correlation (ICC) for test re-test of neurophysiological measurements, including (A) knee-extensors and (B) 
wrist-flexors, and (C) patient reported outcomes and fatigue scales in healthy control (HC), less-fatigued (MS-LF) and highly-fatigued (MS-HF) 
PwMS. The ICC was used to assess the relationship of each measure across the two experiential visits days and was defined as: <0.5 = poor, 0.5-0.75 







































































































Table 5.2: Typical error expressed in raw units and coefficient of variation (%) for between-day measures of force and electromyography derived outcomes for the knee-extensor muscle (Mean ± SD). 
 
HC MS-LF MS-HF 
 
CV CV CV 
Measure N Visit 1 Visit 2 P TE N Visit 1 Visit 2 P TE N Visit 1 Visit 2 P TE 
      (%)      (%)      (%) 
Force Outcomes:                   
MVC (N) 20 412 ± 77 416 ± 80 0.281 12.4 2.6 19 393 ± 66 382 ± 73 0.082 12.2 3.5 19 335 ± 68 340 ± 74 0.345 14.4 2.9 
Qtw, pot (N) 20 151 ± 48 152 ± 44 0.687 8.9 5.5 18 131 ± 38 125 ± 35 0.155 8.4 6.2 18 134 ± 21 136 ± 33 0.552 13.5 8.0 
VA (%) 20 93.3 ± 3.4 92.2 ± 3.3 0.162 1.1 1.3 18 91.7 ± 2.4 91.6 ± 3.3 0.980 1.9 1.9 18 88.1 ± 4.1 88.9 ± 3.8 0.249 1.9 1.8 
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153 ± 52 
 










170 ± 49 
 










189 ± 60 
 







CV: Coefficient of variation; HC, Healthy control, ICC: Intraclass correlation coefficient; MVC: maximum voluntary contraction, N, Number, MS-LF: Less-fatigued people with multiple sclerosis; MS-HF: Highly-fatigued people with multiple sclerosis, Qtw, 
pot potentiated twitch force, TE: Typical error, TTF: Time to task failure, VA: Voluntary activation. MEP: Motor evoked potential, N, Number, RMSEMG, Root mean squared electromyography, SICI: Short interval cortical inhibition, SP: Silent period, Mmax: 
maximum compound action potential, P: p value, TE: Typical error. 
 
5.3.3 Reliability of Neuromuscular Measures of the Wrist-Flexors 
Data for wrist extensor force variables are presented in Table 5.3. MVC, Qtw, pot, VA 
and TTF were not different between experimental visits (p >0.05) in any of the groups. 
Force variables (MVC, and Qtw, pot) showed good to excellent reliability (ICC ≥ 0.83), 
with the typical error and coefficient of variation being relatively low, ranging from 
2.6 to 14.6 N and CV from 5.9 - 10.9%, respectively. Measures of VA demonstrated 
moderate to good test-retest reliability in all groups (ICC: 0.71 - 0.76, Figure 5.2) and 
there was a relatively low degree of random error (coefficient of variation: 1.8 – 2.9%) 
and typical error (2.2 - 2.7%). Similarly, TTF showed good to excellent reliability 
(ICC: 0.79 - 0.94), with low typical error and moderate coefficient of variation ranging 
from 1.6 to 5.6 min and 14.5 to 15.8%, respectively. 
 
Test-retest reliability analysis of surface electromyography variables for the wrist- 
flexors are presented in Table 5.3. There were no between-day (visit 1 and 2) 
differences in any of the transcranial magnetic stimulation measurements for all 
groups (Mmax, AMT, MEP/Mmax, RMSEMG, SICI or SP; p>0.05). Furthermore, data 
for Mmax, AMT, MEP/Mmax and RMSEMG showed excellent test-retest reliability 
(ICC ≥ 0.87), while the typical error and coefficient of variation ranged from 0.08 to 
3.8, with a moderately larger coefficient of variation ranging from 4.6 to 18.7%. 
Between-day measures of SICI and SP were moderate to good (ICC: 0.58 to 0.86) but 




5.3.4 Reliability of Perceived Fatigue and Patient Reported Outcomes 
Perceived fatigue data are presented in Table 5.4. There were no between-day 
differences for any of the self-reported fatigue scales (FSS, MFIS, and CFS; p >0.05), 
with all measures demonstrating excellent test-retest reliability (ICC ≤ 0.89, Figure 
5.2). The typical error (≤ 2.4) and coefficient of variation (≤ 10.4%) were also 
relatively low. Test-retest reliability for patient-reported scales can be viewed in Table 
5.4. There were no between-day differences for the co-existing symptom scales 
(HADS, HADS-Anxiety, HADS-Depression, NARCOMS Pain or PSQI) (p >0.05) 
and excellent reliability (ICC ≤ 0.80) for all groups. The typical error was low (≤ 1.3) 





Table 5.3: Typical error expressed in raw units and coefficient of variation (%) for between-day measures of force and electromyography derived outcomes for the wrist-flexors muscle (Mean ± SD). 
 
 HC      MS-LF      MS-HF  
Measure N Visit 1 Visit 2 P TE CV (%) N Visit 1 Visit 2 P TE CV (%) N Visit 1 Visit 2 P TE CV 
(%) 






136 ± 28 
 










125 ± 24 
 










98 ± 21 
 







Qtw, pot (N) 20 31 ± 16 32 ± 15 0.324 3.3 9.8 16 23 ± 9 25 ± 9 0.158 2.6 10.4 20 26 ± 10 25 ± 9 0.650 3.3 10.9 






22 ± 13 
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10.39 ± 3.98 
 










9.17 ± 9.21 
 



















MEP Threshold 20 45 ± 10 44 ± 9 0.057 2.3 4.8 16 52 ± 12 53 ± 11 0.227 2.5 4.6 17 54 ± 10 54 ± 10 0.661 4.8 6.8 
(AMT%)                   






0.58 ± 0.35 
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0.72 ± 0.21 
 










0.71 ± 0.27 
 












133 ± 22 
 










142 ± 20 
 










155 ± 28 
 







CV: Coefficient of variation; HC, Healthy control, ICC: Intraclass correlation coefficient; MVC: maximum voluntary contraction, N, Number, MS-LF: Less-fatigued people with multiple sclerosis; MS-HF: Highly-fatigued people with multiple sclerosis, Qtw, pot 
potentiated twitch force, TE: Typical error, TTF: Time to task failure, VA: Voluntary activation. MEP: Motor evoked potential, N, Number, RMSEMG, Root mean squared electromyography, SICI: Short interval cortical inhibition, SP: Silent period, Mmax: 
maximum compound action potential, P: p value, TE: Typical error. 
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Self-Reported Fatigue Outcomes: 
Table 5.4: Typical error expressed in raw units and coefficient of variation (%) for between-day measures of self-reported fatigue and patient-reported outcome variables (Mean ± SD). 
 
HC MS-LF MS-HF 
Measure N Visit 1 Visit 2 P TE CV 
(%) 
N Visit 1 Visit 2 P TE CV 
(%) 











10.8 ± 3.7 
 










22.7 ± 6.0 
 










47.0 ± 14.1 
 












1.9 ± 1.4 
 










4.0 ± 2.9 
 










5.9 ± 2.8 
 














7.6 ± 3.8 
 










9.0 ± 5.4 
 










13.2 ± 4.5 
 












5.1 ± 2.8 
 










5.8 ± 3.2 
 










9.0 ± 3.2 
 







Anxiety                   
HADS- 20 2.6 ± 1.7 2.4 ± 1.5 0.545 0.9 11.4 20 3.3 ± 2.8 3.3 ± 2.3 0.804 0.6 15.4 20 4.6 ± 2.5 4.8 ± 2.5 0.330 2.5 16.9 
Depression                   
NARCOMS 20 1.2 ± 1.0 1.2 ± 1.0 1.000 0.2 3.8 20 1.5 ± 1.2 1.6 ± 1.2 0.577 0.3 5.2 20 2.1 ± 1.3 1.9 ± 1.3 0.104 0.08 19.3 






6.9 ± 2.9 
 










7.9 ± 3.6 
 










9.6 ± 4.9 
 







CV: Coefficient of variation; HC, Healthy control, ICC: Intraclass correlation coefficient; MVC: maximum voluntary contraction, N, Number, MS-LF: Less-fatigued people with multiple sclerosis; MS-HF: Highly-fatigued people with multiple sclerosis, Qtw, pot 
potentiated twitch force, TE: Typical error, TTF: Time to task failure, VA: Voluntary activation. MEP: Motor evoked potential, N, Number, RMSEMG, Root mean squared electromyography, SICI: Short interval cortical inhibition, SP: Silent period, Mmax: maximum 
compound action potential, P: p value, TE: Typical error. 
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5.4 Discussion 
The aim of the present study was to establish the test-retest reliability, variability and 
measurement error of a comprehensive set of upper- and lower-limb neuromuscular and 
transcranial magnetic stimulation measures (knee-extensor and wrist-flexor, respectively) in 
people experiencing high and low levels of MS-fatigue, and to compare data from PwMS with 
healthy age and sex-matched controls. 
 
To date, no studies have reported the reliability of neurophysiological correlates of MS-fatigue 
in upper- and lower-limb muscle groups in PwMS experiencing very different levels of fatigue 
(i.e., MS-HF versus MS-LF). This study demonstrates that a broad selection of neuromuscular 
and transcranial magnetic stimulation measurements have good to excellent ICC values (Figure 
5.2) that are in accordance with Koo and Li (2016), but with the exception of moderate test re- 
test reliability of VA, SICI and SP. Moreover, ICC values were generally greater and 
demonstrated better day-to-day reliability in the lower limb compared with the upper limb 
muscles in PwMS. This study also demonstrates that patient-reported outcomes such as, 
fatigue, mood and sleep quality are highly reproducible in PwMS experiencing different levels 
of fatigue. This is the first study to provide data on the repeatability of neuromuscular and 
transcranial magnetic stimulation measures for lower-limb (knee-extensors) and upper-limb 
(i.e., wrist-flexors) muscle groups for a homogenous group of people experiencing high 
(clinically important) and low levels of MS-fatigue. The good to excellent test-retest reliability 
for many of the measures provides support for their utility in studies of MS-fatigue, including 
therapeutic interventions. 
 
Maximum strength and voluntary activation across people experiencing different levels of 
MS-fatigue. 
Manual muscle testing, hand-held dynamometry and isometric or isokinetic dynamometer 
recordings have been used in previous studies in PwMS to assess muscular strength but 
published reliability data for such measures in well-characterised PwMS on the basis of fatigue 
status is limited. Nevertheless, results for maximal muscle force (MVC) were highly 
reproducible and corroborate previously published research on the reliability of force measures 
for the knee extensors (Surakka et al., 2004b) and for grip strength (Schwid et al., 1999) in 
PwMS not characterised by fatigue status. Reliability data were also similar to previous work 
in the elbow flexors (Meeteren et al., 2002) and knee extensors (Frontera et al., 1993; Dvir, 
2004) for healthy individuals. However, the results indicate that in comparison with healthy 
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controls, PwMS were found to be weaker in upper extremity muscles, whereas lower extremity 
strength is relatively preserved. In the present study, the MVC yielded a low measurement error 
at the group level for the knee-extensors compared to the wrist-flexors, which might suggest 
poorer reliability in muscle groups that are more severely affected by MS (see Tables 5.2 and 
5.3). 
 
Voluntary activation was measured using the interpolated twitch technique method and showed 
moderate to good reliability in MS-HF and further moderate to excellent in MS-LF. Data from 
this reliability analysis corroborates previous findings in PwMS whereby consistency in 
measurement and evidence of good reliability but with lower voluntary activation in PwMS 
reveals a central underlying mechanism at least partly explaining the inability to produce higher 
force, as reported elsewhere (Ng et al., 2000b; Ng et al., 2004; Andreasen et al., 2009; Steens 
et al., 2012b; Severijns et al., 2017). The reported low typical error and coefficient of variations, 
particularly for the knee-extensors compared to the wrist flexors, suggests smaller intra-subject 
variation in fatigued PwMS for the lower-limb, which means that the ability to reproduce fine 
motor skills in the wrist might be more compromised by impaired strength and more gross 
motor ability. Additionally, it might also be partly due to the difference in corticospinal 
projections between upper and lower limb, suggesting greater central neural drive. Therefore, 
the larger variability in the upper limb brings to light the possibility that impaired neural drive 
from the motor cortex has a more profound effect on the consistency of upper limb movements 
in fatigued PwMS (Amato et al., 2001). Further exploration of this phenomenon is warranted 
to better understand the differences between people experiencing higher and lower levels of 
MS-fatigue. 
 
However, the technical challenges of measuring voluntary activation in PwMS need to be 
considered. Firstly, it was not possible to measure voluntary activation in four participants 
because of an inability to electrically stimulate sufficient muscle mass, and this might have 
been caused by the presence of greater subcutaneous and intramuscular fat (Ivanyi et al., 1998; 
Tolback et al., 1996). Secondly, voluntary activation was measured during maximal isometric 
contractions performed on a custom-made, adjustable dynamometer. In particular, the wrist 
extensors assessment required the arm and wrist angle to be individually adjusted to optimal 
muscle length, which differed between participants. Previous studies indicate that the force- 
activation relationship is influenced by muscle length in voluntary activation measurements 
(Bülow et al., 1993; Becker & Awiszus, 2001) and the ability to achieve optimal muscle length 
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in all participants is unclear. Nevertheless, the levels of test-retest reliability observed in this 
study support the use of these muscle strength measures and the twitch interpolation technique 
for measuring VA in upper and lower limb muscle groups, consistent with evidence from 
previous studies in healthy individuals and PwMS not partitioned on the basis of fatigue status 
(Merton, 1954b; Strojnik & Komi, 2000; Hartman et al., 2011; Gandevia et al., 2013; Thomas 
et al., 2017). 
 
Fatigability across people experiencing different levels of MS-fatigue 
Using the time to task failure design as a measure of performance fatigability, reliability 
analyses reveal time to task failure can be measured with good to excellent test-retest reliability 
in both the lower limb and the upper limb. The time to task failure was highly reproducible, 
corroborating findings from previous studies in PwMS not characterised by fatigue status (ICC: 
0.71- 0.96, respectively, Schwid et al. (2002)). In fact, the test re-test reliability was higher than 
previously reported by Lambert et al. (2001) who showed poor to moderate reliability. 
However, their study investigated an isokinetic task of dynamic knee extension and flexion, 
rather than a single muscle group contracting isometrically to task failure, as used in the present 
study. Nevertheless, the data reported by Lambert et al. (2001) are important because the 
measures were based on dynamic muscle actions which may be more representative of 
everyday movements than isometric muscle actions. Differences between the time to task 
failure tasks may be an explanation for these discrepant results as sustained muscle actions are 
not synonymous with intermittent muscle actions. Muscle activation (Vøllestad, 1997) and 
brain activation patterns (Liu et al., 2005) differ between sustained and intermittent muscle 
action protocols, which should be taken onto account when quantifying performance 
fatiguability and assessing reliability of the measure. 
 
Corticospinal and Intracortical Properties across people experiencing different levels of MS- 
fatigue 
Corticospinal measures evoked using transcranial magnetic stimulation were highly reliable, 
notwithstanding poorer reliability for active motor threshold in both MS groups. The level of 
test re-test reliability of corticospinal properties corroborated the findings of Meaney et al. 
(2015; >0.80). However, their study explored the within session and test–retest consistency of 
MEP elicited by transcranial magnetic stimulation from the resting tibialis anterior muscle in 
a smaller cohort of PwMS not characterised by fatigue status (N=10; two men, eight women). 
Despite small intra-subject variability, the results were limited by the small number of PwMS 
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taking part, and further studies were recommended (Meaney et al., 2015). Healthy individuals 
demonstrated good to excellent reliability in all transcranial magnetic stimulation -related 
measurements in the present study, consistent with data reported for the upper-limb muscles 
by others (Mortifee et al., 1994; Carroll et al., 2001; Malcolm et al., 2006). In terms of 
reliability, corticospinal excitability (MEP/Mmax) in PwMS was moderate to good, consistent 
with previous research. Furthermore, the greater coefficient of variation for this measure in the 
present study (>10%), signifies a higher intra-subject variability. Overall, average responses to 
transcranial magnetic stimulation measurements were lower in PwMS due to uncomfortable 
nature of the tests, which should be taken into account when taking multiple measures of MEP 
throughout an intervention. 
 
Abnormalities of corticospinal silent periods including lengthening of silent period (SP) have 
previously been reported in various neurological disease states, including stroke (Kukowski & 
Haug, 1992; Braune & Fritz, 1995), Parkinson’s Disease (Priori et al., 1994a) and motor 
neurone disease (Triggs et al., 1992). This study showed that SP measurements are highly 
reliable in PwMS experiencing high (clinically important) and low levels of fatigue, despite 
lower reliability for MS-HF in the wrist flexor muscles. Our results, for SP are consistent with 
those of Reid and colleagues (2002), who reported a high intra-examiner reliability, but poor 
inter-examiner reliability. However, in the present study, a greater intra-subject variability was 
shown, consistent with findings from previous studies that reported across sessions SP 
variations ranging from <5 to 15% in healthy individuals (Orth & Rothwell, 2004; Koski et al., 
2005). One possible influence on SP variability is the high transcranial magnetic stimulation 
intensity required for AMT (Wolf et al., 2004), as observed in the present study for PwMS 
compared to HC, and with the higher intensity comes an increased risk of saturation. 
Additionally, the proposed method of choice for measurement of SP duration has been the 
focus of some discussion (Škarabot et al., 2020). There is evidence that computer automated 
analysis can yield more reliable data that manual analysis (Daskalakis et al., 2003). Despite 
this, previous research by (Hermsen et al., 2016a) compared both methods regarding test–retest 
reliability and demonstrated similar, moderate reliability for visual (manual) and automated 
analysis of SP durations (r = 0.466, r = 0.486, respectively). These latter results support the 
utility of both methodological approaches for deriving this corticospinal measure of inhibition, 
and the results of the present study suggest that the manual method is sufficiently reliable for 
use in studies of PwMS. 
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Evidence for the reliability of SICI in healthy controls is inconclusive (Boroojerdi et al., 2000; 
Maeda et al., 2002; Wassermann, 2002). In the present study, reliability analysis demonstrated 
that SICI in MS-HF and in MS-LF was highly reliable, and with slightly lower test re-test 
reliability for HC (ICC: 0.76-0.85). However, the reported higher coefficient of variation 
(<16%) for SICI could reflect inherent differences between participants, including EDSS, 
disability duration and age (Cahn et al., 2003; McGregor et al., 2012). The strong reliability of 
MVC and Mmax in fatigued PwMS suggests that the greater level of variability for SICI and 
SP was not a result of changes in contraction strength or neuromuscular transmission at the 
level of skeletal muscle, but the impairment of central neural drive. 
 
Due to the large number of women in this study (reflecting the higher prevalence of MS 
amongst females), the effect of menstrual cycle phase on cortical excitability and inhibition 
should be considered a potential confounding factor for neurophysiological measurements, and 
should be taken into account when undertaking repeated measures throughout an intervention 
(Smith et al., 2000; Cahn et al., 2003; Hattemer et al., 2007; Ansdell et al., 2019). Only a few 
transcranial magnetic stimulation reliability studies have included women (Maeda et al., 2002; 
De Gennaro et al., 2003a; Christie et al., 2007; Siniatchkin et al., 2011; Ansdell et al., 2019), 
and few have specified the phase of the menstrual cycle in which transcranial magnetic 
stimulation was performed and the impact on cortical excitability (De Gennaro et al., 2003a; 
Siniatchkin et al., 2011; Ansdell et al., 2019). Hence, the variability of measuring corticospinal 
excitability could be influenced by the timing of assessment sessions in relation to the phase of 
the menstrual cycle in female participants recruited to the present study, as well as pre- and 
peri-menopausal effects. However, the high levels of reliability observed in the present study 
suggest that corticospinal and inhibitory measurements could be useful for studies of 
neuromuscular function in people with MS-fatigue. 
 
Patient reported outcomes across people experiencing different levels of MS-fatigue. 
Self-reported fatigue showed high reliability for all measures and for all groups, consistent with 
previously published studies of PwMS (ICCs of 0.80-0.94; Feng and Rensel (2019)). Fatigue 
might be secondary to sleep and mood problems, which are frequently present in MS and, in 
turn, may result from urinary problems, spasms, pain, or anxiety (Kos et al., 2008). Thus, 
multidimensional approaches to symptom research are important and for the present study we 
included patient-reported scales for co-existing symptoms (HADS, HADS-Anxiety, HADS- 
Depression, NARCOMS Pain or PSQI). The present data demonstrated good to excellent 
82  
reliability for these measures in all groups, with low typical error (≤ 1.3) but larger test-retest 
coefficient of variations than the fatigue scales (≤ 15.4%). Nevertheless, this study has some 
advantages over previous studies. The gender mix and wide spectrum of disease duration and 
range of EDSS scores (0 to 5.0) in this test–retest reliability study means there was good 
representation of the mild-to-moderate PwMS population. Also, adoption of a longer inter- 
session time interval of 7-14 days could be considered a more useful analysis of the temporal 
stability of neurophysiological measures in comparison to previous studies that investigated 
transcranial magnetic stimulation -related and neuromuscular-related measures within hours or 
a few days. Furthermore, a longer time period between repeated measurements allows a 
sufficient period of recovery between sessions and, by conducting the measures at the same 
time of the day, minimises errors caused by diurnal variability. The high test-retest reliability 
of fatigue scale scores over this 7-14-day period is particularly reassuring, as the occurrence of 
severe MS-fatigue can be sporadic, and scores may be influenced by recent symptoms. 
 
5.5 Limitations 
While the present study provides important methodological information, which can be used to 
guide future investigations employing neuromuscular and transcranial magnetic stimulation- 
related measurements in the knee extensors and wrist flexors, the study is not without 
limitations. Specifically, motivation to participate in the research amongst PwMS was low, 
which could have implications for the generalisability of the results to the broader MS 
population, particularly PwMS who are less willing volunteer for research studies. The PwMS 
occasionally gave subjective feedback, such as feeling they would not do well that day due to 
a poor night’s sleep, or because the previous day had been a tiring one. These potential 
confounders cannot be well-controlled, since they are likely to be present whenever a clinical 
measurement in PwMS is attempted, and especially in MS-HF. Nevertheless, participant 
welfare was checked in the lead-up to their assessment visit and re-scheduled if participants 
were experiencing undue levels of MS-fatigue or other debilitating MS symptoms. Lastly, the 
present study extends reliability data through including both on test -re-test reliability (ICC) 
and measurement error, as Schambra et al. (2015) suggest ICC is not suffice to measuring 
reliability as it only looks at agreement between sessions (absolute reliability) and that other 
measures of measurement error (such as, 95% limits of agreement, smallest detectable change 
or minimal detectable change, (Jørgensen et al., 2017)) are also important. 
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5.6 Future Directions 
Moving forward, although the use of single investigator (intra-reliability) is common in small- 
scale experimental studies, to evolve to larger multi-site randomised trials additional research 
is needed to examine the inter-rater reliability of transcranial magnetic stimulation and 
neuromuscular measurements in PwMS classified by fatigue status. Moreover, future studies 
would benefit from the inclusion of both neuroimaging and neurophysiological measures, 
which would provide a more thorough picture of the reliability of neural correlates of perceived 
MS-fatigue and which measures have most potential to improve our understanding of 
therapeutic adaptations underpinning improvements in this debilitating symptom. The latter 
includes exercise studies with regular follow-up assessments. 
 
5.7 Conclusion 
The present study yields novel information on the reliability of neuromuscular- and transcranial 
magnetic stimulation -related measurements of the upper limb and lower-limb in PwMS 
experiencing high and low levels of fatigue. Neuromuscular measurements were generally 
reliable, with several transcranial magnetic stimulation measures displaying high reliability, 
particularly cortical excitability measures, which were found to be the most reliable. The 
application of transcranial magnetic stimulation and neuromuscular assessments in the MS 
setting has potential to provide further insight into the role of corticospinal and intracortical 
excitability in perceived MS-fatigue and performance fatigability. This study included a direct 
comparison of upper and lower limb muscles in contrast to many previous studies which 
focused on studies of single limb reliability. The results suggest that the reproducibility of most 
measures is adequate to support their use in future therapeutic studies aimed at evaluating 
underpinning neurobiological adaptations accounting for changes in perceived fatigue amongst 
PwMS, including those experiencing high (clinically important) levels of fatigue. As such, this 
Chapter presents data on the rigour of the methodological approach used in the next chapter, 
which examines neurophysiological differences at rest and in response to a fatiguing exercise 



























CHAPTER 6- NEUROPHYSIOLOGICAL DIFFERENCES BETWEEN 




Highly fatigued MS patients (MS-HF) have shown an increase in the pattern of cortical 
brain activation and changes in central-peripheral neural communication in 
comparison with MS-LF (Perretti et al., 2004; Tomasevic et al., 2013). This adaptive 
cortical brain reorganisation could be a compensatory adaptation resulting from the 
physiological consequences of MS (i.e., impaired conduction in central motor 
pathways). It might affect the ability of PwMS to maintain sufficient central drive in 
everyday whole-body activities, thus influencing perceived MS fatigue. An improved 
understanding of how perceived MS fatigue is linked to neural control and motor 
function (as important contributing factors to whole body exercise) could have 
significant implications for rehabilitation and therapeutic interventions. 
 
Differences in neurophysiological measures associated with perceived fatigue are 
shown in PwMS. For example, reductions in MVC strength (Rice et al., 1992; Sheean 
et al., 1997; Perretti et al., 2004; Zijdewind et al., 2016; Jørgensen et al., 2017), motor 
function (Ng et al., 2004) and performance fatigability during a motor task (Sheean et 
al., 1997; Liepert et al., 2005; Steens et al., 2012b; Wolkorte et al., 2016), have all 
been reported. Furthermore, several studies have identified neurophysiological 
differences between PwMS experiencing high and low levels of perceived MS fatigue. 
The decrements in strength and force production (performance fatigability) in MS-HF 
versus MS-LF (Ng et al., 2000b; Greim et al., 2007; Andreasen et al., 2009) are 
greatest during sustained voluntary muscle actions, suggestive of a centrally driven 
decline in VA. For this reason, impairments in neuromuscular function in fatigued 
PwMS appear to be, at least in part, attributable to sub-optimal insufficient central 
nervous system activation of skeletal muscle (i.e., impaired VA) during fatiguing 
exercise (Zwarts et al., 2008; Steens et al., 2012b). 
 
The important role of central factors in the more pronounced level of performance 
fatigability observed in fatigued PwMS, is further supported by recent studies showing 
no differences in the relative integrity of corticospinal motor pathways (MEP variables 
and central motor conduction time) between MS-HF and MS-LF (Colombo et al., 
2000; Perretti et al., 2004; Liepert et al., 2005; Steens et al., 2012c) . A significant lack 
of MEP facilitation in the pre-movement phase, has been previously reported after a 
sustained motor task in MS-HF compared to HC and MS-LF (Morgante et al., 2011; 
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Russo et al., 2015). As such, it is possible, disruption of brain networks involved in 
motor preparation, which has been correlated to structural and functional changes in 
frontal-thalamic pathways (Russo et al., 2015), which could partially explain increased 
perceptions of fatigue in PwMS due to an elevated demand on functioning neural 
circuits. However, few studies have compared intracortical facilitation (ICF) or 
intracortical inhibition (SICI) variables between MS-HF and MS-LF. Thus making it 
difficult to understand, whether modulation of the ICF and SICI networks are 
implicated in perceived MS fatigue, and data are further compounded by studies of 
people with relapsing-remitting MS (Liepert et al., 2005; Morgante et al., 2011) and 
progressive MS (Chalah et al., 2019). It remains unclear whether differences in the 
demands of a sub-maximal intermittent task, in homogenous groups of PwMS 
categorised by fatigue status (MS-HF and MS-LF) influence these variables. Thus, the 
role of corticospinal excitability and SICI are not assessed at rest and after a sub- 
maximal fatiguing exercise task warrants further investigation. 
 
In contrast to PwMS, performance fatigability in HC seems to be mainly of peripheral 
origin, i.e., at the level of skeletal muscle (Sheean et al., 1997; Steens et al., 2012c; 
Wolkorte et al., 2015a, 2015b, 2016; Severijns et al., 2017). However, no current 
standardised method is available for assessing performance fatigability and comparing 
it between PwMS experiencing different levels of perceived MS fatigue and HC. 
Performance fatigability has been most commonly assessed in the upper-limb and the 
relative paucity of lower-limb studies needs to be addressed. Especially as PwMS 
commonly report issues of fatigability in relation to lower-limb activities such as 
walking (Severijns et al., 2017). In turn, this could increase the amount of effort 
required for everyday tasks, thus exacerbating perceived fatigue and fatigability. In 
addition, there is a lack of studies that have investigated both upper- and lower-limb 
neurophysiological differences in the same participants, likely due to the physical 
demand and resources available. 
 
The underlying neurophysiological mechanisms contributing to MS fatigue warrant 
further investigation because many previous studies have recruited heterogenous 
groups of PwMS (including, all MS types, single limb, all disabilities levels) and have 
partitioned participants on the basis of one global fatigue score. As such, further 
research in more homogenous groups of PwMS with clearly characterised fatigue 
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status (highly-fatigued; MS-HF and less-fatigued; MS-LF) could improve the 
understanding of neurophysiological differences that are associated with high and low 
levels of perceived MS fatigue. Based on these considerations, the aim of this Chapter 
was to investigate an established battery of neuromuscular measures and performance 
fatigability from Chapter 5 in the upper- and lower-limbs of PwMS experiencing high 





Following ethical approval (3.2.1 Ethical Approval: Institution: HLSPE111114 and 
national health service: 14/LO/2290) and informed consent (3.3.2 Informed Consent), 
forty relapsing-remitting MS participants and twenty healthy controls volunteered to 
participate in this study. Based on previous cross-sectional studies in PwMS and HC 
twenty participants per group was deemed sufficient to observe differences in 
measures of central and peripheral neurophysiological function (e.g., Chalder et al., 
1993; Greim et al., 2007). The experimental groups consisted of the same participants 
from Chapter 5 (see 5.3.1 Participants) and complied with the criteria for participation 
(see3.3 Participants). See Table 6.1 Participant Characteristics. 
 
6.2.2 Preliminary Visit 
Prior to the experimental trials of the study, symptoms of fatigue (3.9.1 Fatigue 
Severity Scale), mood (3.9.2 Anxiety and Depression) and contraindications to 
experimental procedures (Rossini et al. 2009) were assessed. A 60-minute 
familiarisation of the entire neuromuscular protocol was performed (see 3.4 
Familiarisation and 3.6 Neuromuscular Assessment) and experimental controls were 
implemented (3.5 Experimental Criterion). 
 
6.2.3 Experimental Protocol 
In this cross-sectional study, participants visited the laboratory on two separate 
occasions for the neuromuscular assessment of the right lower- and upper- extremity, 
according to limb dominance (Oldfield, 1971). Neuromuscular assessments were 
conducted at the same time of day, separated by 2-14 days. Reliability indices of the 
main variables of interest are presented in Chapter 5 (see Tables 5.2 to 5.4). The main 
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neuromuscular variables reported moderate to excellent test-retest reliability for all 
groups in both the upper and lower-limb, with ICC ranging from 0.58 - 0.98. In 
addition, patient reported psychometric outcomes reported good to excellent test-retest 
reliability, with ICCs ranging from 0.84 - 0.98 (See Figure 5.2). 
 
6.2.4 Neuromuscular Assessment 
Each experimental visit involved neuromuscular data collection (refer to 3.6 
Neuromuscular Assessment and Figure 6.1) before and immediately after a sub- 
maximal intermittent task on the limb that was exercised to task failure, described in 
section 3.7.2 Sub-maximal Test Protocol. For detailed procedures of the dynamometer 
and isometric measurements recorded during isometric MVC and corticospinal 
assessments with transcranial magnetic stimulation during 10% of isometric MVC 
(Brownstein et al., 2018), refer to section 3.6.1 and 3.8. The set-up followed Chapter 
5 using custom-made adjustable isometric dynamometers. Electromyography (EMG) 
activity was also recorded from the knee-extensors and wrist flexors during these 






Figure 6.1 Schematic of neuromuscular protocol, (A) Neuromuscular assessment intervals of 2-14 days between knee-extensors and wrist-flexors, 
(B) Neuromuscular assessment including, motor nerve stimulation, transcranial magnetic stimulation and sub-maximal, intermittent task at 40% 








Percutaneous Nerve Stimulation 
Percutaneous nerve stimulation was delivered to evoke M-wave in the knee extensors 
and wrist flexors (see section 3.6.3). The intensity required to elicit Mmax did not differ 
between groups (HC: 273 ± 137 mA, MS-LF: 300 ± 105 mA and MS-HF: 322 ± 108 
mA, P = 0.417). 
 
Transcranial Magnetic Stimulation 
Single and paired-pulse transcranial magnetic stimulation were delivered to assess 
corticospinal excitability, CSP, and SICI, see section 3.8. AMT was determined at the 
beginning of the neuromuscular assessment. Motor threshold was different between 
groups (HC: 49 ± 9%, MS-LF: 55 ± 9% and MS-HF: 58 ± 9%, P = 0.012), with higher 
AMT intensity for MS-HF vs. HC (P = 0.009). 
 
6.2.5 Perceived Fatigue and Patient Reported Psychometric Outcomes 
Symptomatic fatigue scales were completed at the beginning of first experimental visit 
according to section 3.9.1. The severity, frequency and impact of fatigue in everyday 
life was recorded using different scales. Mood including, anxiety and depression, sleep 
quality and pain experienced were measured at the beginning of first experimental 
visit. For further details, see sections 3.92 – 3.9.4. 
 
6.2.5 Data Analysis 
Voluntary activation was determined using the formula: VA (%) = (1 – [SIT ÷ Qtw, 
pot]) × 100), see section 3.6.3.2. EMG activity was quantified as RMSemg and 
recorded during the middle 500 ms epoch of a 3 s maximal contraction. EMG 
responses recorded from transcranial magnetic stimulation (e.g., MEPs) that were 
contaminated by artefact were excluded from analysis (<2% of trials per session). All 
data analysis was performed offline using Spike 2 (version 6.0, CED, UK). RMSemg 
of rectus fermoris and flexor carpi radialis was normalised to Mmax (RMSemg/Mmax) 
in order to remove the confounding effect of electrode location and body fat, and 
account for changes at the skin-electrode interface and differences in propagation 
along the sarcolemma (Wells & Fewtrell, 2006). 
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6.2.7 Statistical Analysis 
All data are reported as means ± SD in Tables and Figures. Normality of the data was 
assessed using the Shapiro-Wilks test. If the assumption of normality was violated, 
appropriate transformations were performed, with common logarithm used for 
strongly positively skewed ICF and SICI data in Experiments 1 and 2, respectively, 
and reciprocal transformation used for extremely positively skewed ICF data in 
Experiment 2 (Bulmer, 1979). Sphericity was assessed using Mauchly’s test and if 
necessary, controlled using the Greenhouse-Geisser correction. One-way repeated 
measures ANOVA were run for all pre-exercise dependent variables to assess group 
(fatigue severity) changes in neuromuscular function and psychometric reported 
measures. A two-way (2×3) ANOVA was used to assess whether acute mechanical 
(MVC, Qtw,pot) and neural changes (VA, Mmax, RMSemg, MEP/Mmax, SICI, and SP) 
associated with fatigue severity group specific. The independent variables were time 
(PRE and POST) and group (HC, MS-LF and MS-HF). If significant interactions or 
main effects were found, analyses were continued using pairwise comparisons using 
the Bonferroni correction. Upper- versus lower- limb comparison	performed	by	paired	
samples	t-test	&	95%	Cis.	Statistical significance was determined as an alpha of 0.05. 
 
6.3 Results 
Participant characteristics and psychometric measurements were gathered in all 60 
participants (Table 6.1). Two participants withdrew from the study because one person 
with MS relapsed from the MS-HF group and was referred back to the consultant and 
one person with MS from MS-LF group could not perform muscle contractions. The 
lower- and upper-limb neuromuscular assessments described here had completion 
rates of 97% and 90%. In seven PwMS, one of the following indicators were 
incomplete due to failure to respond to transcranial magnetic stimulation and motor 
nerve stimulation for the following reasons: 1) in two MS participants inadequate 
muscle force or inability to generate sufficient muscle force, 2) in three MS 
participants we were unable to obtain accurate MEP or Mmax responses, and 3) two MS 
participants had unrelated existing injuries. There were no statistically significant 
differences between the MS groups (MS-HF and MS-LF) and the control group in age, 
gender, disease duration and EDSS scores (P > 0.05). There were no observed group 
differences for age, gender, MS type, or duration of disease. Details of participant 
characteristics are presented in Table 6.1. 
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Table 6.1 Participant characteristics (Mean ± SD).  
HC MS-LF MS-HF 
N 20 20 20 
Age (years) 44.8 ± 15.1 45.9 ± 9.0 43.6 ± 10.2 
Sex (F/M) 13/7 15/5 15/5 
EDSS (arbitrary units) - 2.1 ± 1.2 2.4 ± 1.4 
Disease Duration (years) - 9.3 ± 3.8 9.9 ± 5.5 
Disease Modification Therapy (Y/N) - 17/3 14/6 
- Tecfidera 7 2 
- Copazone 5 2 
- Tysabri - 3 
- Gilenya - 4 
- Avonex 3 - 
- Lemtrada 1 2 
- Rebrif 1 - 
- Aubagio - - 
-Betaferon - 1 
Other comorbidities (Y/N) 4/16 6/14 9/11 
- Osteoporosis - 1 1 
- Arthritis 1 1 - 
- Trigeminal neuralgia - - - 
- Fibromyalgia - 1 2 
- Underactive thyroid 1 2 2 
-Overactive bladder 2 1 2 
-Type I diabetes - - 1 
- Type II diabetes - - 1 
 
FSS: Fatigue Severity Scale; HADS: Hospital and Anxiety Depression Scale; HC: HC; MS-LF: MS-LF People with Multiple 
Sclerosis; MS-HF: Highly-MS-HF People with Multiple Sclerosis N: Numbers; F: Females; M: Males; EDSS: Extended Disability Status 




6.3.1 Baseline Patient Reported Outcomes 




The mean FSS score was higher in MS-HF (F2,57 = 82.64, P < 0.001) in comparison 
with MS-LF (P < 0.001) and HC (P < 0.001), showing higher levels of fatigue interfere 
with daily activities in MS-HF. Other indices of fatigue severity were also higher in 
MS-HF. Mean CFS scores were higher in the extent and severity of fatigue in MS-HF 
(F2,57 = 19.33, P < 0.001), compared with MS-LF (P = 0.021) and HC (P = 0.004). 
Additionally, compared with MS-LF, MS-HF had higher mean MFIS scores (F2,57 = 
93  
84.07, P < 0.001), testifying to the continuing impact of fatigue on daily life when 
compared to MS-LF (P < 0.001) and HC (P < 0.001). 
 
Mood (Depression and Anxiety), Pain and Sleep Quality 
As shown in Figure 6.2, HADSglobal was higher in MS-HF (F2,57 = 9.15, P < 0.001), 
compared with MS-LF (P = 0.008), and versus HC (P < 0.001). There was no 
difference between MS-LF and HC (P > 0.05). Compared with MS-LF, MS-HF also 
had higher HADSanxiety and HADSdepression scores (anxiety: MS-HF: 9.2 ± 3.3 vs. 
MS-LF: 6.1 ± 4.1, P = 0.006 and depression: MS-HF: 5.0 ± 2.8 vs. MS-LF: 3.4 ± 3.0, 
P = 0.039). There was no difference between MS-LF and HC. Regarding pain, there 
was a group difference, with slightly higher scores among MS-HF and HC (MS-HF: 
2.3 ± 1.2 vs HC: 1.3 ± 1.0, P = 0.032), but with no difference between MS-LF and 
HC. Conversely, PSQI was similar between MS-HF and MS-LF versus HC (9.6 ± 4.9 
vs 7.6 ± 3.5 and 6.7 ± 4.1, P = 0.097), and with >75% of participants reporting poor 
sleep quality within the last month (established cut off > 5; Buysse, Reynolds, & 
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Figure 6.2 Differences between groups for patient reported outcomes, with indicating clinically important cut off levels of symptom scores. When a significant effect 


















































6.3.2 Baseline Neuromuscular Function 
Lower-Limb 
In Table 6.2. MVC force was different between groups (F2, 55 = 6.15, P = 0.004), with 
post-hoc tests showing reduced MVC in MS-HF compared to MS-LF (−58.3 N; P = 
0.044) as well as HC (−77.1 N; P = 0.004). Potentiated twitch force was not different 
between the MS groups and HC (pooled average = 138.5 N, F2, 53 = 1.49, P = 0.233). 
However, VA elicited by motor nerve stimulation was different between groups (F2, 53 
= 11.59, P < 0.001), with greater VA impairment in MS-HF compared to MS-LF 
(−3.6%; P = 0.007) and HC (−5.2%; P < 0.001). 
 
As shown in Table 6.2, corticospinal excitability (MEP/Mmax) did not differ between 
groups (F2, 49 = 2.28, P = 0.113), neither did SP (pooled average = 171.9 ms, F2, 50 = 
2.69, P = 0.078). However, Mmax was different between the groups (F2, 53 = 10.06, P < 
0.001), with post-hoc tests showing reduced Mmax in MS-HF versus HC (−2.6 mV, P 
< 0.001) and MS-LF compared with HC (−2.2 mV, P = 0.003). SICI was also different 
between the groups (F2, 49 = 2.28, P = 0.113), with post-hoc tests showing greater 
inhibition in MS-HF compared to HC (−0.2, P = 0.04). Finally, the pre-stimulus 
normalized RMSemg activity was also different between the groups (F2, 54 = 8.56, P = 
0.001), with post-hoc tests showing less neural drive in MS-HF and MS-LF (−0.3 mV, 



























Table 6.2 Differences in knee-extensor outcomes between groups’ pre -and post- exercise task. When a significant effect of exercise was found, the Δ in a variable from pre-post exercise was 
reported. * MS-HF vs. MS-LF; + MS-HF vs. HC; # MS-LF vs. HC (P <0.05). 
 
Measures  HC MS-LF MS-HF Group effect 
1 × 3 ANOVA 
Pre-post exercise 
2 × 3 ANOVA 
MVC (N) Pre 
Post 
412.0 ± 77.1 
241.4 ± 70.9 
393.2 ± 67.9 
248.3 ± 52.0 
334.9 ± 67.8 *+ 
217.6 ± 55.2 
0.004 0.007 
Qtw, pot (N) Pre 
Post 
150.6 ± 48.1 
91.7 ± 31.8 
131.2 ± 38.5 
87.0 ± 28.4 
133.6 ± 20.6 
92.7 ± 29.0 
0.233 <0.001 
VA (%) Pre 
Post 
93.3 ± 3.4 
79.4 ± 9.7 
91.7 ± 2.4 
74.7 ± 12.2 
88.1 ± 4.1 *+ 
76.3 ± 8.0 
0.001 <0.001 
Mmax (mV) Pre 
Post 
7.3 ± 2.5 
6.8 ± 2.5 
5.1 ± 1.7 # 
4.5 ± 1.5 # 
4.7 ± 1.3 #+ 
4.4 ± 1.3 
<0.001 0.001 
MEP/Mmax (%) Pre 16.8 ± 10.4 10.9 ± 6.1 13.0 ± 7.1 0.113 0.480 
 Post 16.4 ± 10.0 10.3 ± 14.6 10.0 ± 7.9   
MEP amplitude (mV) Pre 
Post 
1.0 ± 0.4 
1.0 ± 0.7 
0.5 ± 0.2 
0.5 ± 0.2 
0.6 ± 0.3 #+ 
0.4 ± 0.2 
<0.001 0.313 
RMSemg (mV) Pre 0.7 ± 0.3 0.4 ± 0.2 # 0.4 ± 0.2 #+ 0.001 0.005 
 Post 0.7 ± 0.2 0.5 ± 0.2 # 0.5 ± 0.2   
SICI (ratio) Pre 
Post 
0.8 ± 0.2 
0.8 ± 0.3 
0.7 ± 0.3 
0.7 ± 0.3 
0.6 ± 0.2 + 
0.5 ± 0.2 
0.004 0.019 
SP (ms) Pre 
Post 
153.3 ± 52.2 
181.6 ± 61.8 
172.8 ± 47.4 
218.9 ± 55.1 
189.5 ± 59.9 
234.9 ± 53.7 
0.078 <0.001 
 
HC, HC; MEP: Motor evoked potential, N, Number, RMSemg, Root mean squared electromyography, SICI: Short interval cortical inhibition, SP: Silent period, Mmax: maximum compound action potential, MS-LF: 















Shown in Table 6.3, MVC force was different between the groups (F2, 50 = 11.71, P < 
0.001), with post-hoc tests showing reduced MVC in MS-HF versus HC (−37.6 N, P 
< 0.001) and MS-LF compared with HC (−30.0 N, P = 0.002). There was no difference 
in MVC between the MS groups. Potentiated twitch force was not significantly 
different between MS groups and the HC (pooled average = 26.9 N, F2, 50 = 1.85, P = 
0.168). However, there was a difference in VA between the groups (F2, 50 = 9.32, P < 
0.001), with post-hoc tests showing an impairment for MS-HF compared with MS-LF 
(−4.5%; P = 0.037) and MS-HF versus HC (−7.0%; P < 0.001). 
 
Mmax did not differ between the groups (pooled average = 9.2 mV, F2, 51 = 1.46, P = 
0.241), nor did corticospinal excitability (MEP/Mmax) (pooled average = 10.9 %, F2, 46 
= 0.858, P = 0.431) or SICI (pooled average = 0.76, F2, 50 = 2.14, P = 0.129). However, 
the length of SP was significantly different between the groups (F2, 50 = 4.91, P = 
0.011), with post-hoc tests showing a more prolonged SP in MS-HF compared with 
HC (28.9 ms, P = 0.009) but there was no difference between MS-LF and HC (P = 
0.367) or between the MS groups (P = 0.460). Pre-stimulus normalized RMSemg 




































Table 6.3 Differences in wrist-flexors outcomes between groups’ pre -and post- exercise task. When a significant effect of exercise was found, the Δ in a variable from pre-post exercise was 
reported. * MS-HF vs MS-LF; + MS-HF vs HC; # MS-LF vs HC (All P <0.05). 
 
Measures  HC MS-LF MS-HF Group effect 
1 × 3 ANOVA 
Pre-post exercise 2 × 3 
ANOVA 
MVC (N) Pre 136.1 ± 28.1 105.1 ± 25.6 98.5 ± 21.3 #+ 0.001 0.002 
 Post 80.5 ± 30.2 71.1 ± 18.9 63.9 ± 27.9   
Qtw, pot (N) Pre 
Post 
31.2 ± 16.0 
22.5 ± 10.8 
23.5 ± 8.6 
19.0 ± 7.5 
26.0 ± 10.3 
21.4 ± 9.6 
0.168 0.023 
VA (%) Pre 
Post 
91.5 ± 4.7 
71.9 ± 12.1 
89.0 ± 4.3 
76.2 ± 12.1 
84.5 ± 5.8 *+ 
73.1 ± 11.2 
0.001 0.001 
Mmax (mV) Pre 
Post 
10.4 ± 4.0 
9.4 ± 3.7 
9.2 ± 3.9 
8.3 ± 4.1 
8.1 ± 4.2 
6.9 ± 3.7 
0.241 0.001 
MEP/Mmax (%) Pre 
Post 
11.8 ± 8.1 
10.6 ± 6.8 
8.8 ± 5.0 
8.3 ± 6.1 
12.0 ± 8.3 
9.3 ± 5.8 
0.431 0.503 
MEP amplitude (mV) Pre 
Post 
1.0 ± 0.5 
0.8 ± 0.3 
0.7 ± 0.3 
0.6 ± 0.2 
0.7 ± 0.2 + 
0.5 ± 0.2 
0.019 0.001 
RMSemg (mV) Pre 
Post 
0.6 ± 0.3 
0.7 ± 0.4 
0.5 ± 0.2 
0.5 ± 0.2 
0.5 ± 0.3 
0.6 ± 0.3 
0.349 0.001 
SICI (ratio) Pre 
Post 
0.9 ± 0.2 
0.8 ± 0.3 
0.7 ± 0.2 
0.6 ± 0.2 
0.7 ± 0.3 
0.6 ± 0.2 
0.129 0.010 
SP (ms) Pre 
Post 
124.5 ± 29.7 
134.1 ± 33.6 
139.1 ± 22.3 
171.7 ± 36.4 
153.4 ± 30.5 + 
206.6 ± 40.6 
0.011 0.001 
 
HC, HC; MEP: Motor evoked potential, N, Number, RMSemg, Root mean squared electromyography, SICI: Short interval cortical inhibition, SP: Silent period, Mmax: maximum compound action potential, MS-LF: MS-LF 









6.3.3 Fatigability and Neuromuscular Function (baseline versus post-fatigue task changes) 
Nineteen MS participants cited muscle pain/tingle, muscle weakness, or an inability to maintain 
concentration as the reason for terminating the sub-maximal isometric, fatiguing task. The 
remaining MS participants and all HC cited non-specific reasons such as ‘had enough’ or 
‘unable to continue’ for terminating the sub-maximal task. 
 
Lower-Limb 
As shown in Figure 6.5(A), MVC force decreased after the fatigue task (F1,55 = 481.894, P < 
0.001). Specifically, a group × time interaction was found for MVC force of the knee-extensors 
(F2,55 = 5.513 P = 0.007), with post-hoc analysis displaying a larger reduction in MVC after the 
fatigue task in HC (mean difference: 170.6 N, P < 0.001), compared with less change in MVC 
for MS-LF and MS-HF (mean difference: 145.0 N and 117.4 N, both P < 0.001). TTF during 
the sub-maximal isometric task was also different between the groups (Figure 6.5(C), HC: 24.6 
± 14.9 vs. MS-LF: 15.8 ± 6.3 vs. MS-HF: 13.2 ± 8.1 mins P = 0.005), with post-hoc tests 
showing shorter TTF in MS-HF and MS-LF MS patients compared with HC (P = 0.005 and P 
= 0.048). However, there was no difference between the MS groups (P > 0.05). Also, no 




Performance fatigability (ΔMVC) was similar in all groups (Figure 6.3 (B), HC: 58.2 ± 13.5 
vs. MS-LF: 63.5 ± 9.7 vs. MS-HF: 65.0 ± 11.3%, respectively, P = 0.174). The two-way 
ANOVA (group × time effect) showed that Qtw,pot decreased pre-post exercise (F1,53 = 140.778, 
P < 0.001), as did Mmax (F1,53 = 13.087, P = 0.001), VA (F1,53 = 144.400, P < 0.001), and 
RMSemg (F1,52 = 8.620, P = 0.005). SP also increased after the fatigue task (F1,50 = 37.904, P 
< 0.001), and there was a decrease in SICI after the fatigue task (F1,51 = 5.896, P = 0.019). No 
differences between the groups in corticospinal excitability (MEP and MEP/Mmax) were found 
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Figure 6.3 Performance fatigability measures: (A) Rate of Force Decline as MVC (N. s), (B) Performance 
Fatigability (MVC as % of baseline) and (C) Time to Task Failure (TTF, minutes). Significant effect between 





As shown in Figure 6.5, MVC force decreased after the fatigue task (F1,50 = 225.163, P < 0.001). 
Specifically, a group × time interaction was found for MVC force of the wrist-flexors (F2,50 = 
7.066 P = 0.002), with post-hoc analysis displaying a larger reduction in MVC after the fatigue 
task in HC (mean difference: 55.6 N, P < 0.001), and with less change in MVC for MS-LF and 
MS-HF (mean difference: 34.0 N, P < 0.001 and 34.5 N, P < 0.001). Likewise, TTF during 
sub-maximal isometric task for the upper-limb was different between the groups (Figure 6.5C), 
HC: 22.5 ± 12.2 vs. MS-LF: 14.2 ± 8.2 vs. MS-HF: 11.1 ± 4.9 minutes respectively, P = 0.001), 














0.002 and P = 0.025). No difference existed between the MS groups (P > 0.05). In addition, 
there was no difference in the rate of force decline (N·s) between the groups (F2, 52 = 7.465, P 
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= 0.952). Performance fatigability (ΔMVC) did not significantly differ between the groups 
(HC: 58.5 ± 16.5 vs. MS-LF: 68.3 ± 11.0 vs. MS-HF: 63.3 ± 18.4%, respectively, P = 0.177). 
The two-way ANOVA (group × time) showed that Mmax decreased after the fatigue task (F1,50 
= 28.847, P < 0.001), as did VA (F1,50 = 88.267, P < 0.001), RMSemg (F1,51 = 12.870, P = 
0.001) and SICI (F1,50 = 7.103, P = 0.010). 
 
Qtw, pot decreased after the fatigue task (F1,50 = 70.132, P < 0.001). Specifically, a group × time 
interaction was found (F2,50 = 4.085 P = 0.023). Post-hoc analysis showed a larger reduction in 
Qtw,pot after the fatigue task in HC (mean difference: 8.7 N, P < 0.001), and with less change in 
Qtw,pot for MS-LF and MS-HF (mean difference: 4.4 N, P = 0.001 and 4.6 N, P = 0.001). 
Additionally, SP increased after the fatigue task (F1,50 = 71.071, P < 0.001). Specifically, a 
group × time interaction was found (F2,50 = 11.808 P < 0.001). Post-hoc analysis showed a more 
prolonged SP after the fatigue task in MS-HF (mean difference: 53.2 ms, P < 0.001) and MS-
LF, with no change in HC (mean difference: 32.6 ms, P < 0.001 and 9.6 ms, P = 0.124). There 
was a trend for an increase in corticospinal excitability (MEP/Mmax) after the fatigue task (F1,45 = 
3.819, P = 0.057) but there was no significant group × time interaction (F2,45 = 0.697, P = 
0.503). 
 
Lower Limb versus Upper-Limb Changes 
A greater reduction in Qtw, pot after the fatigue task was observed in the upper-limb compared 
with the lower-limb in HC (−10.9 [−19.7 to −2.08], P = 0.018), as for MS-LF (−17.6 [−30.7 to 
−4.5], P = 0.018). Additionally, VA (−6.4 [1.04 to 11.85], P = 0.022), and SP (-10.9% [−19.7 
to −2.08, P = 0.018) were reduced in the upper-limb compared with the lower-limb in HC. 
Similarly changes after the fatigue task were observed between upper- and lower-limb for MS- 
HF and for the remaining neurophysiological outcomes in MS-HF and HC. 
 
6.4 Discussion 
This is the first study to compare neurophysiological correlates of perceived MS fatigue, in the 
upper- and lower-limbs of a homogenous group of relapsing-remitting PwMS partitioned on 
the basis of fatigue status (i.e., experiencing high or low levels of perceived MS fatigue). The 
data for values of central drive and modulation of neural drive after a fatigue task (i.e., VA and 
SICI), points to the suggestion that PwMS suffering from high levels of fatigue, require a 
greater demand on central components and less peripheral disturbance. These key findings are 
consistent with simple tasks being perceived as effortful and are further substantiated by the 
103  
accompanying post-exercise fatigue data. Furthermore, these data add weight to the argument 
that MS-HF have neurophysiological responses that differ from their MS-LF counterparts and 
healthy individuals. 
 
Neurophysiological Differences at Baseline 
A number of potential factors might have contributed towards the reduced MVC in both 
muscles in MS-HF versus MS-LF and HC. Psychosocial issues, including depression and poor 
sleep may have been key factors, and may have caused a relative lack of motivation during the 
voluntary contractions. Additionally, VA measured through motor nerve stimulation was 
significantly reduced in MS-HF (lower-limb: 88 and upper-limb: 85). The magnitude of 
impaired VA was similar (85) to that reported by Wolkorte et al. (2016), but lower (95-98). 
than that reported by Andreasen et al. (2009) Methodological differences between the studies 
(i.e., use of an isometric force rig versus isokinetic dynamometry) might explain the different 
results. Interestingly, the results of the present study reported no difference in Qtw,pot at baseline, 
indicating that the intramuscular muscle contractile properties (Qtw,pot) was similar between 
PwMS with high and low levels of fatigue and HC. Accordingly, results from the present study 
suggest that any higher levels of perceived MS-fatigue are likely associated with decrements 
in central nervous system function rather than skeletal muscle (peripheral) impairments in the 
resting, unfatigued state, which concurs with previous studies (Liepert et al., 2005; Conte et 
al., 2009; Morgante et al., 2011; Chalah et al., 2019). 
 
Performance Fatigability 
For both muscle groups, the time to task failure was significantly shorter for both MS groups 
compared to HC. There is evidence that PwMS, are less able to increase cortical drive to 
maintain force during sustained contractions (Post et al., 2009; Steens et al., 2012c). As a 
consequence, the inability to increase central activation results in a decline in voluntary drive 
and subsequent force production at the level of skeletal muscle (Andreasen et al., 2009; 
Skurvydas et al., 2011; Steens et al., 2012b; Steens et al., 2012c). There has been little reported 
evidence of an association between performance fatigability and perceived MS fatigue 
(assessed using self-reported fatigue scales: (Sharma et al., 1995; Iriarte & de Castro, 1998; Ng 
et al., 2004; Enoka & Duchateau, 2016), suggesting that these two fatigue constructs are 
independent. However, a study by Wolkorte et al. (2015a) demonstrated a regression model 
that included performance fatigability, depression and MVC explained 48% of the variance in 
MFIS-physical scores. In addition, Steens et al. (2012b) found that an association between 
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performance fatigability and perceived MS fatigue was related to central fatigue (VA) but not 
to peripheral fatigue (Qtw, pot). However, this might only be true for relapsing remitting MS, as 
performance fatigability did not correlate with perceived fatigue for secondary progressive MS 
using the same model (Wolkorte et al., 2015b). 
 
Post Task Neurophysiological Differences 
A greater decline in MVC force was observed in HC after the fatigue task compared to the MS 
groups, and this is likely attributable to the increased level of effort needed to elicit a higher 
MVC force at baseline. This finding is consistent with previous work showing lower MVC 
force in PwMS compared with HC (Liepert et al., 2005). Although the lower force decline in 
PwMS is likely explained by neuropathic changes, that characterise MS. Some of the force 
decrement could be attributable to deconditioning effects on skeletal muscle (Sharma et al., 
1995; Kent-Braun et al., 1997; de Haan et al., 2000; Skurvydas et al., 2011), as PwMS are 
generally less physically active than healthy populations (Motl et al., 2005). Importantly, 
previous studies have observed anatomical changes within skeletal muscle groups of PwMS; 
specifically, the tibialis anterior has reduced muscle fibre size, fewer Type I fibers and more 
Type II fibers, as compared with healthy controls (Sharma et al., 1995; Kent-Braun et al., 1997) 
These changes, which have the potential to impair MVC and ability to sustain a submaximal 
level of force in PwMS, could be accentuated in MS-HF. 
 
A larger decline in Qtw, pot, showed greater peripheral fatigue in HC, and this is likely to reflect 
the underpinning cause of fatigability in this group (i.e., peripheral skeletal muscle fatigue 
associated with the generation of higher muscle forces). In contrast, the inability to generate 
high MVC force in MS-HF (and hence lower level of overall metabolic effort) could explain 
why MS-HF show less evidence of peripheral fatigue after a fatiguing task. This result is 
consistent with the findings of Skurvydas et al. (2011), who showed that while peripheral 
fatigue in PwMS exists after a fatigability task, it is to a lesser extent than in HC. Therefore, 
the primary source of MS fatigue is likely to be deficits in central activation (Danion et al., 
2000). As VA was similar after the fatiguing task across the groups, this greater relative decline 
from baseline in HC also suggests they experienced some level of central fatigue despite the 
greater level of peripheral fatigue observed. The present study also demonstrated reductions in 
post-fatigue variables (MVC, VA and Qtw,pot) in both muscle groups studied (Table 6.2 and 
6.3) that were two-fold greater than the TE values reported in the previous Chapter. Therefore, 
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it can be concluded that such neuromuscular measures are sensitive to detecting changes 
induced by task-related fatigue in the populations investigated. 
 
The results of the present study extend current knowledge on MS fatigue, suggesting it mainly 
originates from dysfunction of central nervous system neuronal circuits (i.e., reduced 
excitability [evidenced by a higher AMT] and increased inhibition). PwMS have several 
corticospinal abnormalities in comparison to the general population, including higher motor 
thresholds (Liepert et al., 2005; Morgante et al., 2011; Neva et al., 2016), delayed MEP 
latencies (Neva et al., 2016), and longer CSP (Tataroglu et al., 2003), which supports the 
usefulness of transcranial magnetic stimulation as a biomarker of brain functioning in PwMS. 
However, in the context of MS fatigue, the current knowledge on corticospinal excitability 
derived from only a few studies have yielded inconsistent outcomes, including the lack of a 
causal link between intracortical function and voluntary activation (Perretti et al., 2004; Liepert 
et al., 2005; Morgante et al., 2011). The present chapter builds upon this through a more 
robustly executed method, suggesting more research is warrants in larger sample sizes. MS- 
related corticospinal dysfunction mainly suggests a reduction or failure of central inhibitory 
mechanisms leading to facilitation of MEP amplitude following a fatiguing exercise task 
(Leocani et al., 2001; Perretti et al., 2004; Thickbroom et al., 2006; Thickbroom et al., 2008). 
Such adjustments of intracortical circuitry might be linked to the severity of perceived MS 
fatigue. 
 
In the present study, SICI was reduced in MS-HF in comparison with MS-LF, which was 
consistent with data from Liepert et al. (2005) but differed from those obtained in two other 
studies. Morgante et al. (2011) reported no difference in SICI between two groups of patients; 
and Chalah et al. (2019) found increases in SICI in MS-HF compared with MS-LF. This 
observed increase in SICI could be due to MS type, as the study groups were primary 
progressive MS type, in which the likelihood of neuronal damage is significant greater. This 
study’s findings suggest an increased involvement of gamma-aminobutyric acid -inhibitory 
neurotransmission (Rossini et al., 2015), referred to as gamma-aminobutyric acidA mechanisms 
in the processes of cerebral plasticity, and/or the existence of an improper balance between 
cortical gamma-aminobutyric acidA inhibitory mechanisms and glutamatergic facilitatory 
mechanisms as a potential underlying mechanism of perceived MS fatigue (Ayache & Chalah, 
2017). It is important to note, that the sample size was relatively smaller in the 
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above-mentioned studies (n = 16,Liepert et al. (2005); n =21, Morgante et al. (2011), but similar 
to Chalah et al. (2019), n = 38). 
 
The present study identified a prolonged duration of SP in MS-HF at rest and after the fatigue 
task. These findings are in accordance with those of Russo et al. (2017), demonstrating greater 
intracortical inhibition and suggesting the presence of possible motor dysfunction (Tataroglu 
et al., 2003) and reflect spinal contributions (Yacyshyn et al., 2016). In PwMS, modulation of 
gamma-aminobutyric acid -ergic activity (more inhibition) has been associated with greater 
disability (Cawley et al., 2015), though it is unknown whether this phenomenon contributes to 
MS progression or is a compensatory mechanism to protect the brain and maintain optimal 
brain function (Stampanoni Bassi et al., 2017; Chaves et al., 2019). Interestingly, longer SPs 
are indicative of increased intracortical inhibition, greater disability and poorer motor function 
in other clinical populations, such as Huntington’s (Priori et al., 1994b) and stroke (Classen et 
al., 1997). Therefore, future research into the SP and the relationship with SICI in MS-HF is 
warranted. Finally, similar to the fatigue related variables, the changes observed in the present 
Chapter concerning corticospinal excitability and inhibition (see Table 6.2 and 6.3) were 
greater than the typical error presented in Chapter 5. Therefore, it can be concluded that these 
measures are sensitive to detecting changes induced by task-related fatigue in the populations 
investigated. 
 
Differences in Patient-Reported Outcomes Between the Groups 
In the present study, MS-HF exhibited worse symptoms of fatigue, mood (anxiety and 
depression) and pain. These abnormalities may play a role in the pathophysiology of fatigue 
perception and development, particularly high levels of clinical anxiety and depression (HADS 
scores) in MS-HF compared to the other groups. This is consistent with a bi-directional causal 
interaction with fatigue symptoms i.e. fatigue and depression present and effect together 
(Gobbi et al., 2014a; Finke et al., 2015; Chalah et al., 2019); and resonates with recent work 
by Chalah et al. (2019) which reported high scores in MS-HF for depression, anxiety and 
alexithymia. It is possible that MS-HF feel demotivated and melancholic, which might 
contribute to the accentuation of fatigue and faster fatiguability via the manifestation of new 
fears and negative thoughts. Additionally, pain was greater in MS-HF compared with HC, 
despite being similar between the MS groups. Sensory disturbances such as neuralgia, 
dysesthesia, and painful muscle spasms may be experienced by PwMS and often interfere with 
sleep, contribute to physical deconditioning and worsen depression (MacAllister et al., 2005; 
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Krupp et al., 2010). In this way, pain maybe indirectly related to perceived MS fatigue. Sleep 
quality was also assessed via the PSQI and was presented in all groups. Sleep quality data were 
similar to previous studies, which used correlation analysis and did not find a significant 
correlation between measures of sleep quality using the Epworth Sleepiness Scale and total 
MFIS fatigue scores (Nociti et al., 2017; Chalah et al., 2019). The similarities in sleep quality 
between the groups could be further explained by multiple overlapping factors such as pain, 
spasticity, anxiety, depression, bladder dysfunction and medications in PwMS (Kaminska et 
al., 2012). The lack of difference might also be due to multiple underlying sleep disorders, 
particular as sleep disorders such as restless legs syndrome, periodic limb movement disorder, 
and obstructive sleep apnea, are more common in PwMS (Tachibana et al., 1994). Therefore, 
further investigation into additional measures of sleep quality, such as all-night 
polysomnograms and daytime multiple sleep latency tests, are warranted to gain further 
insights into sleep disturbances and fatigue relationships. 
 
6.5 Limitations 
Firstly, the majority of PwMS were only mildly affected with relapsing remitting MS, as 
measured by the EDSS. It is unclear whether in more severely affected PwMS, 
neurophysiological correlates of perceived MS fatigue show the same patterns of response. In 
addition, the existence of anxiety and mood reflects more pronounced somatic disturbances in 
PwMS experiencing high levels of fatigue and this may have affected motivation, thereby 
influencing the reduced neurophysiological performance and level of exerted effort. Lastly, the 
cross-sectional design of this study does not allow causal relationships to be drawn from 
differences in neurophysiological measures and level of MS fatigue being experienced. 
 
6.6 Future Directions 
Future research would benefit from the inclusion of neuroimaging techniques, notably 
magnetic resonance imaging, as identified in Chapter 4, as such techniques can provide more 
detailed insights into the brain regions and sites of dysfunctional connectivity that may 
differentiate MS-HF from MS-LF. In respect of the latter, further work into motor tasks which 
recruit multiple brain areas and muscle groups could provide greater insight in neuromuscular 
function during more complex tasks that are more characteristic of everyday activities in PwMS 
and how this is altered in MS-HF. As highly fatigued PwMS appear to demonstrate a greater 
demand on central components and less peripheral disturbances, research aimed at designing 
and testing the efficacy of therapeutic interventions (including exercise) that could 
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optimise corticocortical neuroplastic adaptations may prove to have the greatest impact on 
perceived MS symptoms and this also warrants further consideration. 
 
6.7 Conclusion 
The present study demonstrated that in the resting state and following exercise, MS-HF 
experience reduced MVC, VA and impaired cortical inhibition. This is likely to result from 
central nervous system insufficiencies linked to a reduced central motor drive and spinal 
contributions over peripheral disturbances. In line with the thesis aims, a multidimensional 
approach using an array of functional neurophysiological measures proved to be a valuable 
method for investigating the neurobiology of perceived MS fatigue and identifying processes 
that may contribute to the subjective experience of this debilitating symptom and impaired 
motor task performance (fatigability). The next Chapter will explore progressive resistance 
exercise as a potential therapeutic exercise modality for ameliorating perceived MS fatigue and 































CHAPTER 7–Progressive Resistance Exercise in Fatigued People with Multiple 
Sclerosis: A Randomised Controlled Feasibility Study 
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7.1 Introduction 
Around ~78% of PwMS do not participate in minimum recommended guidelines for 
meaningful physical activity (Marrie et al., 2009). However, Somerset et al. (2001) reported 
that exercise advice is one of the most common unmet needs of PwMS. Exercise is a safe, non- 
pharmacological treatment strategy for improving health and wellbeing in PwMS, with recent 
systematic reviews highlighting many health benefits, including improvements in muscle 
power, physical and psychosocial functioning, as well as health-related quality of life (Rietberg 
et al., 2005b; Motl et al., 2008; Asano et al., 2009). Other positive effects include 
mood/depression (Ahmadi et al., 2013; Briken et al., 2014) and cognitive disturbances 
(Sangelaji et al., 2016). Exercise has also been shown to mitigate fatigue and be an effective 
strategy for managing symptoms of MS fatigue (Ahmadi et al., 2013; Schmidt & Wonneberger, 
2013; Learmonth et al., 2014), which has been shown to be a problem for PwMS in the previous 
Chapter. Conversely, MS fatigue symptoms may be exacerbated by lower physical activity 
levels (Motl et al., 2008; Motl & Gosney, 2008). 
 
A review of the literature by Andreasen et al. (2011) suggested that progressive resistance 
exercise (PRE) might have more consistent fatigue-reducing effects than aerobic exercise, 
although fewer well controlled trials had studied this exercise modality (Andreasen et al., 
2011). For example, studies have reported improvements in fatigue and physical capacity 
following 8-12 week programmes of twice-weekly PRE (White et al., 2004; Gutierrez et al., 
2005; Dalgas et al., 2010; Dodd et al., 2011), whereas in some studies, higher volumes of 
aerobic exercise (e.g. thrice-weekly aerobic exercise for 12-15 weeks) showed no effect 
(Petajan et al., 1996; Geddes et al., 2009). Furthermore, aerobic exercise can present problems 
for PwMS with ambulatory difficulties and can raise the body’s core temperature to levels that 
may exacerbate MS symptoms in thermosensitive individuals (Davis et al., 2010). PRE can 
overcome both these problems, as exercises can be performed in fully supported (or seated) 
positions and core temperature does not increase to the same extent (Gutierrez et al., 2005). 
Limited evidence of adverse events or symptom exacerbations in studies of PRE have been 
reported in PwMS (Dalgas et al., 2010). 
 
PwMS face distinctive barriers to participation in physical activity, including lack of 
confidence, anxiety, and embarrassment (Becker & Stuifbergen, 2004; Yorkston et al., 2005; 
Borkoles et al., 2008; Brown et al., 2012; Klaren et al., 2013), physical (fatigue, pain, 
overheating, muscle weakness, poor mobility, see review by Halabchi et al. (2017)) and 
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environmental factors (lack of facilities, transport and costs (Becker & Stuifbergen, 2004; 
Rimmer et al., 2004; Sim & Lewis, 2012). Thus, accessible forms of exercise and maintenance 
of exercise-induced fatigue reduction are other important considerations and strategies that can 
facilitate regular long-term participation in exercise are clearly warranted. Home-based PRE 
may a good therapeutic strategy to this end, as it is easily transferrable to the home environment 
(Normandin et al., 2018). One study reported excellent adherence to home-based PRE and 
flexibility exercises with subsequent improvements in activities of daily living in patients with 
knee osteoarthritis, reinforcing the notion that patients with long-term conditions proactively 
engage in home-based PRE (Suzuki et al., 2019). In addition, a study that encouraged PwMS 
to continue PRE after a 12-week period of supervision, reported a sustained improvement in 
fatigue, though this was not statistically significant (Dalgas et al., 2010). More research is 
clearly needed to expand current knowledge and studies focused exclusively on PRE in PwMS 
reporting high levels of self-reported fatigue are clearly warranted. 
 
To date, no studies have focused exclusively on PRE in PwMS reporting high levels of 
perceived fatigue. The significance of investigating the effects of exercise and other therapeutic 
interventions on MS fatigue in a heterogeneous sample of PwMS experiencing high and low 
levels of this debilitating symptom is questionable, and might explain the lack of effect of 
exercise on self-reported fatigue in previous studies (Petajan et al., 1996; DeBolt & McCubbin, 
2004; Schulz et al., 2004; van den Berg et al., 2006; Newman et al., 2007; Geddes et al., 2009). 
In addition, only three previous exercise intervention studies have investigated MS fatigue as 
a primary outcome measure: two short duration aerobic exercise studies in fatigued PwMS 
reporting that the exercise intervention had no effect (Mostert & Kesselring, 2002; Surakka et 
al., 2004a), and a third study by Rasova et al. (2006) that included a non-fatigued control group 
in a comparison of intervention groups, compromising the validity of their positive findings. 
This lack of evidence supports the requirement for more high-quality randomised control trials 
to assess the potential fatigue-reducing effects of PRE in PwMS, and with a secondary aim of 
incorporating skills into long-term self-management strategies. 
 
As a first step, there is a need for feasibility studies to address a series of questions surrounding 
issues of acceptability, adherence to PRE and attrition in PwMS experiencing clinically 
important levels of MS fatigue. Thus, the primary aim of this study was to evaluate the 
feasibility of undertaking a randomised controlled trial aimed at investigating the effectiveness 
of PRE (part supervised, part home-based) in relation to perceived fatigue and other important 
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Following ethical approval (3.2.1 Ethical Approval: Institution: HLSPE010216 and National 
Health Service: 16/SS/0142) and informed consent (3.3.2 Informed Consent), 33 highly 
fatigued PwMS (MS-HF) were recruited over a 12-month period from MS clinics at the 
Newcastle University Teaching Hospitals National Health Service Foundation Trust (Royal 
Victoria Infirmary). This conforms to guidance on feasibility and pilot studies, with 
justification that a sample size of 24 – 50, with 10 to 20 participants per group is recommended 
as sufficient and appropriate for determining variability data for key outcome measures to be 
used in sample size calculations for a larger trial (Dobkin, 2009; Sim & Lewis, 2012; Plow et 
al., 2013). All participants met the criteria for participation (see 3.3 Participants); aged over 18 
years, fulfilled the McDonald criteria (Poser et al., 1983; McDonald et al., 2001), had an EDSS 
score (Kurtzke, 1983) of <4.5 and clinically-important levels of fatigue defined by a fatigue 
severity score (FSS) cut-off score ≥5 (Krupp et al., 1989). Participants were also stable on 
disease modification therapy for ≥3 months prior to recruitment. All were right-handed and had 
normal function of the right limbs (Oldfield, 1971). Participants were excluded if they 
experienced relapses within the preceding 3 months, had other illnesses substantially affecting 
their ability to exercise (confirmed by consultant physician) or who were already physically 
active (≥2 × per week of ≥30 min of moderate to vigorous exercise during the previous 3 
months) and left-handed. Of the thirty-three participants, 16 were randomised to the PRE group 
and 17 to the control group. Table 7.1 presents the participant characteristics. 
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Table 7.1 Characteristics of the resistance PRE and usual care control group. 
 
 PRE Control 
N 16 17 
Age (years) 51.7 ± 9.3 48.2 ± 7.7 
Gender (F/M) 12/4 11/6 
EDSS (arbitrary units) 2.7 ± 1.4 3.3 ± 5.3 
Disease Duration (years) 10.8 ± 4.5 8.8 ± 4.4 
Fatigue Severity Scale 6.1 ± 0.6 5.7 ± 0.6 
Disease modification 13/3 15/2 
Therapy (Y/N)   
- Tecfidera 5 3 
- Copazone 3 5 
- Tysabri 1 1 
- GiLenya 1 4 
- Avonex 1 - 
- Lemtrada 2 - 
- Rebrif - 1 
- Aubagio - 1 
Other comorbidities (Y/N) 6/10 5/12 
- Osteoporosis 1 1 
- Arthritis 2 - 
- Trigeminal neuralgia - 1 
- Fibromyalgia 1 2 
- Underactive thyroid 2 1 
Data are presented as Mean ± SD. * Significance p value <0.05. HC: Healthy Control; MS-LF: Less-Fatigued 
People with Multiple Sclerosis; MS-HF: Highly Fatigued People with Multiple Sclerosis N: Numbers; F: Females; 




7.2.2 Experimental Protocol 
This feasibility study was a parallel randomised controlled trial and it was not possible to blind 
the research team or the participant to group assignment. Participants were randomised on a 
1:1 basis (random selection without replacement) using a computer programme (nQuery 
Advisor 6.0, Statistical Solutions, Ireland) to either a PRE group or a usual-care control group 
(CG). Consistent with CONSORT guidelines (Schulz et al., 2010), this was performed by an 
external researcher not involved in the team and treatment allocation was not disclosed to the 
lead researcher responsible for the day to day supervision of the trial, until all baseline measures 
had been recorded. Participants visited the laboratory on three separate occasions for each 
assessment point (baseline, 6-week follow-up 1 and 12-week follow-up 2). Each assessment 
point involved two separate visits to record neuromuscular assessments of the lower-limb 
(knee-extensor) and upper-limb (wrist-flexor) muscles as well as patient reported outcomes, 
conducted at the same time of day within a time period of 2-14 days. Participants randomised 
to PRE, engaged in 6-weeks of supervised PRE, followed by 6-weeks of home-based PRE. The 
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control group received no external advice or support and both groups received normal clinical 













The PRE intervention consisted of 6-weeks of supervised whole body PRE, performed twice 
weekly and consistent with the ACSM guidelines for prescription of PRE training ("American 
College of Sports Medicine position stand. Progression models in resistance training for 
healthy adults," 2009). Training sessions were organised for Mondays and Fridays, allowing 
participants time to recover between sessions (Carroll et al., 2017) with alternative training 
sessions offered if needed, to maintain twice-weekly attendance. The training sessions were 
arranged so that participants could exercise together in small groups (maximum of 6), as 
participant enjoyment after exercise sessions has been shown as an important determinant of 
physical activity behaviour and associated with greater adherence to exercise prescription in 
PwMS (McAuley et al., 2007). Each session comprised of warm-up mobility exercises, 
followed by 10 PREs (of 1–3 sets of 10–15 repetitions) targeting large skeletal muscle groups 
of the upper and lower extremities using bodyweight and coloured elastic Therabands, and a 
cool-down of stretching exercises (see review by Aboodarda et al. (2016) and "American 
College of Sports Medicine position stand. Progression models in resistance training for 
healthy adults" 2009) The prescribed whole-body exercises incorporated balance tasks (e.g. hip 
flexion, hip extension, hip abduction and hip adduction), knee extension and flexion, bicep 
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curls, and wrist flexion and wall/chair supported squat. Exercises were designed to mimic 
functional everyday activities such as, wrist flexion (grip capabilities and carrying an object 
movement (Jarque-Bou et al., 2020)) and standing supported squats (i.e. standing and sitting 
movement (Lubans et al., 2010; Lloyd et al., 2014)). Figure 7.2 below presents some of the 





Figure 7.2 Participants in the PRE group demonstrating some of the upper- and lower- limb 
theraband resistance exercises, (A) seated wrist-flexion, (B) standing and seated bicep curl, (C) 
hip- flexion, (D) hip -abduction and (E) seated knee-extension. 
 
A controlled progression of the applied load, range of motion and angular velocity in a 
progressive manner to a muscle group has shown to improve muscle strength (Matheson et al., 
2001). Progression of resistance training was determined on the basis of individual capability 
and facilitated by the lead researcher by changing the level of resistance/difficulty (i.e., colour) 
of elastic band, the amount of tension to each band, increasing the number of sets and 
repetitions and level of difficulty (e.g., changing exercise position from sitting to standing). 
Using the rating of perceived exertion (rating perceived exertion; Borg (1982)), beginning at 
“very light” (9/20) and progressing to “somewhat hard” (13/10) during weeks 1-3, and 
continuing to increase the Theraband tension and colour to maintain the rating perceived 
exertion “somewhat hard”. This progression method allowed participants to train to the 
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requisite rating perceived exertion to improve motor performance (used to the movement) by 
building a better tolerance to a greater stimulus. 
 
Audible cueing 
A metronome (MetroTimer) was used to pace each muscle action, with the speed of each 
repetition paced at a cadence of 60 beats·min−1. Each repetition was performed for a total of 7 
s (3 s concentric phase and 4 s eccentric phase). As co-ordinated movements and rhythmic 
perception are intuitively connected, with a connection between the cerebral auditory and 
motor system (Grahn & Brett, 2007; Chen et al., 2008), this suggests that movements 
synchronised to sound might improve connectivity between motor and auditory areas with 
increased rhythmic complexity (Thaut & Thaut, 2005; Thaut et al., 2009; Leung et al., 2017) 
 
Home-based PRE 
The home-based component of the intervention consisted of 6-weeks of PRE, two self-directed 
home-based exercise sessions per week. Home-based exercise sessions mirrored the 
supervised-based sessions in terms of the skeletal muscle groups targeted, intensity and 
duration. Fortnightly telephone contacts from the lead researcher during this period ensured 
that support was maintained, and that PRE programme was properly progressed with 
completion of an exercise logbook and diary. Participants had the opportunity to discuss any 
issues/questions arising from home-based exercises, with the aim of helping promote 
independent exercise participation following the intervention. 
 
7.2.4 Usual Care Control Group 
Participants in the control group were advised to maintain usual national health service care. 
At the end of the study, a one-on-one exercise consultation was offered, along with supporting 
exercise goals and objectives and two further sessions were arranged to run through their PRE 
programme with a Theraband demonstration. 
 
7.2.5 Assessment of Outcomes 
7.2.5.1 Primary Outcomes 
Feasibility 
Feasibility was assessed via recruitment rate to the study, acceptability of the intervention, 
adherence to PRE, attrition, and appropriateness/acceptability of the outcome measures. Figure 
7.3 presents the feasibility outcomes and methods of measurement. Adverse events were also 
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• Determined by recorded recruitment rates across three methods (electronic/paper mail, posters 




• Documented by activity logbooks (self-reporting of exercise time and exertion [RPE] during 
each exercise session), as well as, attendance at supervised training sessions. 
 
Retention and Attrition Rates 
 
• Measured by means of number of participants at recruitment, enrolment and follow-up 




• Monitored via participant diaries each week (i.e. any undesirable outcome, such as injury, 




• Participants assigned to PRE completed a series of open-ended questions focusing on their 
reasons for taking part, side effects, barriers and attitudes towards PRE following the 
intervention. 
 
Figure 7.3 Feasibility was measured by recruitment rates, acceptability of the intervention, 
compliance and attrition, and appropriateness of outcome measures. 
 
 
Perceptual Measures and Patient Reported Outcomes 
Self-reported fatigue scales recorded severity, frequency and impact of fatigue in everyday life 
and were completed at the beginning of each follow up assessment (3.9.1 Fatigue Severity 
Scale, Modified Fatigue Impact Scale, and Chalder Fatigue Scale). Depression and anxiety 
scores using the Hospital Anxiety and Depression Scale (HADS, refer to 3.9.2 Anxiety and 
Depression), sleep quality using the Pittsburgh Sleep Quality Index (PSQI, refer to 3.9.3 Sleep 
Quality), and pain using NARCOMS scale (refer to 3.9.4 Pain), were also monitored with lower 
scores indicating better fatigue and health outcomes. Quality of life was assessed using the 
Multiple sclerosis Quality of Life-54 scale (refer to 3.9.5 Quality of Life), with higher scores 
reflecting a better QOL. 
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7.2.5.1 Secondary Outcomes 
Neurophysiological Assessment 
All participants attended one familiarisation session and two experimental visits (wrist flexor 
and knee extensor measures). Each visit involved 35 minutes of resting neuromuscular data 
collection and a sub-maximal intermittent exercise task to task failure (refer to 3.7.2 Sub- 
maximal Test Protocol). With regard to neuromuscular measurements, the set-up largely 
followed Chapters 5 and 6 with force of the right wrist flexor and knee extensor muscles 
recorded using a custom-made adjustable isometric dynamometer. Participants received 
continuous feedback of their force via a computer screen. 
 
7.2.6 Data Analysis of Neurophysiological Data 
As in previous Chapters, voluntary activation using motor nerve stimulation, was determined 
using the interpolation twitch technique (Allen et al., 1998) by comparing the amplitude of the 
SIT with the amplitude of the Qtw.pot using the formula: VA (%) = (1 – [SIT ÷ Qtw, pot]) × 100) 
(See Chapter 3 = 3.7.1 Voluntary Activation). SICI was quantified as the ratio between the 
amplitude of conditioned MEPs to the amplitude of unconditioned MEPs. Corticospinal 
excitability was determined as the mean MEP amplitude during the 10% MVC as a percentage 
of Mmax. Additionally, MEPs contaminated by artefact or showing evidence of voluntary 
activation during the pre-stimulus period were excluded. The root-mean-square of EMG 
activity (rmsEMG) was also recorded during the middle 500 ms epoch of a 3 s maximal 
contraction. All data analysis was performed offline using Spike 2 (v6, CED, UK). 
 
7.2.7 Statistical Analysis 
Data were analysed using SPSS for Windows version 18.0 (SPSS Inc., Chicago, Illinois, USA). 
Data were first checked for normality using Kolmogorov–Smirnov test and found to be 
normally distributed. Sphericity was assessed using Mauchly’s test and if necessary, controlled 
using the Greenhouse-Geisser correction. To determine whether PRE group improved more 
than control group after 6-weeks and 12-weeks program, neurophysiological and patient report 
outcomes data were analysed by one-way (i.e., condition) analysis of covariance (ANCOVA), 
using baseline values as the covariate. Comparing differences between groups at each time 
point (baseline values at 6-weeks and 12- weeks), is a method that has been recommended for 
the analysis of continuous data measured at baseline and follow-up in randomised controlled 
trial (Vickers et al., 2001; 2005). Standardised mean differences and 95% confidence intervals 
(CI) were calculated from post intervention means and standardised deviation (SD; Hedges and 
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Olkin, 1985). If significant group (i.e., PRE vs Control group) effects were found, analyses 
were continued using pairwise comparisons using the Bonferroni correction. Intention to treat 
analysis was applied, with all participants who were allocated and commenced their program 
included in analysis. To interpret clinical significance of any statistically significant between 
group differences, typical error from Chapter 5 of this thesis were accepted as clinically 
important differences. Statistical significance was determined as an alpha of 0.05. Results are 
presented as mean (± SD) at each time point. As this was a feasibility study, changes in outcome 




Descriptive characteristics of the study participants are shown in Table 7.1. No significant 
differences in demographic or clinical characteristics were found between the PRE and control 
groups. Both groups were largely female (PRE: 75% and Control: 65%). Additionally, 38% of 
PRE group and 29% of control group reported other comorbidities including, osteoporosis, 
trigeminal neuralgia, fibromyalgia and underactive thyroid. Many were stable on disease 
modification treatments throughout the course of the study (PRE: 81% and Control: 88%; 
including, Tecfidera n = 8, Copazone n = 8, Tysabri n = 2, GiLenya n = 5, Avonex n = 1, 
Lemtrada n = 2, Rebrif n = 1 and Aubagio n = 1). 
 
7.3.2 Primary Outcomes 
Recruitment and Retention 
336 PwMS were screened for study eligibility from one site, with 33 (10%) fulfilling the 
inclusion criteria. Most PwMS did not meet the rigorous inclusion criteria (n = 260), due to 
diagnosis of later MS stages (primary progressive or secondary progressive MS), reported by 
the consultant as patients having EDSS >4.5 (n = 212) or because of a recent relapse (n = 48). 
Other reasons included, lack of interest (N = 3), undergoing change to disease-modification 
treatment (N = 22) or lived too far away (N = 18). Between 2017 and 2019, 15 (94%) PRE and 
15 (88%) control group patients completed the supervised phase of the study with reasons for 
premature discontinuation including, unable to contact (N=2), and one participant had a relapse 
and withdrew themselves. Fourteen (88%) PRE and 13 (77%) control group patients completed 
the home-based phase of the study with reasons for premature discontinuation including, 
unable to commit to the study (N=2) and with one participant having a relapse and withdrawing 
themselves (Refer to Appendix 24). 
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Intervention Adherence and Adverse Events 
Mean adherence to the supervised PRE was good with 90 ± 7% (range 75-100%) of the 15 
patients attending 9 ± 1 sessions’ from a total of 12 planned sessions (range 9 – 12 sessions). 
Missed sessions were caused by overwhelming fatigue (n = 4), relapse (n = 1) and reported 
illness (n = 1). Adherence to the home-based PRE was good with the 14 patients attending 79 
± 10% (range 67-100%) of the 12 supervised sessions (range 8 – 12). Missed sessions were 
caused by overwhelming fatigue (n = 5), difficulty finding the time (3) and relapse (n = 1). No 




Around 85% of participants felt confident they would continue with PRE after the intervention. 
When asked during the exist debrief questions about feelings during and after PRE, 93% (n = 
13) gave positive comments, with remarks such as ‘PRE made me feel less sluggish throughout 
the day’, ‘use my stairs with ease’, and that ‘my balance and walking ability had improved’. 
Following PRE, 36% (n = 5) reported feeling ‘happier and more self-confident’, 50% (n = 7) 
reported that they ‘felt tired at first, but this improved’ and 14% (n = 2) continued to feel 
occasional tiredness, but this was reported as manageable. All participants liked the session 
structure because it was tailored and progressed gradually, and that they enjoyed using the 
metro-timer and exercising as a group. However, 29% (n = 4) suggested that a wider variety of 
balance and/or yoga would have been suitable. 
 
7.3.3 Secondary Outcomes 
Overview 
The outcome assessments provided robust measurements of participant’s neurophysiological 
and self-reported measures. In the intervention group, patient reported measures and 
neurophysiological outcomes were obtained in 15 patients (94%) at 6-weeks follow-up due to 
inability to contact and 14 patients (88%) at 12-weeks follow-up because of time commitment. 
In the control group, patient reported measures and neurophysiological outcomes were 
obtained in 15 patients (94%) at 6-weeks follow-up due to relapse occurrence and inability to 
contact and 13 patients (77%) at 12-weeks follow-up because of relapse occurrence and time 
commitment (Appendix 6.7). 
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Effects of PRE on perceived fatigue differences between PRE and control groups 
At 6- and 12-weeks of follow-up, differences between the exercise and control group were 
shown in MFIS, in favour of PRE (6-weeks: F(1, 27) = 19.612, p =0.001, ηp2 = 0.42; 12-weeks: 
F(1, 24) = 10.122, p = 0.004, ηp2= 0.29; Figure 7.4B). No differences were observed between the 
PRE and control groups post intervention for the FSS or CFS fatigue scales (Figure 7.4A, Table 
7.2). 
 
Effects of PRE on Depression, Anxiety, Sleep and Pain between PRE and control groups 
At 6-weeks of follow-up, a difference between the exercise and control group was observed in 
HASDS (F(1, 27) = 11.759, p = 0.002, ηp2 = 0.30) and HADS-Anxiety (F(1, 27) = 12.726, p = 
0.001, ηp2 = 0.32). This was also shown at 12-weeks of follow-up in HADS (F(1, 24) = 10.843, 
p = 0.003, ηp2= 0.31) and HADS-Anxiety (F(1, 24) = 9.109, p = 0.006, ηp2= 0.28). The PRE 
group had reduced symptoms of mood and anxiety versus the controls (Figures 7.4 D & E). 
Pain at 6- and 12-weeks of follow-up showed differences in favour of the PRE group (6-weeks: 
F(1, 27) = 7.679, p = 0.010, ηp2 = 0.22; 12-weeks: F(1, 24) = 6.283, p = 0.019, ηp2= 0.21). Also, 
QOL-Physical (F(1, 27) = 4.985, p = 0.034, ηp2 = 0.16) and QOL-Mental (F(1, 27) = 6.571, p = 
0.016, ηp2 = 0.20) at 6-weeks of follow-up showed differences in favour of the PRE group. This 
was also shown at 12-weeks follow up in QOL-Physical (F(1, 24) = 4.873, p = 0.037, ηp2= 0.17) 
and QOL-Mental (F(1, 24) = 14.410, p = 0.001, ηp2= 0.38; Figure 7.4 G , H & I). There 
were no differences between the PRE and control group post-intervention for sleep quality 
(PSQI) or HADS-Depression (Table 7.2). 
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Table 7.2 Self-reported fatigue and patient reported Outcomes Mean (SD) of groups, mean (SD) difference within groups, and mean difference (95%CI) between groups 
 










Up - Baseline 
12-Weeks Follow- 













PRE CON PRE CON PRE-CON PRE-CON 
Perceived Fatigue Outcomes 
FSS 6.1 5.7 5.9 5.7 5.8 5.6 -0.2 0.0 -0.3 -0.1 -0.1 -0.2 
 (0.6) (0.6) (0.7) (0.6) (0.7) (0.6) (0.2) (0.2) (0.3) (0.3) (-0.3 – 0.2) (-0.4 – 0.1) 
MFIS 47.0 49.9 41.9 50.1 42.9 47.9 -5.2 1.6 -4.4 -0.4 -7.2 ** -4.3 ** 
 (11.6) (8.9) (8.3) (8.4) (8.1) (8.5) (7.2) (2.6) (5.9) (3.3) (-10.6 – -3.9) (-7.1 – -1.5) 
CFS 6.9 6.5 6.8 7.0 7.0 6.8 0.1 0.2 0.2 -0.3 -0.1 0.4 
 (2.3) (2.5) (2.5) (2.3) (2.3) (2.2) (1.3) (1.9) (1.5) (1.9) (-1.4 – 1.1) (-0.9 – 1.7) 
Patient Reported Outcomes 
HADS 14.1 12.5 12.1 13.5 11.7 13.7 -1.9 0.9 -2.3 0.9 -2.2 ** -2.5 ** 
 (5.6) (3.2) (3.6) (3.2) (3.3) (2.7) (3.1) (2.1) (3.7) (3.0) (-3.6 – -0.9) (-4.1 – -1.0) 
HADS- 8.1 7.5 7.0 8.1 7.3 8.0 -1.2 0.5 -1.2 0.5 -1.5 ** -1.3 ** 
Anxiety (4.1) (3.1) (3.1) (2.4) (2.9) (1.7) (1.9) (1.4) (1.9) (2.1) (-2.4 – -0.6) (-2.2 – -0.4) 
HADS- 6.0 5.0 5.1 5.3 4.4 5.7 -0.7 0.4 -1.1 0.4 -0.8 -1.3 
Depression (2.6) (2.6) (1.8) (2.5) (1.7) (2.1) (2.1) (1.7) (2.4) (2.4) (-1.9 – 0.4) (-2.7 – 0.1) 
NARCOMS 2.2 1.6 1.7 1.7 1.8 1.8 -0.5 0.1 -0.4 0.2 -0.5 ** -0.5 * 
Pain (1.3) (1.4) (1.3) (1.2) (1.3) (1.0) (0.5) (0.5) (0.6) (0.6) (-0.8 – -0.1) (-0.9 – -0.1) 
PSQI 9.4 8.6 8.2 9.1 8.2 8.7 -1.3 0.1 -1.3 0.3 -1.2 -1.3 
 (4.1) (4.0) (3.8) (3.2) (3.7) (3.2) (1.0) (2.8) (1.7) (2.6) (-2.6 – 0.1) (-2.8 – 0.2) 
MSQOL- 57.9 53.7 65.6 55.8 64.9 55.9 6.5 0.2 6.3 -1.5 7.1 * 7.9 * 
Physical (18.0) (14.1) (13.9) (15.2) (14.5) (14.3) (9.6) (9.1) (12.2) (8.1) (5.7 – 13.5) (0.5 – 15.3) 
MSQOL- 61.0 55.6 67.5 58.2 70.6 58.2 8.7 0.6 12.9 -0.4 8.2 * 13.0 ** 
Mental (18.0) (13.1) (16.1) (14.5) (16.1) (14.1) (6.0) (10.9) (7.6) (10.4) (1.6– 14.7) (6.0 – 20.1) 
PRE, progressive resistance exercise group; CON, control group; FSS, fatigue severity scale; MFIS, modified fatigue impact scale; CFS, chalder fatigue scale; HADS, hospital and depression scale; HADS-Anxiety; hospital and 



























































































































































Figure 7.4 FSS (A ), MFIS (B ), CFS (C ), HADS (D), HADS-Anxiety, (E), HADS-Depression (F), Pain (G), QOL-Physical (H), and QOL-Mental (I) all 


























































































































At 6-weeks of follow-up differences were shown between the PRE and control group in MVC 
F(1, 27) = 7.727, p = 0.010, ηp2 = 0.22 and VA F(1, 27) = 33.150, p < 0.001, ηp2 = 0.55. A greater 
increase in MVC and VA occurred in the PRE group (see Figure 7.5A & E). No differences 
were observed between the PRE and control groups for MVC or VA at 12-weeks of follow-up. 
Additionally, no difference in Qtw, pot was observed between the PRE and control group at any 
of the post-intervention follow-ups (see Table 7.3). However, Mmax was different in favour of 
the PRE group at the 6-week follow-up (F(1, 27) = 5.647, p = 0.025, ηp2 = 0.17) and 12-week 
follow-up (F(1, 24) = 7.412, p = 0.012, ηp2 = 0.24). 
 
Fatiguability 
There was no difference in TTF between the PRE and control groups at 6-weeks of follow-up 
(p = 0.113) but a difference in favour of the PRE group was observed at 12-weeks of follow up 
(F(1, 24) = 7.865, p = 0.010, ηp2 = 0.25). There were no differences between the groups at any 
follow-up time-point in the rate of force decline (Table 7.3). 
 
Corticospinal and Inhibitory measures 
At 6-weeks of follow-up improvements in MEP amplitude and SP appeared to be greater in the 
PRE group versus control, but between-group differences were not observed (Figure 7.5H & I; 
MEP amplitude, p = 0.055 and SP duration, p = 0.077 and). Neither were there any differences 
between the PRE group and controls for SP at 12-weeks of follow-up, or for MEP/Mmax, SICI 























Table 7.3 Neurophysiological measures in lower-limb (knee-extensors). Mean (SD) of groups, mean (SD) difference within groups, and mean difference (95%CI) between groups 
 
Outcome Groups Difference within groups Difference between groups 











Up - Baseline 
12-Weeks Follow- 













PRE CON PRE CON PRE-CON PRE-CON 
MVC (N) 336.4 352.7 403.3 352.4 398.7 344.1 64.1 9.7 54.9 21.4 54.0 * 35.8 
 (81.4) (105.9) (78.5) (107.6) (89.0) (91.1) (40.6) (63.3) (47.6) (58.4) (14.2 – 93.9) (-7.0 – 78.6) 
Qtw, pot (N) 121.4 128.7 130.9 130.1 122.8 131.2 7.2 3.5 -2.0 8.1 3.4 -9.8 
 (23.6) (43.5) (25.7) (40.6) (25.6) (43.5) (9.4) (18.6) (15.3) (18.6) (-7.7 – 14.5) (-23.3 – 3.8) 
VA (%) 88.7 90.8 91.6 91.2 90.9 91.4 2.9 0.3 2.4 0.6 2.7 ** 1.0 
 (3.6) (3.3) (2.2) (2.7) (2.7) (3.1) (1.9) (1.1) (2.4) (1.4) (1.8 – 3.7) (-0.3 – 2.3) 
TTF (mins) 10.3 12.7 12.7 13.5 13.2 11.9 2.1 0.0 2.5 -1.0 1.9 3.1 * 
 (5.7) (8.2) (6.4) (7.8) (6.4) (6.2) (2.3) (3.6) (2.1) (3.9) (-0.5 – 4.2) (0.8 – 5.3) 
Rate of force -17.0 -14.7 -13.8 -11.6 -13.1 -14.4 3.5 0.7 4.9 -2.5 -0.3 3.7 
decline (12.9) (9.5) (7.4) (5.8) (6.5) (13.8) (9.8) (6.3) (11.9) (11.9) (-4.3 – 3.7) (-4.6 – 12.1) 
(N·Min)             
Mmax (mV) 4.6 5.1 5.8 5.3 5.9 5.0 1.2 0.3 1.1 0.2 0.8 * 0.9 * 
 (1.5) (1.3) (1.7) (1.0) (1.5) (0.9) (1.1) (0.9) (1.1) (0.9) (0.1 – 1.5) (0.2 – 1.8) 
MEP 0.6 0.6 0.9 0.7 0.9 0.7 0.3 0.1 0.3 0.1 0.17 0.2 
Amplitude (0.3) (0.3) (0.6) (0.4) (0.5) (0.4) (0.3) (0.2) (0.3) (0.2) (-0.04 – 0.4) (-0.01 – 0.4) 
MEP/Mmax 14.3 12.7 15.3 13.5 16.0 13.2 0.5 0.0 1.4 -1.0 0.0 0.0 
(%) (7.5) (10.2) (8.1) (9.3) (7.6) (8.8) (5.6) (4.4) (5.6) (5.9) (-0.03 – 0.04) (-0.03 – 0.05) 
rmsEMG 0.6 0.6 0.7 0.6 0.7 0.6 0.2 0.0 0.1 0.0 0.1 0.1 
(mV) (0.3) (0.2) (0.3) (0.2) (0.3) (0.2) (0.3) (0.3) (0.3) (0.1) (-0.05 – 0.32) (-0.2 – 0.3) 
SICI (ratio) 0.6 0.6 0.7 0.6 0.7 0.6 0.1 0.0 0.0 0.0 0.1 0.1 
 (0.2) (0.2) (0.2) (0.2) (0.2) (0.2) (0.2) (0.10) (0.2) (0.2) (-0.04 – 0.20) (-0.06 – 0.28) 
SP (ms) 193.5 149.1 165.1 151.4 184.0 168.3 -30.2 -3.3 -12.5 10.6 25.3 24.9 
 (52.0) (43.3) (45.1) (52.1) (48.7) (47.1) (49.0) (25.1) (26.4) (45.7) (-3.0 – 53.4) (-12.0 – 61.7) 
PRE, progressive resistance exercise group; CON, control group, MVC; maximal voluntary contraction, Qtw,pot; potentiated twitch, VA; voluntary activation, TTF; time to task failure, Mmax; maximal m-wave, MEP; motor evoked 
























































































































Figure 7.5 MVC (A ), Qtw,pot (B ), N.Min (C ), TTF (D), VA, (E), MEP/Mmax (F), SICI (G), SP (H), and MEP Amplitude (I) of the lower-limb muscle, 























































































































































At 6-weeks of follow-up, there was a difference in favour the PRE group in MVC (F(1, 27) = 
7.482, p = 0.011, ηp2 = 0.22) and Qtw, pot (F(1, 27) = 9.426, p = 0.005, ηp2 = 0.26). At 12-weeks 
of follow-up, the difference between the PRE group and controls remained for Qtw, pot (F(1, 24) = 
8.115, p = 0.009, ηp2 = 0.25) but not for MVC (Figure 7.6 A & B). There were no differences 
between the groups at any follow-up time-point for VA or Mmax (Table 7.4). 
 
Fatiguability 
At 6-weeks of follow-up, improvements in TTF and the rate of force decline (N·Min) were 
apparent for the PRE group versus controls, but none of the between-group differences were 
significant (Figure 7.6 D; TTF, p = 0.084 and N·Min, p = 0.147). However, at 12-weeks of 
follow-up, differences in favour of the PRE group were observed for TTF (F(1, 24) = 8.613, p = 
0.007, ηp2 = 0.26) and N·Min; (F(1, 24) = 4.590, p = 0.043 , ηp2 = 0.161; Table 7.4). 
 
Corticospinal and Inhibitory measures 
There were no differences in MEP amplitude, MEP/Mmax, SICI or SP between the PRE and 






























Table 7.4 Neurophysiological measures in upper-limb (wrist-flexors). Mean (SD) of groups, mean (SD) difference within groups, and mean difference (95%CI) between groups 
 
Outcome Groups Difference within groups Difference between groups 











Up - Baseline 
12-Weeks Follow- 













PRE CON PRE CON PRE-CON PRE-CON 
MVC (N) 103.8 114.1 131.8 111.3 133.6 119.0 27.0 -1.8 26.4 8.2 25.2 ** 16.7 
 (31.2) (22.1) (34.5) (22.3) (32.5) (32.1) (28.8) (26.2) (27.7) (32.6) (6.3 – 44.1) (-5.9 – 39.2) 
Qtw, pot (N) 31.5 34.5 36.9 33.8 39.2 35.8 5.7 -1.1 7.9 1.5 6.2 ** 5.8 ** 
 (12.2) (12.4) (13.1) (10.8) (13.2) (11.1) (5.1) (6.4) (5.2) (6.2) (2.1 – 10.4) (1.6 – 10.1) 
VA (%) 87.3 88.8 90.5 90.5 90.1 88.8 3.4 2.2 2.8 1.6 0.7 1.2 
 (3.6) (4.8) (4.2) (3.1) (3.6) (2.5) (3.4) (3.5) (3.5) (2.4) (-1.5 -2.9) (-0.7 – 3.2) 
TTF (mins) 14.2 12.9 16.0 13.1 15.9 11.5 2.5 0.9 2.5 -0.2 1.7 3.0 ** 
 (6.0) (7.3) (5.3) (7.5) (5.1) (5.9) (3.2) (2.0) (3.6) (2.0) (-0.3 – 3.7) (0.9 – 5.2) 
























(-0.3 – 2.0) 
-1.1 * 
(-2.2 – -0.4) 
Mmax (mV) 9.2 8.9 10.2 9.2 9.8 9.3 0.7 0.3 0.7 0.2 0.4 0.4 
























(-0.03 – 0.2) 
0.1 
(– 0.1 – 0.2) 
MEP/Mmax 7.6 9.0 8.2 9.1 8.3 9.2 0.7 -0.3 0.6 -0.5 0.0 0.0 
























(-0.01 – 0.2) 
0.1 
(-0.02 – 0.23) 
SICI (ratio) 0.7 0.7 0.7 0.6 0.8 0.6 0.0 0.0 0.1 0.0 0.1 0.1 
 (0.2) (0.2) (0.2) (0.2) (0.2) (0.2) (0.2) (0.2) (0.2) (0.2) (-0.04 – 0.2) (-0.02 – 0.23) 
SP (ms) 135.2 143.8 158.4 154.7 164.3 160.0 25.2 16.7 28.8 30.2 8.1 -0.2 
 (39.4) (47.1) (54.5) (44.9) (49.7) (37.0) (29.9) (25.2) (29.9) (33.5) (-13.0 – 29.2) (-24.6 – 24.2) 
PRE, progressive resistance exercise group; CON, control group, MVC; maximal voluntary contraction, Qtw,pot; potentiated twitch, VA; voluntary activation, TTF; time to task failure, Mmax; maximal m-wave, MEP; motor evoked 












































































































































































Figure 7.6 MVC (A ), Qtw,pot (B ), N.Min (C ), TTF (D), VA, (E), MEP/Mmax (F), SICI (G), SP (H), and MEP Amplitude (I) of the upper-limb muscle, all 




















































































































































The main aim of the present study was to examine the feasibility of PRE (part 
supervised, part home-based) in highly fatigued PwMS. Compared to usual care alone, 
PRE was found to be feasible with excellent retention (6 weeks, 94%; 12 weeks, 88%) 
and high adherence (>75% of all sessions) in highly fatigued participants. The excellent 
level of adherence to the programme resulted in reductions in perceived fatigue (MFIS), 
mood, anxiety, pain and health-related quality of life following supervised PRE, which 
were maintained following home-based training. Neurophysiological data showed that 
6-weeks of supervised PRE led to improved muscle strength and activation in the upper 
and lower extremities, and with an improvement in TTF also shown after additional 6 
weeks of home-based PRE. This early evidence of efficacy shows that a blended 
programme of supervised and home-based PRE has potential to improve perceived 
fatigue, health and specific neuromuscular function outcomes in individuals with high 
levels of MS fatigue. The present study is an important addition to the evidence-base 
that illustrates the potential therapeutic benefits of PRE in PwMS and the role it could 
play in self-management of MS fatigue. 
 
Feasibility of PRE in Fatigued PwMS 
The evidence of feasibility is noteworthy, as this modality of exercise may represent a 
more accessible option for self-directed structured exercise versus other exercise 
modalities, such as aerobic exercise for some PwMS. Aerobic training via gym-based 
classes and/or expensive gym equipment, or exposure to adverse weather conditions 
may be less appealing than PRE performed in a home setting using resistance bands 
with lower financial cost and higher degree of control regarding safety and rest periods. 
The present study provides further evidence that PRE is an exercise modality is highly 
accessible and adoptable by PwMS, with much potential for excellent adherence and 
maintenance in non-supervised settings, in accordance with previous findings (DeBolt 
& McCubbin, 2004; McCullagh et al., 2008). Interestingly, there is also evidence from 
supervised progressive aerobic PRE studies in PwMS with similar session frequency, 
of slightly lower retention rates (73 to 85% at follow-up; (Petajan et al., 1996; Cakt et 
al., 2010). Therefore, PRE using therabands warrants further investigation to wider MS 
community uptake as an exercise modality that can feasibly be adopted as part of self- 
management strategies in people experiencing hight levels of perceived fatigue. 
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In the absence of any major injuries or adverse events, PRE was shown to be well- 
tolerated by all of the highly-fatigued PwMS recruited to this study. This is in 
agreement with previous studies, which reported no major problems or unpleasant 
experiences related to resistance training in more heterogeneous samples PwMS on the 
basis of fatigue status (DeBolt & McCubbin, 2004; White et al., 2004; Gutierrez et al., 
2005). Although there was some evidence of mild muscle soreness in the latter studies, 
not all participants experienced muscle soreness, and this is likely to reflect 
physiological adjustment to a new exerciser training programme. The present study 
demonstrated a lack of PRE-induced severe symptom exacerbations in a cohort of 
participants that were all experiencing high levels of MS fatigue, which could reflect 
proper instruction and tailoring of PRE to specific capabilities (i.e., standing or seated 
PRE alternatives and use of fans during sessions to prevent heat sensitivities). In the 
present study, the PRE programme was also designed to incorporate regular breaks 
between upper- and lower-limb exercises that could be implemented without difficulty 
by highly-fatigued PwMS. 
 
Changes in Fatigue following PRE 
The results from this study also suggests that PRE can have a positive effect on the high 
levels of perceived fatigue experienced by some PwMS, as shown by the reductions in 
MFIS (7%) in the PRE group following 6-weeks of supervised PRE, and with this being 
maintained after 6-weeks of home-based PRE. These data support previous study 
findings (White et al., 2004; Dodd et al., 2006) but with White et al. (2004) reporting a 
reduction of 24% in MFIS, which is three-fold greater than the present study. This 
might have been due to the lower limb training approach that was used, in comparison 
to the whole-body approach used in the present study, although their participants were 
not recruited on the basis that they were experiencing high levels of MS fatigue at 
baseline. White et al. (2004) reported gradual progression of 2-5% resistance after 
completion of 15 repetitions, whereas the current study was adapted on the basis of the 
participant’s own pace and fatigue sensation. Despite the reduction in MFIS score, no 
changes were observed for the FSS or CFS. A previous PRE intervention in fatigued 
PwMS reported a reduction in the FSS of −0.6 (−1.4 to −0.4) following 12-weeks of 
resistance PRE compared to the present study’s small difference (−0.15, −0.29 to 
−0.01) after 6 weeks. A potential reason for this discrepancy could be a cut-off score of 
>4 used for the FSS. A cut-off score of >5 was used in the present study, suggesting 
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participants (as a whole) were experiencing higher levels of fatigue at baseline. 
Additionally, there was a longer training period of 12-weeks for single-limb training, 
as compared with whole body exercise for a shorter period in the present study. The 
one-dimensional FSS and CFS, versus the multi-dimensional MFIS might be less 
amenable to change following short-term programmes of PRE. Thus, the results of the 
present study suggest that the MFIS could be a more sensitive measure for exercise 
studies in PwMS, and particularly those investigating the impact of PRE in those with 
high levels of perceived fatigue. This being said, more research is warranted to evaluate 
the utility of single and multi-dimensional fatigue scales in large scale trials of exercise 
therapy for fatigue management in PwMS. 
 
Changes in Health Outcomes following PRE 
Mood and anxiety were improved in the PRE group, similar to previous exercise studies 
using different types of PRE in PwMS (Ahmadi et al., 2013; Briken et al., 2014), and 
these results are also consistent with studies showing the beneficial effects of PRE in 
individuals with major depression (Mota-Pereira et al., 2011; Trivedi et al., 2011; 
Silveira et al., 2013). However, the latter studies used different scales, such as the Beck 
Depression Inventory and Beck Anxiety Inventory (Ahmadi et al., 2013)and the 
Inventory of Depressive Symptoms self-report questionnaire (Briken et al., 2014). 
Therefore, future studies of PRE in highly fatigued PwMS would benefit from greater 
consistency in the use of depression and anxiety scales to strengthen the evidence base. 
Pain was also shown to be improved following supervised and home-based PRE (6 
weeks, −28%; 12-weeks, −21%), consistent with previous data (Learmonth et al., 2014) 
which also showed that a 15-minute bout of moderate-intensity PRE had no adverse 
effect on pain or function in PwMS. However, the promising preliminary data from this 
feasibility study needs to be heeded with caution, as a larger scale trial with longer-term 
follow-up needs to be conducted before definite conclusions regarding these health 
outcomes can be drawn. 
 
The PRE group experienced improvements in QOL-Mental and QOL-Physical after the 
supervised component of the programme and these health benefits were maintained 
after home-based PRE (Figure 7.4). This is an interesting finding because it is known 
that health-related quality of life is reduced in PwMS (Miller et al., 2006), and the 
changes observed in the present study were greater than previous work (Dodd et al., 
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2006; Dalgas et al., 2010). Specifically, Dodd and colleagues (2006) used a qualitative 
approach, reporting a reduced QOL-physical component after 10 weeks of bi-weekly 
training. However, earlier research by Romberg et al. (2005) which examined home- 
based combined training found no improvement in health-related quality of life (HR- 
QOL). Reasons for the discrepant findings might be differences between the studies in 
the level of social isolation and support or contact provided to PwMS, as evidence from 
healthy older sedentary subjects supports this notion (Cox et al., 2003). Participant 
feedback from the present study supports this, with PwMS reporting enjoyment from 
the regular social interactions and saw this as a motivational feature, particularly during 
the supervised component of the PRE programme. This seems important because it is 
known that poor health-related quality of life is strongly influenced by loss of 
independency (Takemasa et al., 1998), which can adversely impact social 
connectedness. 
 
Changes in Neuromuscular Function following PRE 
An improvement in muscle strength was observed after 6-weeks of supervised PRE in 
both the upper- (31%) and lower- (21%) limbs in highly fatigued PwMS, suggesting 
the capacity to adapt over a shorter period of exercise time. The magnitude of muscle 
strength improvement was greater than the typical error reported in Chapter 5 (lower: 
14.4, upper: 11.2), indicative of real clinically-important change. This supports 
previous resistance training studies in PwMS not categorised by fatigue status over a 
similar time period of 4-12-weeks (7 – 57%; Swensson et al., 1994; Kasser and Cubbin, 
1996; Harvey et al., 1999; DeBolt & McCubbin, 2004; Taylor et al., 2006; Aimet et al., 
2006). However, this was not in agreement with the non-fatigued findings of Harvey et 
al. (1999), despite similar improvements in quadriceps MVC (28–47%) being reported, 
likely because their study had a smaller sample size (n = 7). 
 
It is also interesting to note that the present study identified a greater improvement in 
upper-limb strength versus lower-limb strength, similar to four previous studies 
reporting notable improvements (3–29%) in upper extremity muscle strength (Kasser 
& McCubbin, 1996; Kraft et al., 1996; Schwid et al., 1999; Taylor et al., 2006). This 
should be considered in the context of evidence of a more pronounced strength deficit 
in the lower extremities amongst PwMS and older people (Skelton et al., 1994; Bassey 
et al., 1992). The proposed greater strength increase recognises that training specificity 
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is important, i.e., in the present study, knee-extension and wrist flexion exercises were 
incorporated into the whole-body exercise programme. However, muscle strength was 
not maintained after the home-based PRE, with a possible explanation due to the limited 
tailoring of PRE over the phone in a home setting and less effective progression as 
strength improved, unlike the face-to-face supervised setting which allows adjustments 
to the training load consistent with individual responses and capabilities. Fatigability 
by way of time to task failure improved after supervised and home-based PRE, 
suggesting that along with an increase in strength, there was a tangible impact on the 
ability to sustain muscular work, and this is likely to be important for day-to-day 
functioning. This is further supported by participants anecdotally commenting on 
having greater energy to do more walking and house tasks with less frequent breaks 
and using walking aids less, supporting all-round functional improvements. Moreover, 
the present results corroborate reports regarding the effect of strength training in 
patients with neuromuscular disorders such as spinal muscular atrophy or 
facioscapulohumeral muscular dystrophy (McCartney et al, 1989; Spector et al. 1996). 
 
Increased VA following 6-weeks of supervised PRE, in only the lower-limb, with no 
further increases after home-based PRE. These changes are greater than the typical error 
(1.9%) showing a real change outside the variability of the measure in highly fatigued 
PwMS. This change might be related to the more pronounced strength deficit observed 
in the lower extremity in PwMS (Skelton et al., 1994; Bassey et al., 1992), suggesting 
more potential to enhance neural drive with lower-limb PRE. To date, no studies have 
reported neural drive changes using VA in PwMS after PRE. Previous studies in healthy 
individuals have reported changes in muscle strength (Moritani and de Vries, 1980) and 
neural drive (EMG based) to muscles in first 3-5 weeks (Aagaard et al., 2002; Tallent et 
al., 2017). In PwMS, Dalgas et al. (2013) reported EMG increases of 36% after training 
2 days a week for 12-weeks and Fimland et al. 2010 reported an increase of 40% after 
3 weeks. The larger increase in EMG might be due to the higher training frequency of 5 
days a week in the latter study (Fimland et al., 2010), unlike the 2 days a week protocol 
used in the present study, which was chosen to reduce risk of injury and allow 
appropriate recovery periods. While changes in MEP amplitude and inhibition (SP) 
were found after 6-weeks of supervised PRE, no differences were observed for the 
lower-limb (Table 7.3 & Figure 7.5) but suggest some possible early indicative signs 
of cortical plasticity accompanying the strength gains observed in the 
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present study. However, as longer-term structural plasticity occurs between sessions, 
not within sessions (Mednick et al., 2011), it might be that a twice-weekly PRE stimulus 
for 6-12-weeks is not optimal for such central nervous system adaptation (Kleim et al., 
2004). Previous resistance exercise studies in PwMS have not explored corticospinal 
excitability and inhibitory responses, thus supporting the need for further research for 
greater exploration of these measures. 
 
7.3 Limitations 
The main limitation of this study was the lack of experimental control over the blinding 
of participants to the intervention and lack of blinding in the follow-up assessments. 
Another limitation of the present study could be restricting neurophysiological 
assessments to the right limb (identified using the Oldfield questionnaire). It can, 
therefore, not be stated whether the contralateral limb would have shown the same 
pattern of adaptations. Furthermore, compliance to home-based PRE was reportedly 
lower compared to the supervised PRE. Although, the participants benefited from 
fortnightly phone calls for support and the opportunities for advice and questions, 
superior support could have been provided to improve compliance. For example, 
remote use of online platforms for support, including fitness apps, real-time video 
conferencing, more regular phone calls/texts and “booster” face to face sessions are 
support mechanisms that could be used in future studies. Lastly, most relapsing- 
remitting PwMS are receiving a disease-modifying drug. Although, such information 
is described in the present study, it is poorly reported or not accounted for in previous 
trials of PRE training. This issue means that no clear understanding of the benefits of 
PRE in the context of disease-modifying drug use is available and this is an important 
issue when considering prescribing PRE to PwMS. 
 
7.4 Future Directions 
Based on the present study, representing a selected group of mildly affected PwMS 
(EDSS 0-5) with high fatigue, future directions could focus on PRE for more severely 
impaired PwMS (EDSS > 5.5) with high fatigue. Kraft et al. (1996a, 1996b) reported 
that resistance training was well tolerated and had beneficial effects in four PwMS 
having an EDSS greater than 6. Further research could also include assessment of both 
left and right extremities for neurophysiological measures, to explore whether the most 
affected limb might have a greater improved pattern of adaptations during whole body 
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PRE, particularly as more irreversible neuronal damage might be present, potentially 
limiting adaptability. Compliance to home-based PRE was good, yet additional work is 
still required to examine the efficacy and long-term compliance to PRE programmes 
within other supervised and community led settings such as local gymnasiums, 
community centres, aged residences, and a combined home/supervised center-based 
approach. Furthermore, little is known about PRE within the context of MS relapses 
(Maurer et al., 2018) and safety aspects must be considered, such as discontinuation of 
PRE during a relapse for safety. When and how PRE should be reinitiated after 
resolution of a relapse, and if PRE is only suitable after certain types of relapses might 
provide further insight into common causes of drop-out in PRE studies in PwMS. 
Lastly, patient feedback described improved balance and walking ability, however no 
gait, walking or balance assessments were included, which could provide further insight 
into falls reduction and increased independence. Thus, walking and balance measures 
might be considered, as there is incomplete evidence regarding the effects of resistance 
training on functional capacity. Previous studies reported no change in gait speed 
(Harvey et al. 1999, White et al. 2004), whereas some studies have shown significant 
improvements in functional capacity, including gait, stair climbing ability and ‘timed 
up and go’ (Kraft et al. 1996; Taylor et al. 2006). Further investigation into whether 
study participants reliably demonstrate placebo responses across different fatigue status 
groups (MS-HF vs MS-LF) could distinguish such individuals from non-responders to 
exercise interventions in the future and better understand psychological responses to 
exercise (Lindheimer et al., 2020). 
 
7.5 Conclusion 
The aim of this chapter was to establish whether progressive resistance exercise 
(supervised and home-based) is a feasible exercise modality for PwMS experiencing 
high levels of fatigue and explore health benefits via measures of neuromuscular 
function and patient reported outcomes. This Chapter demonstrated that a part 
supervised, part home-based PRE programme on 2 days per week was safe and well 
tolerated by fatigued PwMS. Additionally, home-based resistance training was 
effective for maintaining the supervised-based improvements in fatigue, mood, health- 
related quality of life and time to task failure. However, the improved muscle strength 
associated with supervised PRE, accompanied by enhanced muscle activation, was not 
maintained after the home-based exercise component. The apparent ineffectiveness of 
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home-based training to maintain the improvements in neuromuscular function was most 
likely due to the slight reduction in adherence and PRE training volume and intensity 
during the home-based training. Nevertheless, this study provides clear evidence that 
PRE has much potential to induce a positive effect on MS fatigue, when evaluating MS 
fatigue as the primary outcome measure, emphasising the need for future studies within 
this field. This study also demonstrates the potential of PRE to improve measures of 
neuromuscular function over usual care in PwMS. Future studies should be designed as 
adequately powered randomised controlled trials, with fatigue as the primary endpoint, 




































The primary aim of this thesis was to establish whether neurophysiological differences 
between highly-fatigued (MS-HF) and less-fatigued (MS-LF) could be reliably 
distinguished, and to investigate the feasibility and potential of PRE as a therapeutic 
exercise intervention for ameliorating perceived MS-fatigue. To meet this aim, four 
studies were conducted. The aim of Study 1 (Chapter 4) was to understand the current 
evidence-base regarding neurophysiological and neuro-structural differences between 
people experiencing high and low levels of fatigue via a systematic review of cross- 
section studies. The aim of Study 2 (Chapter 5) was to assess the test-retest reliability, 
measurement variability and measurement error of upper- and lower-limb 
neuromuscular and transcranial magnetic stimulation measures in MS-HF and HS-LF 
and healthy controls. Based on the findings of Study 2, Study 3 (Chapter 6) investigated 
differences between MS-HF, MS-LF and HC, for a range of neurophysiological 
measures, including an isometric fatiguing exercise task in the upper- and lower-limb 
(performance fatigability measure), with the aim of understanding which 
neurophysiological correlates best distinguish MS-HF from MS-LF. Finally, the aim of 
Study 4 (Chapter 7) was to evaluate the feasibility of (and glean preliminary evidence 
of efficacy for) PRE (part-supervised, part-home-based) as a therapeutic exercise 
intervention for ameliorating perceived MS-fatigue. This latter study was developed to 
address the relative paucity of studies that have recruited a homogenous sample of 
PwMS experiencing a high level of fatigue, and in which perceived fatigue is the 
primary outcome. This final chapter briefly summarises the main findings of this PhD 
programme and concludes with a brief discussion of the implications of this research 
and future directions for research in this area. 
 
8.2 Principal Findings 
Chapter 4 (Study 1) was the first systematic review and meta-analysis to synthesis the 
current evidence base comprising studies which used a dichotomised model (MS-HF 
versus MS-LF) to provide insights into structural and neurophysiological correlates of 
MS-fatigue. Synthesising and meta-analysing the current evidence base was a step 
towards overcoming some of the limitations of previous research (e.g., small sample 
sizes, conflicting evidence, unknown effect size estimates, etc.). This chapter shed some 
light on neuro-structural differences between MS-HF and MS-LF by means of 
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neuroimaging techniques and indicated greater cortico-subcortical atrophy (total brain 
loss -22.7 ml, mainly attributable to a volumetric reduction in grey matter -18.8 ml) in 
highly-fatigued PwMS. This chapter also helped to consolidate the evidence for the 
involvement of specific areas of localised damage and impaired connectivity in severe 
MS fatigue, for example, basal ganglia circuitry, including the striatocortical and 
striatothalamic networks, responsible for motor control, motor planning, attentional 
control and the integration of afferent and efferent information. The findings also 
suggested an increased volume of T1-weighted hypointense lesions in MS-HF, perhaps 
reflecting activated immune inflammatory pathways or irreversible pathological 
changes which are important features of the disease (Morris et al., 2016). These results 
concur with functional magnetic resonance imagery and electroencephalogram data 
suggesting functional reorganisation within cortico-subcortical networks as a 
compensatory response to MS brain lesions, and adaptative neural processing within 
certain networks resulting in an increase in energy demand (Filippi & Rocca, 2004; Kos 
et al., 2008). Therefore, the consolidated neuroimaging evidence-based was most useful 
for helping to discern key neurostructural differences in PwMS partitioned by fatigue 
status, implying that impairment (and/or atrophy) of specific brain structures and 
networks may place an elevated demand on functioning (non-pathological) neural 
circuits, and that this could be involved in increased perceptions of MS fatigue. 
 
A synthesis of the evidence-base that used neuromuscular techniques identified 
peripheral and central correlates of MS fatigue via reduced muscle strength (MVC), 
impaired voluntary activation (central motor drive) and an increased level of upper- 
limb fatigability in MS-HF versus MS-LF and HC. This suggests an impaired ability to 
fully activate skeletal muscles during motor tasks in MS-HF (Zijdewind et al., 2016). 
The deconditioning effects of relative physical inactivity after an MS diagnosis, might 
further compound these underpinning issues and exacerbate MS-fatigue (Sebastiao et 
al., 2017), as inactivity can lead to disuse atrophy and neurophysiological changes 
affecting skeletal muscle activation, leading to impaired muscular strength and function 
(Rice et al., 1992). In turn, this could increase the amount of effort required for everyday 
tasks. No differences were shown in the relative integrity of corticospinal (MEP 
variables or central motor conduction time), intracortical inhibition (SICI) or 
intracortical facilitation (ICF) pathways between MS-HF and MS-LF. This may be at 
odds with evidence of altered functional connectivity and hyperactivation in fronto- 
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parietal cortical regions, sensorimotor network and subcortical areas important for 
motor, sensory and cognitive processing in MS-HF (Tartaglia et al., 2008; Specogna et 
al., 2012; Rocca et al., 2016; Bisecco et al., 2017; Jaeger et al., 2018). However, at 
present very few studies have compared SICI or ICF variables between MS-HF and 
MS-LF, making it difficult to draw definitive conclusions about the extent to which 
modulation of intracortical inhibitory or facilitatory networks could be implicated in 
MS-fatigue. 
 
For some key variables, there is a small number of studies and the overall quality rating 
of included studies was ‘moderate’, as such, caution is needed when interpreting these 
results. Nevertheless, Chapter 4 robustly synthesises the existing evidence-base, and by 
consolidating available neuro-imaging and neurophysiological data, provides new 
insights into neurobiological differences that exist between MS-HF and MS-LF. This 
is an important step in delineating key homeostatic and psychophysiological pathways 
underpinning perceived fatigue and fatigability in PwMS. Although data from 
neuroimaging studies was needed to understand neurostructural correlates of MS 
fatigue, such techniques were beyond the scope of available resources for this PhD 
programme and could not be included in future chapters. In contrast to neuro-imaging 
techniques, neurophysiological measures are more accessible and are well-tolerated by 
PwMS and so were used for the experimental studies (Chapters 5-7) in this thesis. 
 
Chapter 5 (Study 2) was an original study showing good to excellent test-retest 
reliability for a range of neuromuscular and transcranial magnetic stimulation measures 
assessed in the upper- and lower-limb muscles of people experiencing high and low 
levels of MS fatigue. The primary finding was that MVC, TFF, MEP amplitude, SP 
were highly reproducible in MS-HF, which extends current literature on the reliability 
of force measures for the knee extensors (Surakka et al., 2004b) and for grip strength 
(Schwid et al., 1999) in PwMS not characterised by fatigue status. There is similar 
evidence from previous work in the elbow flexors (Meeteren et al., 2002) and knee 
extensors (Frontera et al., 1993; Dvir, 2004) of healthy individuals. These findings 
suggest that these neurophysiological measures hold much promise for future adoption 
in exercise training and other therapeutic interventions for fatigue management in 
PwMS, in particular, having the potential to shed more light on how underpinning 
neurophysiological changes impact perceptions of MS fatigue. In the present study, 
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MVC showed low measurement error for the knee-extensors compared to the wrist- 
flexors, which might suggest poorer reliability for larger muscle groups, or for muscle 
groups that are more severely affected by MS (see Tables 5.3 and 5.4). The findings of 
this chapter demonstrated moderate test re-test reliability for VA, SICI MEP amplitude, 
and with corticospinal excitability (MEP/Mmax) found to be moderate to good, 
consistent with previous research for PwMS more generally. Furthermore, the greater 
coefficient of variation for this latter measure in the present study (>10%), signifies a 
higher intra-subject variability. A possible reason for lower reproducibility was that the 
average responses to transcranial magnetic stimulation measurements were lower in 
PwMS due to the uncomfortable nature of the tests, which should be taken into account 
when taking multiple measures of MEP. Interestingly, day-to-day reliability 
demonstrated greater reliability in the lower-limb compared with the upper limb 
muscles in PwMS, also observed for VA. Another interesting observation was the low 
coefficient of variations and typical errors in the knee-extensors compared to the wrist 
flexors in MS-HF, which may suggest greater reliability for muscle groups requiring 
less fine motor control, perhaps having adverse implications for motor control in every- 
day upper-limb tasks, such as lifting and carrying shopping bags and hoovering. 
 
A high level of test-retest reliability was shown for patient-reported outcomes, 
including fatigue, mood and sleep quality, in PwMS experiencing different levels of 
fatigue. The high test-retest reliability of fatigue scale scores over this 7-14-day period 
is particularly reassuring, as the occurrence of severe MS-fatigue can be sporadic, and 
scores may be influenced by recent symptoms. However, a limitation of this study was 
the low motivation to participate in the research due to multiple site visits amongst 
PwMS, which could have implications for the generalisability of the results to the 
broader MS population, particularly PwMS who are less willing volunteer for research 
studies. These patient-reported outcomes are potential confounders for the reliability of 
neurophysiological measures and may be sporadically present when such clinical 
measurements are taken in PwMS, especially relevant for MS-HF. However, in the 
studies presented in this thesis, participant welfare was checked in the lead-up to 
assessment visits and re-scheduled if participants were experiencing undue levels of 
MS-fatigue or other debilitating MS symptoms. This flexible approach might have 
influenced the higher reproducibility observed and should be considered for future 
experimental research. Based on the high reproducibility and tolerance to most of the 
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neurophysiological assessments undertaken, the results of Chapter 5 (Study 2) support 
their utility in future studies of MS-HF. 
 
Thus, on basis of the promising findings reported in Chapter 5 (Study 2), Chapter 6 
(Study 3) aimed to identify reliable neurophysiological correlates of severe MS-fatigue 
in homogenous groups of PwMS partitioned on the basis of fatigue status (MS-HF vs 
MS-LF). The primary findings at rest were impaired patterns of muscle strength 
(MVC), shorter time to task failure and voluntary activation (VA), with no perceptible 
impairment of intramuscular muscle contractile properties (Qtw,pot ) in MS-HF versus 
MS-LF. Therefore, the presence of a high level of perceived MS-fatigue seems to be 
associated with decrements in central nervous system function rather than skeletal 
muscle (peripheral) impairments in the resting, unfatigued state, as previously 
highlighted (Liepert et al. 2005; Morgante et al. 2011; Conte et al. 2016; Chalah et al. 
2019). Of course, associated psychosocial issues, including depression and poor sleep 
quality may have been key factors causing a lack of motivation to perform an MVC or 
any voluntary movement. Performance fatigability was also compared between MS-HF 
and MS-LF in Chapter 6 (Study 3). There is only limited evidence of an association 
between performance fatigability and perceived MS fatigue (assessed using self- 
reported fatigue scales) in the literature (e.g., Sharma et al., 1995; Iriarte et al., 1998; 
Ng et al., 2004), suggesting that these two fatigue constructs may be unrelated 
independent. However, Chapter 6 (Study 3) suggests that performance fatigability and 
perceived MS fatigue are both related to central drive (VA) but not impaired skeletal 
muscle contractile function (Qtw, pot; Steens et al., 2012). 
 
Chapter 6 (Study 3) also showed reductions in post-fatigue task variables (MVC, VA 
and Qtw,pot) in both muscle groups studied amongst MS-HF (Table 6.2 and 6.3) that 
were two-fold greater than the typical error values reported in the previous chapter, as 
well as impaired central drive and modulation of neural drive after a fatigue task (i.e. 
VA and SICI). Interestingly, longer SPs are indicative of increased intracortical 
inhibition, greater disability and poorer motor function in other clinical populations, 
such as Huntington’s (Priori et al., 1994) and stroke (Classen et al., 1997, Gray et al., 
2017). Therefore, future research into the SP and its relationship with SICI in MS-HF 
is warranted. Finally, the differences observed in the present Chapter concerning 
corticospinal excitability and inhibition for MS-HF (see Table 6.2 and 6.3) were greater 
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than the typical error presented in Chapter 5. Therefore, it can be concluded that these 
measures are sensitive to detecting differences between MS-HF and MS-LF induced by 
task-related fatigue. This suggests that PwMS suffering from high levels of fatigue, 
require a greater demand on central components and less peripheral disturbance. These 
key findings are consistent with simple tasks being perceived as more effortful in MS- 
HF, due to more impaired central nervous system function (or impairments within 
specific brain regions and networks) resulting in less ability to increase cortical drive 
to maintain force. The proposed decline in voluntary drive and force production at the 
level of skeletal muscle is substantiated by the post-fatigue task data and previous 
research (Andreasen et al., 2009; Skurvydas et al., 2011; Steens et al., 2012b; Steens et 
al., 2012c). It is also consistent with previous work showing force decrements could be 
attributable to deconditioning effects on skeletal muscle atrophy and central drive 
(Kent-Braun et al., 1994a, 1994b, 1997; Haan et al., 2000; Sharma et al., 2005; 
Skurvydas et al., 2011), as PwMS are generally less physically active than healthy 
populations (Molt et al., 2005). 
 
Finally, Chapter 7 (Study 4) contributed new knowledge regarding the utility of PRE 
as a feasible therapeutic exercise option for MS-HF. The study presented in this chapter 
showed that PRE was feasible, with excellent retention (6 weeks, 94%; 12 weeks, 88%) 
and high adherence (>75% of all sessions) in MS-HF. Chapter 7 (Study 4) showed that 
there were no PRE-induced symptom exacerbations in a cohort of participants that were 
all experiencing high levels of MS fatigue, which could reflect the importance of proper 
instruction and tailoring of PRE to specific capabilities (i.e., standing or seated PRE 
alternatives and use of fans during sessions to prevent heat sensitivities). The excellent 
level of adherence to the programme translated into preliminary evidence of efficacy in 
respect of reductions in perceived fatigue (MFIS), mood, anxiety, pain and health- 
related quality of life following supervised PRE, which were maintained following 
home-based training. The lack of observed changes in FSS and CFS might have been 
due to the one-dimensional format of these self-report tools which could potentially be 
less amenable to change following short-term programmes of PRE. Thus, the results of 
the present study suggest that the MFIS could be a more sensitive measure for exercise 
studies in PwMS, and particularly those investigating the impact of PRE in those with 
high levels of perceived fatigue. 
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Chapter 7 (Study 5) also showed that 6-weeks of supervised PRE led to improved 
muscle strength and activation in the upper and lower extremities, and with an 
improvement in time to task failure also shown after additional 6 weeks of home-based 
PRE. The magnitude of muscle strength improvements reported was greater than the 
typical error reported in Chapter 5 (lower: 14.4, upper: 11.2), indicative of real 
clinically-important change, and supporting previous resistance training studies in 
PwMS not categorised by fatigue status (Swensson et al., 1994; Kasser and Cubbin, 
1996; Harvey et al., 1999; DeBolt & McCubbin, 2004; Taylor et al., 2006; Aimet et al., 
2006). The present study identified a greater improvement in upper-limb versus lower- 
limb strength, and this may have been due to more pronounced MS-related impairments 
in the lower extremities amongst our sample population of PwMS. Time to task failure 
also improved after supervised and home-based PRE, suggesting that along with an 
increase in strength, there was a tangible impact on the ability to sustain muscular work, 
and this could be important for day-to-day functioning. Interestingly, central 
adaptations were also evidenced by increased VA following 6-weeks of supervised PRE 
in the lower-limb, but with no further improvement after home-based PRE. This change 
was greater than the typical error (1.9%) showing a real change outside the variability 
of the measure in highly fatigued PwMS but curiously, translated into a less pronounced 
improvement in lower-limb force production. To date, no studies have reported neural 
drive changes using VA in MS-HF after PRE, warranting further exploration of this. 
However, the promising preliminary data from this feasibility study needs to be heeded 
with caution, as a larger scale trial with longer-term follow-up needs to be conducted 
before definite conclusions can be drawn. 
 
It is important to mention that while PRE has shown both neural and secondary 
adaptative benefits for highly fatigued individuals, this could also be applied to, and 
benefit, less-fatigued PWMS. As MS is a progressively condition, PRE might help slow 
fatigue development over time in less-fatigued PwMS by preventing worsening of 
neurological lesion/disturbance development. However, this needs to be confirmed in 
future robust randomised controlled trials. This thesis acknowledges that use of a 
dichotomous recruitment model (MS-HF versus MS-LF) has the potential limitation 
that MS fatigue may be sporadic in nature, where some PwMS experience high levels 
of fatigue on some days but not others. To further advance the design of optimal 
exercise interventions for people experiencing high levels of MS fatigue in the future, 
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measuring fatigue over a longer period of time would provide a greater degree of 
confidence in the dichotomous recruitment model. 
 
In conclusion, the results presented in this thesis add to the current body of literature 
by: (i) consolidating the existing evidence base via a comprehensive systematic review 
and meta-analysis of cross-sectional studies that examined MS fatigue via a 
dichotomised model (MS-HF versus MS-LF); (ii) showing that neurophysiological 
measures linked to MS fatigue can be reliably measured in the upper- and lower-limbs 
of MS-HF; (iii) providing new insights into neurophysiological differences that exist 
between MS-HF and MS-LF; and (iv) showing that PRE is a feasible exercise modality 
in MS-HF that has potential to reduce the debilitating effects of fatigue and other 
commonly reported adverse health effects. 
 
8.3 Directions for Future Research 
A current gap in the literature is the impact of exercise therapy for ameliorating 
cognitive impairments (and cognitive fatigue) in people experiencing high levels of MS 
fatigue. Cognitive impairment reportedly affects around 65% of PwMS and can occur 
in the absence of physical disability (Hoffman et al., 2007). Dysfunctions in speed of 
information processing, attention, memory and executive functions are most typically 
observed in PwMS (Rogers and Panegrys, 2007). During Chapters 5 and 6 throughout 
the fatiguing exercise task, participants described their “mental struggle” to focus on 
performing the task while watching the visual cue displayed on the computer screen. 
This might be reflective of more compromised cognitive processing and greater 
susceptibility to cognitive fatigue in MS-HF. This could be further explored using 
electroencephalography, measuring activity-related evoked potentials during the visual 
and auditory aspects of the fatiguing exercise task used in this thesis, to identify 
impairments related to the speed of information processing. Further to this, Chapter 4 
identified neuroimaging techniques to be the most useful for demonstrating 
neurostructural differences in PwMS partitioned by fatigue status, e.g., highlighting 
lesions within specific brain regions and areas with impaired connectivity as well as 
elevated demands on functioning neural circuits, which may influence the severity of 
MS fatigue symptoms. Functional magnetic resonance imagery perhaps has the most to 
offer in this respect, and its use in future studies of MS-HF at rest and during a fatiguing 
task is warranted. This approach would improve our understanding of how different 
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patterns of movement-associated cortical and subcortical activation might contribute to 
the severity of fatigue symptoms in PwMS, further extending the findings of work 
presented in this thesis and that of others (e.g., Filippi et al, 2002). 
 
Based on the positive findings of Chapter 7 (Study 5), a fully powered randomised 
controlled trial of PRE in highly fatigued PwMS is also warranted. This trial should 
take into consideration how the intervention could be implemented within clinical 
practice, if PRE is shown to be clinically and cost-effective. This would mean 
ascertaining what would be required to run such a service within the national health 
service or via referral to a community-based exercise class with the remit of training 
PwMS correct PRE technique. Qualitative work embedded in the trial could involve 
focus groups with patient representatives, physiotherapists, health commissioners and 
community-based exercise professionals to understand the barriers and facilitators to 
implementation. The trial should also explore dose-response relationships between PRE 
and MS fatigue (as well as other important health outcomes) as a means of developing 
PRE recommendations, i.e., the frequency, intensity, duration and week volume of PRE 
required for PwMS to realise optimal health benefits. 
 
High adherence was also reported for the supervised training group. This might reflect 
the benefits of this programme in relation to the flexible approach applied and the range 
of resistance exercises used, i.e., two 1hr sessions a week, broken down to 2 x 30 
minutes of upper and lower body exercises, respectively, as well as regular breaks being 
encouraged. Adherence was also very good during the home-based exercise, perhaps 
due to first 6 weeks of supervised exercise being used to build confidence and learn 
proper and safe exercise technique, alongside regular contact with myself with the aim 
of maintaining rapport and self-confidence. Finally, during this unprecedented 
worldwide COVID-19 pandemic, where access to therapeutic exercise support has been 
limited or non-existent, this thesis provides encouraging evidence of an accessible 
exercise modality which can be supported remotely and adopted by many MS-HF in 
their home environment. The intervention comprised a mixture of face to face and 
home-based exercise, along with regular remote support and this thesis shows that such 
a flexible blend of exercise training can be beneficial and well adopted during a future, 
more socially distanced care setting (post COVID-19 pandemic). The extent to which 
this approach removes a common barrier to exercise participation in PwMS (i.e., travel 
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to an exercise facility), especially those experiencing the highest levels of MS fatigue 
and including those with more severe MS disability, is another important avenue for 
future research. The extent to which this approach removes common barriers to exercise 
participation in PwMS, especially those experiencing the highest levels of MS fatigue, 






The originality of this work is the identification and recruitment of the PwMS by fatigue 
status (highly-fatigued and less-fatigued) and using a fatigue self-reported scale as the 
primary outcome not the secondary outcome, as used in previous work. Although the 
recruitment process for all studies was challenging, the main originality, significance 
and rigour of this work is that it identified those with high level of MS fatigue and 
distinguished important neurophysiological differences between people in the two 
fatigue states at baseline and after a performance task. The neurophysiological 
outcomes identified in this thesis can collectively, with other secondary outcomes 
assessed, be used to power future randomised controlled trials of resistance exercise, to 
further understand the impact of this intervention on perceived fatigue and fatigability 
in people with MS. Another novel aspect was the use of a metronome during 
progressive resistance exercise. External pacing may help to evoke neuroplastic 
adaptations which bypass the neurophysiological lesions and MS disturbances, and this 
should be further explored in future research. In summary, this thesis provides robust 
preliminary evidence suggesting that this type of exercise training could be beneficial 
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Appendix 3 – Transcranial Magnetic Stimulation Screening Questionnaire 
 
Faculty of Health and Life Sciences 
Northumberland Building 
Newcastle upon Tyne 
NE1 8ST 
Tel 0191 227 3571 
Fax 0191 227 4515 
 
Participant Name: Date: Version: 
Screening Questionnaire 
Please answer the following questions by ticking the Yes or No boxes below. When 
you are finished the researcher will go over the answers with you. 
 
 
Question Yes No 
1. Do you have a heart pacemaker, artificial heart 
valves, pacing wires or defibrillator? 
  
2. Do you have any implanted devices (e.g. 
programmable hydrocephalus shut; nerve 
stimulator; cochlear implant; aneurysm clip; 
insulin, drug or infusion pump)? 
  
3. Have   you   had   any   surgery   to   your   head 
(including ears/eyes/brain), neck or spine? 
  
4. Have you ever sustained any injuries involving 
metal to the eyes and/or any other part of the 
body? 
  
5. Have you ever had a fit or blackout, or do you 
have epilepsy? 
  




Thank you for taking the time to answer the questions. 
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Appendix 4– Oldfield Handed Inventory Questionnaire 
Faculty of Health and Life Sciences 
Northumberland Building 
Newcastle upon Tyne 
NE1 8ST 
Tel 0191 227 3571 
Fax 0191 227 4515 
Participant Name: Date: Version: 
Edinburgh Handedness Inventory Questionnaire 
Please indicate your preferences in the use of hands in the following activities by 
putting + in the appropriate column. Where the preference is so strong that you would 
never try to use the other hand unless absolutely forces to, put ++. If any case, you are 
really indifferent put + in both columotor nerve stimulation. Some of the activities 
require both hands. In these cases, the part of the task, or object, for which hand 
preference is wanted is indicated in brackets. Please try to answer all the questions, 
and only leave a blank if you have no experience at all of the object or task. 
 Left Right 
1. Writing   
2. Drawing   
3. Throwing   
4. Scissors   
5. Toothbrush   
6. Knife (without fork)   
7. Spoon   
8. Broom (upper hand)   
9. Striking Match (match)   
10. Opening box (lid)   
11. Which foot do you prefer to kick with?   
12. Which eye do you use when using only one?   
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Northumberland Building 
Newcastle upon Tyne 
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Tel 0191 227 3571 
Fax 0191 227 4515 
 
 
Participant Information Sheet 
 
 
Study Title: A Feasibility Study of Progressive Resistance Exercise in Fatigued People 
with Multiple Sclerosis. 




You are being invited to take part in a research study. The research is being carried out 
by Paula Ellison and colleagues at Northumbria University with collaborators at 
University of East Anglia and Oxford Brookes University. We are working together 
with the Neurology Department at The Royal Victoria Infirmary Hospital, Newcastle 
to further understand the effects of exercise on key fatigue and health outcomes. This 
is so we may be able to further understand fatigue in people with multiple sclerosis and 
extend our knowledge on fatigue management strategies. Before you decide, it is 
important for you to understand why the research is being done and what it will involve. 
Please take the time to read the following information carefully and discuss it with 
others if you wish. Ask us if there is anything that is not clear or if you would like more 
information. 
 
What is the purpose of this study? 
Over half of all people with multiple sclerosis experience fatigue as one of their most 
disabling symptoms, defined as “a subjective lack of physical and/or mental energy 
that interferes with activities of daily life”. The purpose of this study is to look at how 
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well people with multiple sclerosis who experience high levels of fatigue respond to 
exercise therapy recognised as progressive resistance exercise compared with no 
exercise. Resistance exercise may have more fatigue-reducing effects than aerobic 
exercise (running and cycling). Resistance exercise can be performed in fully supported 
(or seated) positions; body core temperature does not increase to the same extent as 
aerobic exercise and is easily transferrable to the home environment. We want to look 
at whether progressive exercise using resistance bands is a possible intervention for 
people with multiple sclerosis and understand the impact of the intervention on key 
health and fatigue outcomes. 
Why have I been chosen? 
 
We are looking for relapsing-remitting multiple sclerosis (relapsing remitting MS) 
who are experiencing high levels of fatigue. Your local consultant neurologist and/or 
MS nurse believes you may satisfy our criteria for participating and/or you have showed 
an interest to the advert for this study. We believe your participation can provide us 
with useful information about this problem in MS. 
 
Do I have to take part? 
No, it is up to you to decide whether or not to take part in this study. If you choose to 
take part, you will be given this information sheet to keep and will be asked to sign a 
consent form. If you decide to take part in this study, your general practitioner (GP) 
will be contacted. You are still free to withdraw at any time and without giving reason. 
If you start to take part in the study, but decide to withdrawal at a later date, we may 
use data collected unless requested otherwise at the point of withdrawal. 
What will happen to me if I take part? 
 
You will be asked to come in for a familiarisation session (~1 hr) to explain all the tests 
and then a baseline assessment (two x 1 ½ hr sessions separated by 2-7 days) will take 
place. Following baseline assessment of fatigue and health outcomes, you will be 
randomly assigned into one of two groups: (i) experimental group, or (ii) control group. 
There is an equal chance of being assigned to either group. The experimental group will 
attend two 1 hour supervised resistance exercise sessions per week (separated by at 
least 48 hours) for a total of 6-weeks. These sessions will take part on Monday and 
Friday and will be in a group setting of 4-6 people. At 6-weeks you will be reassessed 
(two x 1 ½ hr sessions separated by 2-7 days) and asked to complete the training 
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independently at home with regular contact with the researcher over the phone. At 12- 
weeks you will undergo your final assessment (two x 1 ½ hr sessions separated by 2-7 
days). The control group will carry on standard care and attend assessments at 
familiarisation, baseline, and 6- and 12-weeks. Following 12-weeks of standard care, 
you will be provided with free resistance exercise bands along with a program and 
receive a one-on-one phone call to discuss your fitness objectives and goals concerning 
how resistance exercise may benefit you. 
 
Neurophysiological assessment 
During this assessment, you will perform simple motor tasks of the wrist and leg 
muscles. You will also be given a booklet, which will contain a number of fatigue and 
health related questionnaires. You will be able to sit with the researcher and go through 
the questionnaires individually and have the opportunity to raise any questions. Some 
of the questionnaires may be considered intrusive and you should not feel obliged to 
answer all the questions. This booklet will be completed at home. 
 
What the visit will involve: 
On arrival of the testing session: 
• You and the researcher will go through the questionnaire booklet. 
• You will then be briefly talked through the testing process and what is expected. 
• You will then have time to ask any questions and discuss any queries. 
 
 
During this visit you will complete a screening questionnaire to assess any potential 
reasons for you not to participate such as, metal implants and epilepsy. For your comfort 
you will be seated in an upright chair and the wrist or leg muscles will be stabilised in 
a specially designed rig. During the visits we will be measuring the activity of your 
wrist and leg muscles, which will require the application of small stick on electrodes to 
your leg and arm muscles. We will measure the pathways from the brain connecting to 
the muscles and the origin of fatigue. 
 
Transcranial magnetic stimulation. 
This involves using a device for producing pain-free stimulation to the brain that is 
involved in controlling movement. In response to this stimulus, muscles of the body 
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generate a natural brief contraction. This muscle activity can be recorded and provide 




This involves a device for applying non-invasive stimulation of the targeted muscle at 
rest and during a simple motor task. This will allow further understanding into the origin 
of fatigue. In response to this stimulus, muscles of the body generate a natural brief 
contraction and will provide information on the strength of the muscle and the measure 
of muscle activity. 
 
Progressive resistance exercise (PRE) 
You will be prescribed an individualised resistance exercise programme and given an 
exercise log to record the content of each session. For 0-6 weeks you will attend the 
facility for supervised resistance exercise sessions. Progressive resistance exercise will 
be performed using resistance exercise bands, with the intensity of the exercise 
progressing according to your individual capabilities. This will be based on your rating 
of difficulty during the exercise. Each session will be supervised and monitored for 
progress and you will be provided with support and advice. If you feel you would need 
protective eyewear, this will be provided. During weeks 6-12, you will not attend the 
facility for resistance exercise but will complete two self-directed home-based exercise 
sessions per week. Home-based exercise sessions will mirror the facility-based sessions 
undertaken in weeks 0-6, in terms of the muscle groups being targeted, intensity and 
duration. Fortnightly telephone contacts from the researcher during this period will 
ensure that support is maintained, the exercise programme is properly progressed, and 
that you have the opportunity to discuss any issues arising. 
 
Standard care control group 
You will maintain your usual daily activity and standard medical care during weeks 0- 
12 weeks. Following 12-weeks of standard care, you will be provided with free 
resistance exercise bands and program and receive a one-on-one phone call to discuss 
your fitness objectives and goals and how resistance exercise may benefit you. You will 





























What are the possible disadvantages and risks of taking part? 
As you will be performing repetitive movement of your wrist and leg muscles, there is 
a small risk you may experience an increase in tiredness or pain. This is likely to be 
mild, but we will monitor this while you are in the study. If you experience increased 
tiredness or pain, which cannot be explained by anything other than taking part in the 
study, you may be withdrawn from that treatment and upon consensus to continue to 
provide outcome data. As this study requires an ‘exercise’ and ‘control’ group design, 
you may be chosen to take part as a ‘control’. This will involve maintaining your normal 
Allocated to progressive 
resistance exercise group 




Follow up assessment 6- 
and 12-weeks 





12-weeks standard care 
Follow up assessment 6- 
and 12-weeks 
One-on-one detailed phone 
call and exercise program 
handout 
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daily lifestyle throughout the study course and come in for your neurophysiological 
testing sessions only. You will, however, receive an exercise program, resistance bands 
and a one-on-one phone call with the researcher to discuss resistance exercise benefits 
for you and health goals of exercise at the end of the study duration. 
Is there any discomfort involved? 
There might be some brief, mild discomfort from the electrical stimulation. If you find 
the stimulations too uncomfortable, you will be invited to rest between tests, and you 
may rest at any time during the experiment. 
 
What are the possible benefits of taking part? 
All participants will benefit from a more comprehensive assessment of their wrist and 
leg function than is available to them in routine clinical practice. Participants allocated 
to the progressive resistance exercise group may find that a program of supported 
progressive resistance exercise is practical for them and proves successful in terms of 
indicative changes in key fatigue and health outcomes. There is no benefit for the 
participants allocated to the control group. The control group will however be given a 
one-on-one consultancy with the researcher and could benefit from learning about 
potential benefits associated with resistance exercise. 
 
What will happen if I don’t carry on with the study? 
 
You can withdraw from the study at any time, but any information collected may be 
used unless you request otherwise at the point of withdrawal. 
 
Will my taking part in this study be kept confidential? 
 
All information that is collected about you during the course of the research will be kept 
strictly confidential. In any documentation other than consent form you will be referred 
to as a participant number rather than name allowing you to remain 
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anonymous. Any information collected will be kept under protected password locked 
computer and key lock cabinet for safekeeping. 
 
What will happen to the results of the research study? 
 
The results of this study are likely to be published in scientific journals. No personally 
identifiable information will be published. You may request an individualised report 
ten weeks after study participation. 
 
Who is organising and funding the research? 
 
The University of Northumbria and Multiple Sclerosis Society. 
 
Who has reviewed the study? 
 
This study was given a favourable opinion by the NATIONAL HEALTH SERVICE 
Research Ethics Committee. In addition, the research and development department at 
the hospital trust has agreed for this research to be carried out. 
 
For further information about the study, please contact the Researcher or 
Principle Investigator on: 
Researcher: Principle Investigator: 
Paula Ellison Dr Martin Duddy (Consultant Neurologist) 
University of Northumbria Royal Victoria Infirmary (RVI) 
Tel: 0191 243 7018 Tel: 0191 282 5995 
Email: paula.ellison@northumbria.ac.uk Email: Martin.duddy@nuth.national health 
service.uk 
 
If you want to speak to an independent adviser (someone outside this study), the 
contact details are provided below: 
 
Dr Mark Baker (consultant Neurologist) 
Royal Victoria Infirmary (RVI) 
Tel: 0191 282 4578 
Email: Mark.Baker@nuth.national health service.uk 
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If you feel you would need to make a compliant, the contact details are provided 
below: 
 
Patient Advice and Liaison Service (PALS) 
Freephone: 0800 0320202 (09.00-4.30 Monday to Friday) 
Text: 01670 511098 
Fax: 01670 511260 
Email: northoftynepals@nhct.national health service.uk 
 
 
If you have read this Participant Information Sheet and would be interested in 
taking part in this study, please contact the research nurses on the contact details 
provided below: 
 
Lisa Robson and Joanna Forsyth (MS Research Nurses) 
Royal Victoria Infirmary (RVI) 
Tel: 0191 282 9303 
196  










[Insert first line address] 






Dear [Insert Recipient Name] 
 






Faculty of Health and Life Sciences 
Northumberland Building 
Newcastle upon Tyne 
NE1 8ST 
Tel 0191 227 3571 




‘The feasibility of progressive resistance exercise for ameliorating symptoms of fatigue in people with multiple 
sclerosis’. 
 
The study is funded by The Multiple Sclerosis Society and has been given a favourable ethical opinion by the 
University of Northumbria and a Research Ethics Committee. I would like to offer you the opportunity to learn more 
about the purpose of the study and what your participation would involve. This information has been outlined in a 
Participant Information Sheet which will be emailed or posted to you upon your request. Please note that you are 
under no obligation to participate in this entirely voluntary study. You can request a Participant Information Sheet 








If you would like to discuss this study with the Primary Investigator of the research team, Dr Martin Duddy at the 
Royal Victoria Hospital, is happy to respond to queries. His contact details are stated below. 
 
Dr Martin Duddy 
Consultant Neurologist 
The Royal Victoria Infirmary 
Tel: 0191 282 5995 
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Title of Study: A Feasibility Study of Progressive Resistance Exercise in Fatigued People with 

























Name of Participant 
(NAME IN BLOCK LETTERS) 
 Signature  Date 
Name of Person taking consent 



















Faculty of Health and Life Sciences 
Northumberland Building 
Newcastle upon Tyne 
NE1 8ST 
Tel 0191 227 3571 
Fax 0191 227 4515 
Participant Name: Date: Version: 
Fatigue Severity Scale (FSS) 
Please circle a number to the right of each of the following nine statements to indicate 
how much you agree with the statement. “1” represents “strongly disagree”, “4” 




1. My motivation is lower when I am 
fatigued. 
1 2 3 4 5 6 7 
2. Exercise brings on my fatigue. 1 2 3 4 5 6 7 
3. I am easily fatigued. 1 2 3 4 5 6 7 
4. Fatigue interferes with my physical 
functioning 
1 2 3 4 5 6 7 
5. Fatigue causes frequent problems for me. 1 2 3 4 5 6 7 
6. My fatigue prevents sustained physical 
functioning. 
1 2 3 4 5 6 7 
7. Fatigue interferes with carrying out 
certain duties and responsibilities. 
1 2 3 4 5 6 7 
8. Fatigue is among my three most disabling 
symptoms. 
1 2 3 4 5 6 7 
9. Fatigue interferes with my work, family 
and/or social life. 
1 2 3 4 5 6 7 
Thank you for taking the time to answer the questions. 
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Appendix 9 – The Hospital Anxiety and Depression Scale 
 
Faculty of Health and Life Sciences 
Northumberland Building 
Newcastle upon Tyne 
NE1 8ST 
Tel 0191 227 3571 
Fax 0191 227 4515 
Participant Name: Date: Version: 
 
 
Hospital Anxiety and Depression Scale (HADS) 
Clinicians are aware that emotions play an important part in most illnesses. If your 
clinician knows about these feelings, he or she will be able to help you more. This 
questionnaire is designed to help the clinician to know how you feel. Read each item 
below and underline the reply which come closest to how you have been feeling in the 
past week. (Don’t take too long over your replies; your immediate reaction to each item 
will probably be more accurate than a long, thought-out response.) 
 
 
I feel tense or ‘wound up’ 
Most of the time 
A lot of the time 
From time to time, occasionally 
Not at all 
I feel as if I am slowing down 
Nearly all the time 
Very often 
Sometimes 
Not at all 
I still enjoy the things I used to enjoy 
Definitely as much 
Not quite so much 
Only a little 
Hardly at all 
I get a sort of frightened feeling like 
‘butterflies’ in my stomach 





I get a sort of frightened feeling as if 
something awful is about to happen 
Very definitely and quite badly 
Yes, but not too badly 
A little, but it doesn’t worry me 
Not at all 
I have lost interest in my appearance 
Definitely 
I don’t take as much care as I should 
I may not take quite as much care 
I take just as much care as ever 
I can laugh and see the funny side of things 
As much as I always could 
Not quite so much now 
Definitely not so much now 
Not at all 
I feel restless as if I have to be on the move 
Very much indeed 
Quite a lot 
Not very much 
Not at all 
Worrying thoughts go through my mind 
A great deal of the time 
A lot of the time 
Not too often 
Very little 
I look forward with enjoyment to things 
As much as I ever did 
Rather less than I used to 
Definitely less than I used to 
Hardly at all 




Most of the time 
I get sudden feelings of panic 
Very often indeed 
Quite often 
Not very often 
Not at all 




Not at all 







Thank you for taking the time to answer the questions. 
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Faculty of Health and Life Sciences 
Northumberland Building 
Newcastle upon Tyne 
NE1 8ST 
Tel 0191 227 3571 
Fax 0191 227 4515 
Participant Name: Date: Version: 
 
 
Modified Fatigue Impact Scale (MFIS) 
Following a list of statements that describe how fatigue may affect people. Fatigue is a 
feeling of physical tiredness and a lack of energy that many people experience from 
time to time. In medical conditions like MS, feelings of fatigue can occur more often 
and have a greater impact than usual. Please read each statement carefully, and then 
circle the number that best indicates how often fatigue has affected you in this way 
during the past 4 weeks. (If you need help marking your responses, tell the interviewer 
the number of the best response). Please answer every question. If you are not sure 
which answer to select, please choose the one answer that comes closest to describing 
you. The interviewer can explain any words or phrases that you do not understand. 
 
Because of my fatigue during the past 4 weeks…. 
 
 
 Never Rarely Sometimes Often Almost 
always 
1. I have been less alert. 0 1 2 3 4 
2. I have had difficulty 
paying attention for long 
periods of time. 
0 1 2 3 4 
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3. I have been unable to 
think clearly. 
0 1 2 3 4 
4. I have been clumsy and 
uncoordinated. 
0 1 2 3 4 
5. I have been forgetful. 0 1 2 3 4 
6. I have had to pace myself 
in my physical activities. 
0 1 2 3 4 
7. I have been less motivated 
to do anything that requires 
physical effort. 
0 1 2 3 4 
 
Because of my fatigue during the past 4 weeks…. 
 Never Rarely Sometimes Often Almost 
always 
8. I have been less motivated 
to participate in social 
activities. 
0 1 2 3 4 
9. I have been limited in my 
ability to do things away 
from home. 
0 1 2 3 4 
10. I have trouble 
maintaining physical effort 
for long periods. 
0 1 2 3 4 
11. I have had difficulty 
making decisions. 
0 1 2 3 4 
12. I have been less 
motivated to do anything 
that requires thinking. 
0 1 2 3 4 
13. My muscles have felt 
weak. 
0 1 2 3 4 
14. I have been physically 
uncomfortable. 
0 1 2 3 4 
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15. I have had trouble 
finishing tasks that require 
thinking. 
0 1 2 3 4 
16. I have had difficulty 
organising my thoughts 
when doing things at home 
or at work. 
0 1 2 3 4 
17. I have been less able to 
complete tasks that require 
physical effort. 
0 1 2 3 4 
18. My thinking has been 
slowed down. 
0 1 2 3 4 
19. I have had trouble 
concentrating. 
0 1 2 3 4 
20. I have limited my 
physical activities. 
0 1 2 3 4 
21. I have needed more rest 
more often for longer 
periods. 
0 1 2 3 4 
 
Thank you for taking the time to answer the questions. 
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Appendix 11 – Chalder Fatigue Scale 
 
Faculty of Health and Life Sciences 
Northumberland Building 
Newcastle upon Tyne 
NE1 8ST 
Tel 0191 227 3571 
Fax 0191 227 4515 
Participant Name: Date: Version: 
 
 
Chalder Fatigue Scale 
We would like to know more about any problems you have had with feeling tired, weak 
or lacking in energy in the last month. Please answer ALL the questions by ticking the 
answer which applies to you most closely. If you have been feeling tired for a long 
while, then compare yourself to how you felt when you were last well. Please tick only 
















    
Do you need to rest 
more? 
    
Do you feel sleepy 
or drowsy? 






    
Do you lack energy?     
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Do you have less 
strength in your 
muscles? 
    
Do you feel weak?     
Do you have 
difficulties 
concentrating? 
    
Do you make slips 
of the tongue when 
speaking? 
    
Do you find it more 
difficult to find the 
right word? 









How is your 
memory? 
    
 
Thank you for taking the time to answer the questions. 
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Appendix 12 – Pittsburgh Sleep Quality Index 
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Northumberland Building 
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NE1 8ST 
Tel 0191 227 3571 
Fax 0191 227 4515 
 
Participant Name: Date: Version: 
 
 
Pittsburgh Sleep Quality Index (PSQI) 
 
The following questions relate to your usual sleep habits during the past month only. 
Your answers should indicate the most accurate reply for the majority of days and 
nights in the past month. Please answer all questions. 
 
1. During the past month, when have you usual gone to bed at night? 
Usual bed time    
2. During the past month, how long (in minutes) has it usually take you to fall 
asleep each night? 
Number of minutes    
3. During the last month, when have you usually gotten up in the morning? 
Usual getting up time    
4. During the past month, how many hours of actual sleep did you get at night? 
(This may be different than the number of hours you spend in bed.) 




For each of the remaining questions, tick the best response. Please answer ALL 
questions. 
 
















(a)…cannot get to sleep within 30 
minutes 
    
(b)…wake up in the middle of the 
night or early morning 
    
(c)…have to get up to use the 
bathroom 
    
(d)…cannot breathe comfortably     
(e)…cough or snore loudly     
(f)…feel too cold     
(g)..feel too hot     
(h)…had bad dreams     
(i)…have pain     
(j) Other reason (s), please describe  
How often during the past month 
have you had trouble sleeping 
because of this? 
    
 
 
Very Good Fairly Good Fairly Bad   Very Bad 
6. During the past month, how would 
you rate your sleep quality overall? 
 
Not during Less than Once or twice Three or more 
past month once a week a week times a week 
7. During the past month, how often 
have you taken medicine 
(prescribed or ‘over the counter’) 
to help you sleep? 
 
8. During the past month, how often 
have you had trouble staying awake 
while driving, eating meals, or 
engaging in social activity? 
 
No problem Only a very Somewhat of A very big 
at all slight problem a problem problem 
9. During the past month, how much 
of a problem has it been for you 
to keep up enough enthusiam 




10. Do you have a bed partner or 
room mate? 
No bed Partner/ Partner in same 
partner or roommate in room, but not Partner in 
roommate  other room same bed same bed 
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(a)…loud snoring     
(b)…long pauses between breathes 
while asleep 
    
(c)…leg twitching and jerking while 
you sleep 
    
(d)…episodes of disorientation or 
confusion during sleep 
    
(e) Other restlessness while you 
sleep; please describe 
 
    
 
Thank you for your time. 
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Appendix 13 – NARCOMS Pain Scale 
 
 
Faculty of Health and Life Sciences 
Northumberland Building 
Newcastle upon Tyne 
NE1 8ST 
Tel 0191 227 3571 
Fax 0191 227 4515 
Participant Name: Date: Version: 
 
NARCOMS Pain Questionnaire 
 
Please read all the categories, and check the single category that most 
accurately describes your pain (regardless of cause) in the past month. 
Compare your current condition to your experience before you developed MS. 
 
 
0 Normal: No symptoms of pain. 
I have not noticed any problems with pain. 
 
1 Minimal Pain 
I notice some problems with pain, but they do not interfere with my 
activities. 
 
2 Mild Pain 
Occasionally, pain forces me to change some of my activities (e.g. 
once a week or less). 
 
3 Moderate Pain 
Frequently, pain affects some of my activities (e.g. several times a 
week). 
 
4 Severe Pain 
Every day, pain problems force me to modify my daily activities. 
 
5 Total Disabling Pain 




Thank you for your time. 
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Appendix 14– Rating of Perceived Exertion Scale 
 
 
RATING OF PERCEIVED EXERTION 
6 
7 Very, very light 
8 








17 Very hard 
18 




























































































81.5 ± 5.7 
 
 




1.29 ± 0.2 
82.4 ± 2.5 
 
 




1.32 ± 0.19 







1.38 ± 0.13 
Brain parenchymal fraction, 
lesion volume and NAA/Cr and 
DTI/MT indices were similar for 
MS-HF and MS-LF. Greater 
regional atrophy of grey matter 
structures and nearby white 
matter in MS-HF vs HC, found in 
frontal/parietal and basal ganglia 
regions. 
Bakshi et al. 
(1999) 
66 MS 46 MS-HF 
20 MS-LF 
MS-HF: 
41.0 ± 1.4 
MS-LF: 










Means for the 











Brain atrophy; T1- 














 No significant differences were 
found in any magnetic resonance 
imagery measures between MS- 
HF and MS-LF groups. No 
significant correlation between 
fatigue and any of the regional or 
global magnetic resonance 
imagery measures. 
Bernitsas et al. 
(2017) 
29 RR 15 MS-HF 
14 MS-LF 
MS-HF: 
43 ± 2.9 
MS-LF: 
















6 ± 0.12 
MS-LF: 









T2 Lesion volume (ml) 
Thalamus volume (ml) 
Pallidus volume (ml) 
 
Superior cerebellar 
peduncle volume (ml) 
Fractional anisotropy 
(FA) 
14.0 ± 9.7 
 
11.5 ± 1.1 
 
2.6 ± 0.27 
 
207.3 ± 27.5 
 
0.24 ± 0.02 
15.3 ± 22.1 
 
14 ± 2.2 
 
3.0 ± 0.49 
 
246.1 ± 35.9 
 
0.27 ± 0.03 
 Significantly lower subcortical 
grey matter volumes (thalamus, 
pallidus, and superior cerebellar 
peduncle) found in basal ganglia 
regions. FSS scores inversely 
correlated with thalamus and 
pallidus volumes. Lower 
fractional anisotropy and greater 
mean diffusivity in MS-HF vs 
MS-LF, demonstrating neuronal 
disruption. 
        Mean diffusivity (×10−3 
mm2/s) 
 
0.88 ± 0.08 
 
0.82 ± 0.04 
 




















resonance Normalised brain 
volume (ml) 
 
428 ± 97 
 
1444 ± 89 
 
1513 ± 71 
Normalised brain volume, grey 
matter, white matter, T2 lesion 
































Grey matter volume 
(ml) 
 
White matter volume 
(ml) 
 
777 ± 63 
 
 
650 ± 43 
 
793 ± 61 
 
 
651 ± 35 
 
824 ± 52 
 
 
688 ± 35 
different between MS-HF vs MS- 
LF. MS-HF showed more 
extensive white matter damage 
than MS-LF for mean diffusivity 
and fractional anisotropy. 
      
T2 Lesion volume (ml) 10.1 ± 13.8 11.2 ± 12.1 
  








































































White matter volume 
(ml) 
 
8.3 ± 12.9 
 
 
1439 ± 96 
 
 




654 ± 40 
 
11.2 ± 11.8 
 
 
1450 ± 89 
 
 









1519 ± 80 
 
 




689 ± 37 
Significantly increased 
functionality in posterior 
cingulate cortex but decreased in 
anterior cingulated cortex in MS- 
HF vs MS-LF and HC. 
Reorganisation found in both 
default mode network and 
sensorimotor network at rest. T2 
lesion volume, normalised brain 
volume, grey matter and white 
matter volume were not 
significantly different between 
MS-HF vs MS-LF but were 








33.3 ± 8.2 
MS-LF: 
34.4 ± 8.8 
HC: 





















[ 4 (Mean)] 
MS-HF: 
5.1 ± 0.75 
MS-LF: 


















2.17 ± 0.25 
 
 
9.2 ± 7.9 
 
 
3.8 ± 1.3 
 
2.25 ± 0.21 
 
 
8.8 ± 7.7 
 
 
4.5 ± 0.8 
 






5.1 ± 0.9 
Significant reductions in 
putamen, caudate and thalamus 
volumes and cortical thickness of 
the superior frontal gyrus and 
inferior parietal gyrus in MS-HF 
vs MS-LF and MS vs HC. T2 
lesion volume was not 
significantly different for MS-HF 
vs MS-LF. 
          
Caudate (ml) 
 
4.1 ± 0.5 
 
5.1 ± 0.5 
 
5.2 ± 0.8 
 
          
Thalamus (ml) 
 
4.7 ± 0.9 
 
6.8 ± 0.8 
 
6.1 ± 0.8 
 
          
Superior frontal gyrus 
cortical thickness (mm) 
 
2.30 ± 0.28 
 






          
Inferior parietal gyrus 
cortical thickness (mm) 
 
2.04 ± 0.28 
 
2.52 ± 0.21 
  







39.1 ± 8.9 
MS-LF: 
37.6 ± 6.6 
HC: 










































8.9 ± 10.8 
 
 
0.93 ± 0.06 
 
 
0.20 ± 0.01 
 
7.2 ± 4.7 
 
 
0.96 ± 0.04 
 
 





0.91 ± 0.05 
 
 
0.23 ± 0.01 
T2 lesion volume and DTI 
indices were not significantly 
different for MS-HF vs MS-LF 
but the latter differed between 
MS and HC. 




40.0 ± 0.6 
 
40.4 ± 1.2 
 
40.6 ± 1.0 
 
Cogliati Dezza 






37.3 ± 4 
MS-LF: 























42.1 ± 7.3 
MS-LF: 









Thalamus volume (ml) 
 
Intracranial volume (ml) 
 
Central sulcus area 
(mm) 
 
14.1 ± 1.8 
 
1440 ± 200 
 
13.3 ± 1.5 
 
1490 ± 230 
 
14.7 ± 1.5 
 
1500 ± 210 
Thalamus volume and rolandic 
thickness/asymmetry were not 
significantly different for MS-HF 
vs MS-LF or HC. 
         Left 1.72 ± 0.07 1.72 ± 0.18 1.78 ± 0.14  
         
Right 1.71 ± 0.10 1.68 ± 0.18 1.72 ± 0.15 
 
Colombo et al. 
(2000)** 














































 Significantly higher volume of 
lesions for MS-HF vs MS-LF, 
found in the parietal lobe and 
white matter regions (internal 
capsule, periventricular areas). 







37.72 ± 5.9 
MS-LF: 
34.96 ± 5.87 
HC: 

















5.6 ± 0.85 
MS-LF: 













Intracranial volume (ml) 
 
 






















Grey matter and white matter 
atrophy in MS-HF vs MS-LF, 
found in areas related to the 
sensorimotor networks. 
Decreased resting functionality 
between the supplementary motor 
area and associative somato- 
sensory cortex in MS-HF vs MS- 































Brain cortical grey 
matter volume (ml) 426.20 ± 35.22 425.58 ± 51.88 440.82 ± 35.13 
Significantly greater cerebellar 
cortical lesion volume, brain 
cortical volume and most 








3.54 ± 1.65 
MS-HF: 
3.0 Tesla 
scanner T1 lesion volume (ml) 7.7 ± 12.0 4.7 ± 4.0 
 subcortical grey matter structures 
(thalamus, caudate, putamen, 






5.19 ± 0.68 
MS-LF: 
2.20 ± 0.73 
(Achieva, 
Phillips) Brain cortical lesions 
(mm3) 
 
900.0 ± 973.6 
 
874.20 ± 870.0 
 amygdala, accumbens) in MS-HF 
vs MS-LF and MS vs HC. 
Supports the theory of cortico- 
       HC: 
2.65 ± 0.88 
 
Cerebellar cortical 
lesion volume (mm3) 
 
91.56 ± 93.18 
 
27.40 ± 56.29 
 
94.36 ± 11.43 
striatal network impairment in 
MS fatigue. 
         
Cerebellar grey matter 
volume (ml) 
 
88.87 ± 8.42 
 
92.53 ± 16.96 
 
94.36 ± 11.43 
 
         
Thalamus volume (ml) 12.65 ± 1.42 12.06 ± 1.97 13.75 ± 1.18 
 
          
Putamen volume (ml) 
 
10.22 ± 2.10 
 
10.82 ± 1.73 
 
12.29 ± 1.40 
 
          
Caudate volume: (ml) 
 
6.47 ± 0.99 
 
6.70 ± 1.05 
 
7.56 ± 0.75 
 
          
Amygdala volume (ml) 
 
3.50 ± 0.61 
 
3.66 ± 0.50 
 
3.86 ± 0.55 
 




1.28 ± 0.27 
 
1.33 ± 0.26 
 
1.55 ± 0.26 
 
Derache et al. 
(2013) 



















































Regional grey matter 
density. Regional and 
global deep white 
matter lesion volume, 



















the groups and 
correlations 
reported. 
 Significant lower grey matter 
density in MS-HF versus MS-LF 
for the bilateral middle, superior 
and inferior frontal, left temporal 
and parietal cortex. Total fatigue 
score was negatively correlated 






        Echo speed 
8.3) 














   FSS 
[>36 (Total)] 
MS-HF: 
60 ± 3 
MS-LF: 




















692 ± 48 
 
 




703 ± 58 
 
 




739 ± 28 
Lower grey matter volume and 
white matter volume in MS-HF 
vs MS-LF and HC. 








39.3 ± 8.2 
MS-LF: 












FSS [ 25 
(total)] 
MS-HF: 
39.5 ± 7.1 
MS-LF: 













Pattern of brain 
activation during a 
simple motor task 
(maximum finger- 
tapping frequency and 


















Data reported as 
brain scans and 
brain activation 













Compared to MS-HF, MS-LF 
showed more significant 
activations of the ipsilateral 
cerebellar hemisphere, ipsilateral 
rolandic operculum, ipsilateral 
precuneus, contralateral thalamus 
and contralateral middle frontal 
gyrus during a simple motor task. 
In contrast, MS-HF had more 
significant activation of the 
contralateral cingulate motor 
area. Significant inverse 
correlations were found between 
FSS scores and relative activation 
of the contralateral intraparietal 
sulcus, ipsilateral rolandic 
operculum and thalamus. 









42.8 ± 11 
MS-LF: 
40.5 ± 10.5 
HC: 










































Grey matter volume 
(ml) 
 
White matter volume 
(ml) 
 
1487 ± 106 
 
 
670 ± 76 
 
 
817 ± 50 
 
1509 ± 107 
 
 
685 ± 70 
 
 
825 ± 61 
 
1577 ± 85 
 
 
735 ± 50 
 
 
841 ± 48 
T1 and T2 lesion volume, 
normalised brain volume, grey 
matter and white matter volume 
did not significantly differ 
between MS-HF vs MS-LF but 
MS was lower vs HC. Reduced 
fractional anisotropy of the right 
anterior thalamic radiation and 
right uncinate fasciculus in MS- 
HF versus MS-LF. 
         T1 lesion volume (ml) 6.4 ± 7.6 5.8 ± 5.9   
          
T2 lesion volume (ml) 
 
8.9 ± 10.0 
 
















42.3 ± 10.3 
MS-LF: 
41.0 ± 10.5 
HC: 










































T1 lesion volume (ml) 
 




6.8 ± 7.9 
 




6.1 ± 6.1 
 
1609 ± 86 
Normalised brain volume, T1 and 
T2 lesion volumes were not 
significantly different for MS-HF 
vs MS-LF. 
         T2 lesion volume (ml) 9.7 ± 10.7 8.8 ± 8.3   
Gonzalez 







42.2 ± 11 
MS-LF: 
36.3 ± 9.4 
HC: 























































0.55 ± 0.87 
Decreased introception condition 
accuracy score and reduced grey 
matter voume in introceptive 
areas (bilateral insula, right 
anterior cingulate cortex) in MS- 
HF versus HC. Increased 
connectivity between the right 
anterior cingulate cortex and left 
insula in MS-HF versus HC. 







41.9 ± 6.8 
MS-LF: 
44.5 ± 11.2 
HC: 























54.6 ± 5.1 
MS-LF: 
29.8 ± 9.3 
HC: 












Lateral ventricles (ml) 
 
Third ventricle (ml) 
 
79.3 ± 3.6 
 
26.6 ± 15.5 
 
2.6 ± 1.7 
 
78.7 ± 3.2 
 
28.2 ± 16.0 
 
2.6 ± 1.1 
 
81.4 ± 3.0 
 
17.3 ± 6.9 
 
2.0 ± 1.0 
Brain parenchymal fraction, 
lateral, third and fourth ventricle 
volumes were not significantly 
different for MS-HF vs MS-LF or 
HC. 
         Fourth ventricle (ml) 2.1 ± 0.9 2.0 ± 0.8 1.9 ± 0.8  









43.1 ± 6.3 
MS-LF: 
42.9 ± 11.7 
HC: 























56 ± 3 
MS-LF: 











Cortical thickness by 
region (mm): 
 
80.8 ± 4.8 
 
81.0 ± 4.3 
 
81.8 ± 2.6 
Significantly decreased cortical 
thickness in right inferior parietal 
lobe, right cingulate cortex and 
the right precuneus for MS-HF vs 
MS-LF and HC. 
         Gyrus rectus Left 3.0 ± 0.4 3.2 ± 0.3 3.3 ± 0.2  
         
Olfactory cortex left 2.9 ± 0.3 2.9 ± 0.3 3.1 ± 0.1 
 
         
Inferior parietal right 3.0 ± 0.4 3.2 ± 0.2 3.1 ± 0.1 
 
         






         Superior temporal pole 
right 3.5 ± 0.4 3.6 ± 0.3 3.8 ± 0.2 
 
Medial temporal pole 
right 3.4 ± 0.4 3.6 ± 0.4 3.8 ± 0.3 
Anterior cingulate right 2.9 ± 0.4 3.0 ± 0.2 3.0 ± 0.2 
Middle cingulate left 2.9 ± 0.4 2.9 ± 0.3 3.1 ± 0.2 
Middle cingulate right 2.9 ± 0.4 3.0 ± 0.2 3.1 ± 0.2 
Insula left 2.7 ± 0.3 2.7 ± 0.3 2.9 ± 0.1 
Insula right 2.7 ± 0.3 2.7 ± 0.2 2.9 ± 0.2 
Parahippocampus right 2.9 ± 0.3 2.9 ± 0.4 3.0 ± 0.2 
Hidalgo de la 







44.3 ± 12.4 
MS-LF: 
35.0 ± 11.8 
HC: 





































Grey matter volume 
(ml) 
White matter volume 
(ml) 
1502 ± 102 
 
682 ± 74 
 
819 ± 42 
1545 ± 86 
 
720 ± 58 
 
826 ± 46 
1577 ± 84 
 
736 ± 57 
 
841 ± 43 
Significantly higher T1 and T2 
lesion volumes and lower 
normalised brain volume and 
grey matter volume in MS-HF vs 
MS-LF. Resting state functional 
connectivity was not significantly 
different for MS-HF vs MS-LF or 
HC. 
         T1 lesion volume (ml) 6.0 ± 6.5 3.5 ± 3.5   
         
T2 lesion volume (ml) 9.0 ± 8.3 5.7 ± 5.3 
  
         
nRThal volume (ml) 9.6 ± 1.2 9.8 ± 0.9 10.3 ± 0.8 
 
         
nLThal volume (ml) 9.8 ± 1.0 10.1 ± 0.9 10.7 ± 0.8 
 














































Total T1 white matter 




Grey matter volume 
(ml) 





1522.4 ± 65.5 
 
804.2 ± 57.2 
 




1548 ± 88.4 
 
824.2 ± 63.8 
 




1565.5 ± 82.3 
 
829 ± 63.6 
 
736.5 ± 40.6 
Significantly reduced functional 
connectivity of the whole caudate 
nucleus with sensorimotor and 
frontal, parietal, and temporal 
cortex regions in MS-HF vs MS- 
LF and HC. T1 lesion volume, 
normal brain volume, grey matter 
volume and white matter volume 





         
Caudate volume (ml) 
 
Putamen volume (ml) 
9.3 ± 1.0 
 
12.5 ± 0.9 
9.5 ± 0.78 
 
12.7 ± 0.9 
9.7 ± 1.08 
 
13.3 ± 0.9 
MS-HF vs MS-LF but was lower 
for MS-HF than HC. 










53 ± 9.4 
MS-LF: 




























5.7 ± 0.9 
MS-LF: 
2.6 ± 0.9 
HC: 












T2 lesion volume (ml) 
 
 







Thalamus volume (ml) 
 
18.8 ± 22.0 
 
 







13.2 ± 1.2 
 
12.0 ± 14.5 
 
 







13.4 ± 1.5 
 
0.48 ± 1.23 
 
 







15.1 ± 1.3 
Decreased functional 
connectivity for MS vs HC 
between the left medial thalamic 
nuclei and left angular gyrus and 
reduced functional connectivity 
between the left posterior 
thalamic nuclei and left 
supramarginal gyrus, as well as 
decreased right medial thalamic 
nuclei connectivity with bilateral 
caudate/thalamus and left 
cerebellar areas. MS also had 
increased FC between the left 
anterior thalamic nuclei and 
anterior cingulate cortex 
bilaterally. Data for MS-HF and 
MS-LF obtained by 








41.1 ± 10.9 
MS-LF: 




















4.9 ± 0.8 
MS-LF: 








Total brain volume (ml) 
 
Grey matter volume 
(ml) 
White matter volume 
(ml) 
983.8 ± 102.8 
 
425.6 ± 64.4 
 
558.2 ± 84.4 
995.7 ± 72.6 
 
447.1 ± 50.7 
 
548.6 ± 58.5 
 Significantly higher T1 lesion 
volume in MS-HF vs MS-LF. 
Total brain volume, grey matter 
volume, white matter volume and 
T1 and T2 lesion volumes were 
not significantly different for 
MS-HF vs MS-LF. 
         T1 lesion volume (ml) 1.3 ± 1.6 0.8 ± 1.0  
         
T2 lesion volume (ml) 4.3 ± 5.0 3.2 ± 3.4 
 


















Means for the 




















 Median T2 lesion volume was 
not significantly different for 





Pardini et al. 
(2010) 
40 RR 15 MS-HF 
25 MS-LF 
MS-HF: 
41.3 ± 4.4 
MS-LF: 

















MS: 31.1 ± 
18.0 
MS-HF: 
20.2 ± 10.0 
MS-LF: 

























1600 ± 900 
 
 





1500 ± 200 
 Significant involvement of 
different frontal (fronto-frontal, 
fronto-straital, fronto-occipital 
and fronto-limbic) networks in 
the pathophysiology of MS 
fatigue. Significant correlation 
between MFIS and white matter 
regions, within fronto-striatal 
networks. 








45.4 ± 9.7 
HC: 














30.3 ± 16.1 
HC: 


















8.60 ± 6.3 
 T2 lesion volume was 
significantly higher and thickness 
of the posterior and inferior 
parietal cortex, supramarginal 
gyrus and thalamus volume lower 
for MS-HF vs MS-LF. 








46.6 ± 9.3 
MS-LF: 
40.0 ± 5.8 

























33.6 ± 4.8 
MS-LF: 
14.3 ± 3.8 
HC: 













(RS-FC) scans before, 
immediately after and 
30 min after execution 
of the paced auditory 




















as graphs and 
correlation 
coefficients. 
MS-HF experienced stronger RS- 
FC 30 min post-PASAT between 
the left superior frontal gyrus and 
occipital, frontal and temporal 
areas. Also, in MS-HF, the left 
superior frontal gyrus was 
hyperconnected with the left 
caudate nucleus immediately post 
task and hypoconnected at 30 
min post with the left anterior 
thalamus. 







38.0 ± 7.7 
MS-LF: 
38.6 ± 8.5 
HC: 

































Total brain volume (ml) 
 
Grey matter volume 
(ml) 
 
White matter volume 
(ml) 
 
T2 Lesion load-volume 
(ml) 
1596 ± 79 
 
795 ± 66 
 
 
801 ± 55 
 
 
7.7 ± 5.0 
1560 ± 51 
 
770 ± 45 
 
 
790 ± 60 
 
 
8.9 ± 10.7 
1649 ± 48 
 
826 ± 58 
 
 
822 ± 42 
Significantly greater atrophy of 
left central sulcus, precentral 
gyrus and primary motor cortex 
region in MS-HF vs MS-LF and 
HC. T2 lesion volume, total brain 
volume, white matter volume, 
grey matter volume and 
intracranial volume were not 
significantly different for MS-HF 
vs MS-LF but were lower 
compared to HC. 







33.8 ± 6.2 
MS-LF: 























1493 ± 131 
 
1540 ± 100 
 
1519 ± 115 
T2 lesion volume and normalised 
brain volume were similar for 
MS-HF and MS-LF and for MS 





   HC: 









6 (2-10) 37.7 ± 7.7 
MS-LF: 







T2 lesion volume (ml) 
 
 
8.1 ± 8.5 
 
 
8.8 ± 6.0 
 frontal-parietal lobes and basal 
ganglia regions in MS-HF vs 
MS-LF. 
















































T2 lesion volume (ml) 
 
Mean diffusivity (×10−3 
mm2/s) 
 
Grey matter average 
 
 
White matter average 
 





White matter average 
 
 
Cervical cord average 
 





0.94 ± 0.06 
 
 
0.79 ± 0.02 
 





0.39 ± 0.02 
 
 
0.47 ± 0.04 
 





0.97 ± 0.07 
 
 
0.82 ± 0.06 
 





0.36 ± 0.03 
 
 







0.89 ± 0.03 
 
 
0.77 ± 0.02 
 





0.41 ± 0.02 
 
 
0.59 ± 0.06 
Significantly greater brain white 
matter fractional anisotropy and 
reduced fMRI activation in the 
left anterior and posterior cervical 
cord quadrants in MS-HF vs MS- 
LF and HC. 





















































Grey matter Volume 
(ml) 
White matter Volume 
(ml) 
 
T1 lesion volume (ml) 
 
T2 lesion volume (ml) 
 




1477 ± 109 
 
665 ± 85 
 
811 ± 46 
 
6.0 ± 6.1 
 




14.03 ± 1.13 
1525 ± 90 
 
691 ± 60 
 
835 ± 61 
 
5.7 ± 5.6 
 




14.27 ± 1.27 
1572 ± 93 
 
726 ± 58 
 
846 ± 52 
 
0.02 ± 0.04 
 




15.90 ± 1.13 
Significantly greater T2 lesion 
volume and atrophy of the right 
accumbens, right inferior 
temporal gyrus, left superior 
frontal gyrus, and forceps major 
in MS-HF vs MS-LF and HC. 
Lower fractional anisotropy 
(forceps major, left inferior 
fronto occipital fasciculus and 
right anterior thalamic radiation) 
in MS-HF vs MS-LF and HC. T1 
lesion volume, normal brain 
volume, grey matter volume and 
white matter volume were not 
significantly different for MS-HF 
vs MS-LF but were lower 





         
Caudate volume (ml) 
 










Pallidus volumen (ml) 
 








6.12 ± 0.64 
 
8.48 ± 0.71 
 
0.75 ± 0.13 
 
2.70 ± 0.22 
 
6.87 ± 0.57 
 




0.92 ± 0.05 
 




0.16 ± 0.01 
 
0.38 ± 0.02 
6.43 ± 0.71 
 
8.69 ± 0.92 
 
0.85 ± 0.14 
 
2.67 ± 0.22 
 
7.05 ± 0.64 
 




0.92 ± 0.05 
 




0.16 ± 0.01 
 
0.38 ± 0.02 
6.77 ± 0.57 
 
9.18 ± 0.71 
 
0.85 ± 0.13 
 
2.59 ± 0.22 
 
7.30 ± 0.50 
 




0.90 ± 0.04 
 




0.15 ± 0.01 
 
0.39 ± 0.02 
 







42.6 ± 11.2 
MS-LF: 
40.0 ± 9.1 
HC: 








































Grey matter volume 
(ml) 
White matter volume 
(ml) 
 
T1 Lesion volume (ml) 
T2 Lesion volume (ml) 
1434 ± 117 
 
637 ± 80 
 
795 ± 43 
 
4.4 ± 5.6 
 
6.2 ± 7.5 
1448 ± 118 
 
648 ± 80 
 
800 ± 43 
 
4.1 ± 4.5 
 
5.7 ± 6.0 
1566 ± 296 
 
766 ± 58 
 
858 ± 41 
Abnormal recruitment of 
sensorimotor networks in fronto- 
parietal–temporal lobes and basal 
ganglia. Normalised brain 
volume, grey matter volume, 
white matter volume, T1 and T2 
lesion volumes were not 
significantly different for MS-HF 













43 ± 8 
MS-LF: 
42 ± 10 
HC: 





















6.0 ± 0.6 
MS-LF: 


























































43.3 ± 6.9 
Reduced cerebral glucose 
metabolism bilaterally for MS- 
HF versus MS-LF in the 
prefrontal area involving the 
lateral and medial prefrontal 
cortex and adjacent white matter, 
in the premotor cortex, putamen, 
and the right supplementary 
motor area. Reductions also 
observed in the white matter 
extending from the rostral 
putamen toward the lateral head 
of the caudate nucleus. Suggests 
MS fatigue is associated with 
frontal cortex and basal ganglia 
dysfunction. 








42.8 ± 12.8 
MS-LF: 
50.5 ± 8.8 
HC: 






































T1 lesion volume (ml) 
Total brain volume (ml) 
Lateral ventricles 
 
Third and fourth 
ventricle volume 
 
Corpus callosum index 
Axial and radial 
diffusivity of the corpus 
callosum 
81 ± 4 
 
3.71 ± 2.57 
 
1201 ± 109 
 
40.92 ± 24.68 
 
4.22 ± 1.47 
 




81 ± 4 
 
7.07 ± 15.77 
 
1219 ± 131 
 
36.00 ± 30.87 
 
3.43 ± 4.46 
 
0.329 ± 0.068 
 
 
0.0013 ± 0.0001 
85 ± 15 
 
0.03 ± 0.08 
 
1281 ± 73 
 
16.78 ± 6.43 
 
2.72 ± 1.27 
 




Brain parenchymal fraction, total 
brain volume, lateral ventricle 
volume, third and fourth ventricle 
volume, T1 lesion volume, axial 
and radial diffusivity were not 
significantly different for MS-HF 
vs MS-LF but differed from HC. 










36.4 ± 9 
HC: 












range = 0-20) 




Means for the 















T2 Lesion volume (ml) 
 





56.6 ± 16.8 
 





19.1 ± 8.3 
 Greater grey matter atrophy (left 
superior frontal gyrus, bilateral 
middle frontal gyrus) in MS-HF 
vs MS-LF. Higher T1 and T2 
lesion volumes for MS-HF vs 
MS-LF (left frontal and right 
parieto-temporal white matter 
regions mainly affected). 
Reported T1 and T2 gadolinium 
enhancing lesion volumes, so 















40.9 ± 8.9 
MS-LF: 















Means for the 











during execution of a 














as brain scans 
and activation 
coordinates. 
MS-HF demonstrated greater 
activation of the right premotor 
area, putamen and dorsolateral 
prefrontal cortex (i.e. motor 
attentional network) in 
comparison with MS-LF. 
Stefancin et al. 
(2019) 
22 RR 10 MS-HF 
12 MS-LF 
MS-HF: 
27.0 ± 5.5 
MS-LF: 























5.5 ± 0.9 
MS-LF: 


















12.4 ± 19.6 
 No significant difference in T2 
lesion volume between MS-HF 
and MS-LF. 
Tartaglia et al. 
(2004) 
60 MS 34 MS-HF 
26 MS-LF 
MS-HF: 
42.1 ± 6.9 
MS-LF: 























VE MS : 












13.44 ± 13.4 
 




1.44 ± 0.15 
 
11.24 ± 13.2 
 




1.48 ± 0.18 
 Significantly lower NAA/Cr in 
MS-HF vs MS-LF, suggesting 
diffuse periventricular axonal 
injury is associated with MS 
fatigue. 
Tedeschi et al. 
(2007) 
222 RR 197 MS-HF 
25 MS-LF 
MS-HF: 
39.0 ± 9.2 
MS-LF: 







6 ± 5.7 
FSS [ 5 
(Mean)] 
 
Means for the 









Abnormal white matter 
fraction 
 
White matter fraction 
Grey matter fraction 
T1 lesion volume (ml) 
T2 lesion volume (ml) 
0.02 ± 0.01 
 
0.34 ± 0.03 
 
0.49 ± 0.04 
 
2.6 ± 3.8 
 
17.5 ± 16.7 
0.01 ± 0.01 
 
0.35 ± 0.03 
 
0.52 ± 0.03 
 
0.9 ± 1.7 
 
7.1 ± 6.6 
 Significantly higher lesion 
volume, white matter and grey 
matter atrophy in MS-HF vs MS- 
LF. 


















[ 5 (Mean)] 




Frontal white matter 
lesion volume (%) 
 
0.12 ± 0.18 
 
0.09 ± 0.02 
 Significantly lower NAA/Cr in 
















5.9 ± 0.7 
MS-LF: 
3.6 ± 1.15 
HC: 
3.2 ± 1.2 
(Magnetom 
Vision) Lentiform nucleus lesion volume (%) 
 
NAA/Cr 
Frontal white matter 
Lentiform nucleus 
NAA/Cho 












1.67 ± 0.17 
 




1.48 ± 0.24 
 




1.14 ± 0.17 
 
0.81 ± 0.13 
 




1.73 ± 0.12 
 




1.53 ± 0.17 
 




1.14 ± 0.12 
 






1.77 ± 0.19 
 




1.45 ± 0.24 
 




1.15 ± 0.33 
 
0.81 ± 0.20 
MS-HF vs MS-LF and HC, 
indicative of axonal dysfunction. 
Tomasevic et 
al. (2013)** 
20 RR 11 MS-HF 
9 MS-LF 
MS-HF: 
38.5 ± 3.2 
MS-LF: 
















[ 16 (Mean)] 
MS-HF: 
36.6 ± 10.2 
MS-LF: 











T2 lesion volume (ml) 
 
Lesion relative fraction 
(%) 
 
Thalamus volume (ml): 





82 ± 1 
 
11.0 ± 8.3 
 
0.02 ± 0.01 
 




1.71 ± 0.07 
 
1.70 ± 0.09 
81 ± 2 
 
17.2 ± 8.1 
 
0.03 ± 0.03 
 




1.73 ± 0.18 
 
1.67 ± 0.18 
 T2 lesion volume, thalamus 
volume and brain parenchymal 
fraction were not significantly 
different for MS-HF vs MS-LF. 
van der Werf 














 Feeling tired 



























 Regional lesion load was not 
significantly different for MS-HF 
vs MS-LF. Fatigue severity was 
not related to the total extent of 
cerebral abnormalities, or to 
magnetic resonance imagery - 





       Means for the 
2 MS groups 
not reported. 
     Suggests factors other than focal 
lesions or cerebral atrophy 
mediate levels of perceived MS 
fatigue. 

































Means for the 












Lesion volume (ml) 
 
Mean grey matter 
fraction (%) 
Mean white matter 
fraction (%) 
Mean cerebrospinal 








Basal ganglia fractional 
anisotropy 
Basal ganglia mean 
diffusivity (×10−3 
mm2/s) 








0.440 ± 0.036 
 
0.395 ± 0.025 
 
0.165 ± 0.028 
 
0.835 ± 0.028 
 
0.275 ± 0.027 
 
 
1.426 ± 0.334 
 
 
0.252 ± 0.014 
 
 
0.980 ± 0.146 
 
 
0.110 ± 0.005 
 
 




0.443 ± 0.027 
 
0.392 ± 0.026 
 
0.164 ± 0.024 
 
0.836 ± 0.024 
 
0.289 ± 0.021 
 
 
1.266 ± 0.221 
 
 
0.255 ± 0.015 
 
 
0.912 ± 0.116 
 
 
0.111 ± 0.006 
 
 




0.456 ± 0.025 
 
0.394 ± 0.023 
 
0.150 ± 0.024 
 
0.850 ± 0.024 
 






0.262 ± 0.012 
 
 
0.870 ± 0.077 
 
 
0.115 ± 0.004 
 
 
0.490 ± 0.029 
Significant reduction in global 
grey matter fraction was found 
for MS-HF versus HC but not 
MS-LF. Reduced fractional 
anisotropy and increased mean 
diffusivity values were found in 
MS-HF versus MS-LF for the 
thalamus and basal ganglia, 
including the caudate nucleus, 
globus pallidus and putamen. 
Suggests morphologic and 
microstructural alterations in 
thalamic regions are related to 
cognitive fatigue in early MS. 
Fractional anisotropy and mean 
diffusivity values in the thalamus 
were significantly correlated with 
information processing speed, 
cognitive flexibility and overall 
cognitive impairment. 
Yaldizli et al. 
(2011) 
70 RR 28 MS-HF 
42 MS-LF 
MS-HF: 
43.7 ± 11.4 
MS-LF: 

















9 ± 6.8 
FSS 
[ 4 (Mean)] 
MS-HF: 
5.27 ± 1.09 
MS-LF: 








T2 Lesion load (ml) 
 










8 ± 28.6 
20 ± 71.4 





32 ± 76.2 
10 ± 23.8 
 Significantly greater atrophy of 






         Contrast enhancing 










1 ± 3.6 
 





5 ± 11.9 
 




30 RR 16 MS-HF 
14 MS-LF 
MS-HF: 






















[≥ 5.1 (mean)] 
MS-HF: 
6 ± 0.12 
MS-LF: 


















15.3 ± 5.9 
 No significant difference in T2 
lesion volume between MS-HF 
and MS-LF. 







42 ± 8 
MS-LF: 
38 ± 5 
HC: 



















52 ± 6 
MS-LF: 
22 ± 10 
HC: 




















5.5 ± 6.4 
 Lower NAA/Cr concentration in 
the tegmentum of pons driven by 
higher Cr concentration in MS- 
HF vs HC (found in white matter 
regions). T2 lesion volume data 
obtained for MS-HF and MS-LF 
by communication with the lead 
author. 

























































 T1 and T2 lesion volume was not 
significantly different for MS-HF 
vs MS-LF. 
Data are presented as mean ± SD or median with intracortical range or total range in parentheses; ^ Original data received from the lead author; ** article has 
both structural and function neurophysiological measurements; RR, relapsing-remitting multiple sclerosis; SP, secondary progressive multiple sclerosis; PP, 
primary progressive multiple sclerosis; RSP, relapsing secondary progressive multiple sclerosis; EDSS, Extended Disability Status Scale; MS, Multiple 
Sclerosis; MS-HF, multiple sclerosis-highly fatigued; MS-LF, multiple sclerosis-less fatigued; HC, healthy controls; FSS, Fatigue Severity Scale; MFIS, 
Modified Fatigue Impact Scale; MRI; Magnetic Resonance Imagery, fMRI; Functional Magnetic Resonance Image 




















Technique Outcomes MS-HF MS-LF HC Summary of findings 
Andreasen et al. 
(2009) 
















































148 ± 32 
 
 
95.9 ± 5.1 
 
 
1.02 ± 0.08 
 
173 ± 49 
 
 
99.2 ± 0.99 
 
 
1.05 ± 0.14 
 Significantly lower voluntary 
activation in MS-HF vs MS- 
LF. Maximum voluntary 
contraction force was not 
significantly different for MS- 
HF vs MS-LF. 
Andreasen et al. 34 RR 17 MS-HF MS-HF: MS- MS-HF: MS-HF: FSS Isometric     Significantly lower voluntary 
(2010)** 7 HC 17 MS-LF 43 (27- HF: 3 (1-3.5) 5 (1-14) [>5 dynam-    activation in MS-HF vs MS- 
   53) 5/12 MS-LF: MS-LF: (Mean)] ometer    LF. 
   MS-LF: MS-LF: 2 (1.5- 3 (0-9) MS-HF:      






 6.3 (5-7) 
MS-LF: 
 Voluntary activation 
(%) 98.1 (85.1-100) 99.8 (96.9-100) 
 
   HC: 1/6 0 (0-2)  2.8 (1-4)      
   39 (31-    HC:      
   45)    2.7 (2-4)      






















11.9 ± 6.6 
MS-LF: 



















MEP threshold (%) 
SICI 2 ms (%) 
SICI 4 ms (%) 
ICF 12 ms (%) 
54.7 ± 13.3 
 
63.9 ± 20.9 
 
44.3 ± 37.5 
 
160.8 ± 68.9 
61.6 ± 18.3 
 
35.0 ± 40.8 
 
9.5 ± 73.3 
 
159.9 ± 78.2 
 SICI 2 ms (%) was 
significantly higher in MS-HF 
versus MS-LF. No difference 
between MS-HF and MS-LF 
for SICI 4 ms (%) or ICF 12 
ms (%). 


























3.9 ± 4.1 
MS-LF: 





42.1 ± 7.3 
MS-LF: 











1.08 ± 0.08 
 
 
2.94 ± 0.70 
 
2.53 ± 0.55 
 
0.99 ± 0.10 
 
 
3.28 ± 1.00 
 
3.27 ± 0.76 
 
0.98 ± 0.08 
 
 
3.43 ± 1.02 
 
3.51 ± 0.86 
Significantly higher resting 
left hemispheric primary 
sensorimotor activity power 
and higher inter-hemispheric 
coherence during movement 
in MS-HF vs MS-LF and HC. 
         Inter-hemispheric 
symmetry index - 
movement: 
 
1.06 ± 0.34 
 
0.99 ± 0.35 
 










0.27 ± 0.15 
 
0.25 ± 0.16 
0.27 ± 0.14 
 
0.27 ± 0.11 
0.15 ± 0.08 
 
0.16 ± 0.08 
 
Colombo et al. 
(2000)** 
























































 Central motor conduction 
time was not significantly 
different for MS-HF vs MS- 
LF. 
          




          






























5.2 ± 4.3 
MS-LF: 
6.3 ± 7.1 
Presence 




























plasticity) and paired 
associative stimulation 
(reflecting long-term 
























Effects of attention on cortical 
plasticity differ in MS-HF 
versus MS-LF. In MS-LF 
attention improves the MEP 
size increase whereas in 
patients with fatigue, attention 
leaves responses unchanged. 
Suggests MS fatigue reflects 
disrupted cortical attentional 
networks related to movement 
control. 
































Post fatigue task force 












96.8 ± 8.4 
Greater fatigability in MS-HF 
vs MS-LF and HC. 






33 ± 8 
MS-LF: 






 1.5  FSS [≥33 
(Total)] 
Means for 







(ERS) of the 10 and 18- 
22 Hz bands (cortical 


















Reduced post-movement 18 – 
22 Hz ERS in MS-HF versus 
MS-LF and inverse 
correlation between the 
amount of ERS and the 





       not 
reported. 
 control of voluntary 
movement). 
   inhibitory circuits acting on 
the motor cortex after 
movement termination may 
be involved in the patho- 
physiological mechanism of 
MS fatigue. 



















3.1 ± 0.93 
MS-LF: 
2.9 ± 0.9 
 FSS [  4 
(Mean)] 
MS-HF: 
5.3 ± 0.4 
MS-LF: 





Resting motor threshold 
(%) 
 
Motor evoked potential 
amplitude (mV) 
 
Motor evoked potential 
latency (ms) 




0.54 ± 0.26 
 
 
15.7 ± 1.23 
 
46.2 ± 3.6 
 
 
0.57 ± 0.19 
 
 
15.7 ± 1.56 
 
40.9 ± 6.1 
 
 
0.65 ± 0.27 
 
 
15.3 ± 1.24 
Significant reductions in SICI 
2-3 ms (%) at rest in MS-HF 
vs MS-LF and HC. 
Significantly lower grip 
strength in MS-HF vs HC. 
Motor response, resting motor 
threshold, motor evoked 
potential amplitude and 
latency was not different for 
MS-HF vs MS-LF or HC. 
        SICI 2-3 ms (%) 54.6 ± 27.3 35.9 ± 10.2 31.2 ± 14  
        
ICF 11-13 ms (%) 168 ± 37 179 ± 39 150 ± 35 
 
        
Motor response (mV) 18.6 ± 3.8 14.4 ± 6.5 19.5 ± 4.8 
 
         
Grip strength (Nm) 
 
87 ± 20.2 
 
102.5 ± 21.1 
 
120 ± 14.4 
 
















1.8 ± 0.6 
MS-LF: 
1.6 ± 0.6 
MS-HF: 
8.4 ± 3.4 
MS-LF: 




4.9 ± 0.8 
MS-LF: 























ICF 10 ms (%) 
 
 








132 ± 40 
 
 








123 ± 41 
 
 








140 ± 35 
Significantly reduced pre- 
movement facilitation in MS- 
HF vs MS-LF and HC. 
Central motor conduction 
time was prolonged in both 
MS groups vs HC. SICI 2 ms 
(%) and ICF 10 ms (%) was 
not significantly different for 
MS-HF vs MS-LF or HC. 















 FSS [ 4 
(Mean)] 
MS-HF: 










182.8 ± 60.7 
 
97.2 ± 4.9 
166.9 ± 7.9 
 
98.7 ± 2.3 




Small group of PwMS and 
MS-LF (N=3), not justifying 
statistical comparisons. Data 






       3.0 ± 0.6 
HC: 
3.0 ± 0.4 
  
Post fatigue task force 
(% baseline force) 
 
 
83.0 ± 25.3 
 
 
49.8 ± 12.3 
 
 
56 ± 20 
 













3.4 ± 1.7 
MS-LF: 
2.7 ± 1.6 
 FSS [>4 
(Mean)] 
MS-HF: 
5.8 ± 0.8 
MS-LF: 
3.1 ± 0.8 
HC 












Muscle activation (%) 
 
 





85.1 ± 23.8 
 
 





89.2 ± 22.5 
 
 





96.0 ± 13.0 
Lower maximum voluntary 
contraction force and muscle 
activation in MS-HF vs MS- 
LF and HC. 





















3.4 ± 1.0 
MS-LF: 
2.3 ± 0.5 
 FSS [>37 
(Total)] 
MS-HF: 


















contraction force (N) 
 
Motor evoked potential 
threshold (%) 
 
Motor evoked potential 
amplitude (mV) 
 
85.3 ± 14.7 
 
 
72.5 ± 9.1 
 
 
0.79 ± 0.89 
 
93.2 ± 25.5 
 
 
67.8 ± 10.9 
 
 
1.32 ± 1.25 
 
90.2 ± 20.6 
 
 
61.5 ± 8.0 
 
 
2.33 ± 1.75 
Maximum voluntary 
contraction force, motor 
evoked potential amplitude, 
threshold, latency, duration, 
and post-exercise MEP 
facilitation were not 
significantly different 
between MS-HF and MS-LF. 
        Motor evoked potential 
latency (ms) 
 
28.9 ± 5.6 
 
25.0 ± 3.6 
 
23.5 ± 2.1 
 
        Motor evoked potential 
duration (ms) 
 
21.4 ± 6.8 
 
16.9 ± 4.3 
 
15.9 ± 3.9 
 











2.6 ± 1.4 
MS-LF: 
2.7 ± 1.7 
MS-HF: 
4.5 ± 2.4 
MS-LF: 
















Fatigability expressed as 
decline in force and 
voluntary activation 














 FSS fatigue scores did not 
correlate with fatigability. 
Suggests perceived MS 
fatigue is independent of 
fatigability. 






41 ± 7 
MS-LF: 






2.0 ± 1.0 
MS-LF: 
2.0 ± 1.0 
 FSS [≥36 
(Total)] 
MS-HF: 
50 ± 7 
MS-LF: 

























Post-task PMF was 
significantly decreased in 
MS-HF versus MS-LF and 
abnormalities were correlated 
with the performance decay. 





        (Magstim 
200 Co) 
STIMULATION before 
and after 5 min of 
sequenced finger- 
tapping movements at a 
fixed frequency of 2 Hz. 
   between MS fatigue and 
functional impairment within 
circuits engaged in movement 
preparation, upstream the 
corticospinal tract. 






























Post fatigue task force 












44 ± 9 
Fatigability was not 
significantly different 
between MS-HF vs MS-LF. 
Sebastiao et al. 
(2017) 


















13.9 ± 9.1 
MS-LF: 


























51.5 ± 19.9 
 
 





66.9 ± 28.6 
 
 
165.1 ± 58.3 
 Significantly lower knee 
flexor peak torque and 
cardiorespiratory capacity in 
MS-HF vs MS-LF. 












































97.2 ± 1.7 
 Lower voluntary activation in 
MS-HF vs MS-LF. 























5.5 ± 0.8 
MS-LF: 
3.7 ± 0.2 
HC: 













contraction force (N) 
 
 
Post fatigue task force 









36.3 ± 13.1 
 
 
92.1 ± 7.9 
 




33.8 ± 5.0 
 
 
99.0 ± 1.5 
 









Lower voluntary activation in 
MS-HF vs MS-LF and HC. 
Maximum voluntary 
contraction force and 
fatigability was not 
significantly different 






          
Central motor 
conduction time (ms) 
 
9.8 ± 2.6 
 




Tomasevic et al. 
(2013)** 













0.4 ± 0.5 
MS-LF: 
0.3 ± 0.5 
MS: 

























27.5 ± 4.8 
 
 
0.07 ± 0.02 
 
0.03 ± 0.02 
 
 
1.40 ± 0.38 
 
16.7 ± 3.6 
 
 
0.06 ± 0.05 
 
0.05 ± 0.04 
 
 
2.20 ± 0.55 
 Significantly faster 
frequencies of cortico- 
muscular coherence and 
increase correction rate during 
handgrip in MS-HF vs MS- 
LF. 



































23.4 ± 6.2 
EEG Model 
CUEE60M, 









Beta 1 band (13-20 Hz) 
 
 





1.007 ± 0.004 
 
 





0.989 ± 0.009 
 
 





0.985 ± 0.005 
Functional connectivity 
changes of the left sensory 
cortical network at rest, 
mediated by beta band 
oscillatory activity in MS-HF 
vs MS-LF. 
Wolkorte et al. 
(2015a)^ 















5.3 ± 0.6 
MS-LF: 






contraction force (N) 
 
 
Post fatigue task force 
(% baseline force) 
 




27.47 ± 8.52 
 




36.03 ± 12.40 
 Lower maximum voluntary 
contraction force and greater 
fatigability in MS-HF vs MS- 
LF. 




















1.4 ± 1.0 
MS-LF: 






























45 ± 11 
Maximum voluntary 
contraction force was not 
significantly different 
































4.9 ± 1.4 
MS-LF: 










5.6 ± 0.7 
MS-LF: 

















Post fatigue task force 
(% baseline force) 
 
24.3 ± 10.3 
 
 
83.7 ± 12.3 
 
 
26.5 ± 8.5 
 
27.4 ± 7.0 
 
 
89.3 ± 9.7 
 
 
30.9 ± 13.9 
 
32.1 ± 9.6 
 
 
93.9 ± 5.8 
 
 
37.2 ± 12.3 
Maximum voluntary 
contraction force was similar 
between MS-HF and MS-LF. 
Greater fatigability in MS-HF 
vs MS-LF. 
 
Data are presented as mean ± SD or median with intracortical range or total range in parentheses; ^ Original data received from the lead author; ** article has both structural and function 
neurophysiological measurements; RR, relapsing-remitting multiple sclerosis; SP, secondary progressive multiple sclerosis; PP, primary progressive multiple sclerosis; RSP, relapsing 
secondary progressive multiple sclerosis; EDSS, Extended Disability Status Scale; MS, Multiple Sclerosis; MS-HF, multiple sclerosis-highly fatigued; MS-LF, multiple sclerosis-less 
fatigued; HC, healthy controls; FSS, Fatigue Severity Scale; MFIS, Modified Fatigue Impact Scale; MRI, Magnetic Resonance Imagery, fMRI; Functional Magnetic Resonance Imagery; 














Appendix 17 -. Methodological quality of the included studies evaluated using the Cross-Sectional/Prevalence Study Quality Scale, 
recommended by the Agency for Healthcare Research and Quality (AHRQ): EB reported; — not reported; U unclear; NA not applicable. 
Scores of 0-3 indicate “low quality”, 4–7 “moderate quality” and 8–11 “high quality”. <l original data acquired from senior author of the 
publication; lI¢ Studies not used for meta-analysis; Q studies providing neuroimaging and neurofunctional data. 
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List inclusion and exclusion criteria for 
exposed and unexposed subjects (cases and 





































Indicate whether or not subjects were 

















Indicate if evaluators of subjective 
components of study were masked to other 

















Describe any assessments undertaken for 
quality assurance purposes (e.g., test/retest of 






















































If applicable, explain how missing data were 


















Summarize patient response rates and 
























Clarify what follow-up, if any, was expected 
and the percentage of patients for which 
incomplete data or follow-up was obtained 
4 5 4 6 4 7 6  8  
 
























Codella et al. (2002)     — — — — —   — — NA 3 Low 
Cogliati Dezza et al. (2015) 0     — — — — —   — — NA 3 Low 
Colombo et al. (2000)   0     —   — — — — — — NA 3 Low 
Conte et al. (2016)         —   —   —     NA 7 Mod 
Cruz Gomez et al. (2013)     — — — — —   — — NA 3 Low 
Damasceno et al. (2016)     — —   — —   —   NA 5 Mod 
Derache et al. (2013)         — — — —   —   NA 5 Mod 
Dobryakova et al. (2018)  D     — — — —       — NA 5 Mod 
Filippi et al. (2002)       — —             NA 8 High 
Gobbi et al. (2014a)     —   — — —   —   NA 5 Mod 
Gobbi et al. (2014b)       —     — —   —   NA 6 Mod 
Gonzalez Campo et al. (2019)       — — — —   — —   NA 4 Mod 
Greim et al. (2007)     — — — — —   — — NA 3 Low 
Hanken et al. (2015)     — — —   —   — — NA 4 Mod 
Hanken et al. (2016)     — — — — —   —   NA 4 Mod 
Hidalgo de la Cruz et al. (2017)     — — — —         NA 6 Mod 
Jaeger et al. (2018)     — — — — —   — — NA 3 Low 





Liepert et al. (2005)     — — — — — — — — NA 2 Low 
Lin et al. (2019)  D     — — — —       — NA 5 Mod 
Morgante et al. (2011) 0       — — —         NA 7 Mod 
Ng et al. (2000)  D     — — — — — — — — NA 2 Low 
Ng et al. (2004)  D     — — — —   —     NA 5 Mod 
Niepel et al. (2006)         —         — — NA 7 Mod 
Pardini et al. (2010)     —   — — — — — — NA 3 Low 
Pellicano et al. (2010)  D     — — — — — — — — NA 2 Low 
Perretti et al. (2004)     —   — — —   — — NA 4 Mod 
Pravata et al. (2016)       — — — —         NA 6 Mod 
Riccitelli et al. (2011)     —   — — —   — — NA 4 Mod 
Rocca et al. (2009)     —   — — —   — — NA 4 Mod 
Rocca et al. (2012)       —     —     —   NA 7 Mod 
Rocca et al. (2014)     —   — — —   — U NA 4 Mod 
Rocca et al. (2016)     —     — —   —   NA 6 Mod 
Roelcke et al. (1997)     — — — —     —     NA 5 Mod 
Romani et al. (2004)       — — — —     —     6 Mod 





Sander et al. (2016)       — —           NA 8 High 
Scheidegger et al. (2012)  D     — — — — — U — — NA 2 Low 
Sebastiao et al. (2017)     — — — — —   —   NA 4 Mod 
Severijns et al. (2019)  D     — — — — —   — — NA 3 Low 
Specogna et al. (2012)       — —   —   — —   NA 5 Low 
Steens et al. (2012)  D     — — — — — — — — NA 2 Low 
Stefancin et al. (2019)     — — — —   — —   NA 4 Mod 
Sepulcre et al. (2009)  D         —         — — NA 7 Mod 
Tartaglia et al. (2004)       — — —       — NA 6 Mod 
Tedeschi et al. (2007)     — — — — —   — — NA 3 Low 
Tellez et al. (2008)     — — — —         NA 6 Mod 
Tomasevic et al. (2013) 0     — — — — —   — U NA 3 Low 
van der Werf et al. (1998)       — —   —   — —   NA 5 Mod 
Vecchio et al. (2017)       — — — — —   — — NA 3 Low 
Wilting et al. (2016)   — — — — —   —     NA 4 Mod 
Wolkorte et al. (2015a)  D     — — — —         NA 6 Mod 
Wolkorte et al. (2015b)  D       — — —         NA 7 Mod 





Yaldizli et al. (2011)                 — — NA 8 High 
Yarraguntla et al. (2019)     — — — —     — —   5 Mod 
Zaini et al. (2016) <I     — — — —   U   U NA 4 Mod 
Zellini et al. (2009)       — —   —     — — NA 5 Mod 





















Appendix 18- Summary of the results of meta-analyses for neuroimaging studies (MS-HF versus MS-LF). Data are presented as absolute mean 






Appendix 19- Summary of the results of meta-analyses for neurophysiology studies (MS-HF versus MS-LF). Data are presented as absolute 













Neuroimaging variables  
Mean normalised brain volume (ml) 11 336 375 -22.74 (-37.72, -7.76) 0.003  ²=7.24; p=0.70; I²=0% 
Brain parenchymal fraction (%) 6 129 159 0.17 (-0.54, 0.88) 0.64  ²=3.03; p=0.70; I²=0% 
Grey matter volume (ml) 9 306 318 -18.81 (-29.60, -8.03) 0.0006  ²=5.71; p=0.68; I²=0% 
White matter volume (ml) 9 306 318 -6.41 (-13.98, 1.15) 0.10  ²=2.94; p=0.94; I²=0% 
Thalamus volume (ml) 8 234 286 -0.56 (-1.44, 0.31) 0.21  ²=88.55; p<0.00001; I²=92% 
Putamen volume (ml) 4 163 178 -0.40 (-0.69, -0.10) 0.008  ²=4.89; p=0.18; I²=39% 
Caudate volume (ml) 4 163 178 -0.45 (-0.95, 0.04) 0.07  ²=27.43; p<0.00001; I²=89% 
Accumbens volume (ml) 2 53 59 -0.09 (-0.15, -0.03) 0.003  ²=0.36; p=0.55; I²=0% 
Amygdala volume (ml) 2 53 59 -0.00 (-0.15, 0.14) 0.95  ²=1.27; p=0.27; I²=19% 
Pallidus volume (ml) 2 46 46 -0.23 (-0.50, 0.04) 0.09  ²=2.90; p=0.09; I²=66% 
T1-weighted Lesion volume (ml) 9 483 334 1.10 (0.47, 1.73) 0.0007  ²=8.90; p<0.35; I²=10% 
T2-weighted lesion volume (ml) 21 730 596 1.19 (-0.43, 2.80) 0.15  ²=42.25; p<0.003; I²=53% 
Fractional anisotrophy 3 60 60 -0.01 (-0.02, 0.01) 0.29  ²=8.99; p=0.01; I²=78% 
Mean diffusivity (×10−3 mm2/s) 3 60 60 0.01 (-0.03, 0.05) 0.72  ²=9.04; p=0.01; I²=78% 
NAA/Cr ratio 3 67 56 -0.12 (-0.27, 0.03) 0.11  ²=7.63; p=0.02; I²=74% 





















Neurophysiological variables       
Upper-limb MVC (N) 6 130 69 -3.55 (-7.11, 0.01) 0.05  ²=3.23; p=0.66; I²=0% 
Lower-limb MVC (N) 4 72 55 -19.23 (-35.93, -2.53) 0.02  ²=2.43; p=0.49; I²=0% 
Upper-Limb voluntary activation (%) 3 33 29 -5.77 (-8.61, -2.93) < 0.0001  ²=0.45, p=0.80; I²=0% 
Lower-limb voluntary activation (%) 3 36 29 -2.16 (-4.24, -0.07) 0.04  ²=0.11; p=0.94; I²=0% 
Motor evoked potential threshold (%) 3 61 34 -0.05 (-5.46, 5.36) 0.99  ²=3.09; p=0.21; I²=35% 
Motor evoked potential amplitude (mV) 2 40 17 -0.09 (-0.42, 0.23) 0.57  ²=1.18; p=0.28; I²=15% 
Motor evoked potential latency (ms) 2 40 17 1.70 (-2.09, 5.50) 0.38  ²=5.21; p=0.02; I²=81% 
Central motor conduction time (ms) 2 32 19 -0.74 (-2.75, 1.27) 0.47  ²=0.05; p=0.82; I²=0% 
Short interval intracortical inhibition (%) 3 45 42 -1.06 (-30.08, 27.96) 0.94  ²=10.64; p=0.005; I²=81% 
Intracortical facilitation (%) 3 45 42 1.74 (-18.36, 21.84) 0.87  ²=0.72; p=0.70; I²=0% 




Appendix 20 - Summary of the results of meta-analyses for neuroimaging studies (MS-HF versus HC). Data are presented as absolute mean 



































 ²=7.80; p=0.45; I²=0% 
Brain parenchymal fraction (%) 5 118 90 -2.06 (-3.12, -0.99) 0.0002  ²=5.65; p=0.23; I²=29% 
Grey matter volume (ml) 8 290 343 -58.96 (-79.21, -38.72) <0.00001  ²=27.73; p=0.0002; I²=75% 
White matter volume (ml) 8 290 343 -33.22 (-44.28, -22.15) <0.00001  ²=15.68; p=0.03; I²=55% 
Thalamus volume (ml) 6 208 235 -1.67 (-2.25, -1.09) <0.00001  ²=28.00; p<0.0001; I²=82% 
Putamen volume (ml) 4 163 148 -1.07 (-1.50, -0.63) <0.00001  ²=10.82; p=0.01; I²=72% 
Caudate volume (ml) 4 163 145 -0.84 (-1.15, -0.53) <0.00001  ²=8.95; p=0.03; I²=66% 
Accumbens volume (ml) 2 53 59 -0.17 (-0.34, -0.01) 0.04  ²=4.19; p<0.04; I²=76% 
Amygdala volume (ml) 2 53 59 -0.10 (-0.56, 0.36) 0.67  ²=7.08; p<0.008; I²=86% 
T1-weighted lesion volume (ml) 2 49 48 4.66 (2.42, 6.90) <0.0001  ²=3.42; p=0.06; I²=71% 
Fractional anisotrophy 2 45 65 -0.02 (-0.04, 0.01) 0.31  ²=25.86; p<0.00001; I²=96% 
Mean diffusivity (×10−3 mm2/s) 2 45 65 0.02 (0.01, 0.03) 0.0009  ²=0.00; p=1.00; I²=0% 
NAA/Cr ratio 2 33 27 -0.10 (-0.18, -0.01) 0.03  ²=0.01; p=0.91; I²=0% 
 
Appendix 21 - Summary of the results of meta-analyses for neurophysiological studies (MS-HF versus HC). Data are presented as absolute 






















      
Upper-limb MVC (N) 5 69 82 -8.73 (-16.71, -0.75) 0.03  ²=9.01; p=0.06; I²=56% 
Lower-limb MVC (N) 2 17 29 -63.94 (-128.18, 0.31) 0.05  ²=1.91; p=0.17; I²=48% 
Motor evoked potential threshold (%) 2 40 19 8.46 (2.73, 14.18) 0.004  ²=1.75; p=0.19; I²=43% 
Motor evoked potential amplitude (mV) 2 40 19 -0.74 (-2.13, 0.65) 0.30  ²=7.28; p=0.007; I²=86% 
Motor evoked potential latency (ms) 2 40 19 2.81 (-2.09, 7.71) 0.26  ²=14.24; p=0.0002; I²=93% 
Short interval intracortical inhibition (%) 2 24 18 11.93 (-10.99, 34.86) 0.31  ²=2.09; p=0.15; I²=52% 
Intracortical facilitation (%) 2 24 18 1.67 (-22.96, 26.30) 0.89  ²=1.17; p=0.28; I²=15% 








Appendix 22 - Summary of the results of meta-analyses for neuroimaging studies (MS-LF versus HC). Data are presented as absolute mean 

















Neuroimaging variables       
Mean normalised brain volume (ml) 9 333 356 -51.59 (-71.80, -31.38) <0.00001  ²=15.57; p=0.05; I²=49% 
Brain parenchymal fraction (%) 5 150 90 -1.95 (-3.46, -0.44) 0.01  ²=15.27; p=0.004; I²=74% 
Grey matter volume (ml) 8 301 343 -41.39 (-62.63, -20.16) 0.0001  ²=32.39; p<0.0001; I²=78% 
White matter volume (ml) 8 301 343 -25.51 (-37.27, -13.76) 0.0001  ²=16.43; p=0.02; I²=57% 
Thalamus volume (ml) 6 263 235 -1.10 (-2.13, -0.07) 0.04  ²=103.20; p<0.00001; I²=95% 
Putamen volume (ml) 4 178 148 -0.65 (-0.93, -0.38) <0.00001  ²=5.01; p=0.17; I²=40% 
Caudate volume (ml) 4 178 148 -0.36 (-0.66, -0.06) 0.02  ²=8.48; p=0.04; I²=65% 
Accumbens volume (ml) 2 53 59 -0.10 (-0.31, 0.11) 0.36  ²=7.18; p=0.007; I²=86% 
Amygdala volume (ml) 2 53 59 -0.03 (-0.29, 0.24) 0.85  ²=3.06; p=0.08; I²=67% 
T1-weighted lesion volume (ml) 2 56 48 5.81 (3.93, 7.69) <0.00001  ²=0.18; p=0.68; I²=0% 
Fractional anisotrophy 2 46 65 -0.02 (-0.04, -0.00) 0.04  ²=11.63; p=0.0007; I²=91% 
Mean diffusivity (×10−3 mm2/s) 2 46 65 0.03 (0.00, 0.06) 0.03  ²=3.79; p=0.05; I²=74% 




Appendix 23 - Summary of the results of meta-analyses for neurophysiological studies (MS-LF versus HC). Data are presented as absolute 



















Neurophysiological variables       
Upper-limb MVC (N) 5 48 82 -5.33 (-8.79, -1.86) 0.003  ²=2.65; p=0.62; I²=0% 
Lower-limb MVC (N) 2 8 29 -74.31 (-166.56, 17.93) 0.11  ²=4.21; p=0.04; I²=76% 
Motor evoked potential threshold (%) 2 17 19 5.60 (1.02, 10.18) 0.02  ²=0.04; p=0.84; I²=0% 
Motor evoked potential amplitude (mV) 2 17 19 -0.33 (-1.15, 0.48) 0.42  ²=2.03; p=0.15; I²=51% 
Motor evoked potential latency (ms) 2 17 19 0.67 (-0.62, 1.96) 0.31  ²=0.51; p=0.47; I²=0% 
Short interval intracortical inhibition (%) 2 25 18 0.58 (-10.37, 11.53) 0.92  ²=1.04; p=0.31; I²=4% 
Intracortical facilitation (%) 2 25 18 3.90 (-40.99, 48.79) 0.86  ²=3.55; p=0.06; I² =72% 
Upper-limb post-fatigue task MVC (%) 4 49 109 -2.91 (-6.78, 0.96) 0.14  ²=1.49; p=0.68; I²=0% 
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Lost to 6-week follow up (n=1): 
• Unable to contact (n=1) 
Lost to 6-week follow up (n=2): 
• Relapse (n=1) 
• Unable to contact (n=1) 
Analysis 
Analysis at 6-week (n=15): 
• Feasibility measures (n=15) 
• Health and fatigue measures 
(n=15) 
• Excluded from analysis (n=0) 
Analysis at 6-week (n=15): 
• Feasibility measures (n=15) 
• Health and fatigue measures 
(n=15) 
• Excluded from analysis (n=0) 
Allocation 
Enrolment 
Allocated to PRE group (n=16): 
• Received allocated intervention 
(n=16) 
Allocated to Control group (n=17): 
• Received standard care 
(n=17) 
Lost to 12-week follow up (n=1): 
• Time commitment (n=1) 
Lost to 12-week follow up (n=2): 
• Relapse (n=1) 
• Time commitment (n=1) 
Analysis at 12-week (n=14): 
• Feasibility measures (n=14) 
• Health and fatigue measures 
(n=14) 
• Excluded from analysis (n=0) 
Analysis at 12-week (n=13): 
• Feasibility measures (n=13) 
• Health and fatigue measures 
(n=13) 
• Excluded from analysis (n=0) 
